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ABSTRACT
 
ALICE K. FORTUNE-GREELEY: Comparative effectiveness and cost of preoperative breast 
MRI in elderly breast cancer patients 
(Under the direction of William R. Carpenter, PhD) 
 
Preoperative breast magnetic resonance imaging (MRI) has been used increasingly 
in the preoperative evaluation of women with newly diagnosed breast cancer. Despite its 
rapid adoption, limited evidence exists to support the routine use of breast MRI, creating 
controversy in breast cancer management. Existing evidence suggests that breast MRI may 
change treatment patterns, leading to surgical treatment delay and more extensive surgeries 
but may not improve patient outcomes. This study is one of the first to examine the 
association between preoperative breast MRI and surgical planning (i.e., time to complete 
surgery and type of initial surgery), short-term outcomes (i.e., re-excision and second breast 
cancer event rates), and cost in the elderly women using a large, population-based dataset. 
In this observational, retrospective analysis, we identified women diagnosed with 
early-stage (I-IIB), operable breast cancer from 2004-2007 in the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare dataset. Medicare claims were used to 
define the initial treatment phase, to identify breast cancer treatments, and to categorize 
Medicare payments. Second breast cancer events (i.e., recurrence or a second primary 
breast cancer) were identified through an algorithm validated in breast cancer patients. To 
control for measured confounders, we used propensity score methods. 
Twelve percent of our sample had a preoperative breast MRI. Compared to women 
who did not undergo breast MRI, we found that receipt of breast MRI was associated with a 
median 15-day delay in complete surgery and an increased likelihood of a mastectomy as 
the initial surgery. Breast MRI was not significantly associated with re-excision rates, but 
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was associated with an increased hazard of a second breast cancer event.  Women who 
received a breast MRI had higher total all-cause and breast cancer-attributable costs during 
the initial treatment phase than those women who did not undergo a breast MRI. 
Since findings from this dissertation indicate that breast MRI was associated with a 
slight surgical delay and an increased likelihood of a mastectomy in the absence of 
evidence for improved short-term outcomes, healthcare providers and elderly breast cancer 
patients should consider these factors when making informed decisions about whether the 
use of breast MRI is appropriate.  
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CHAPTER 1: INTRODUCTION
Advanced imaging modalities in cancer care are being adopted rapidly, but scientific 
evidence about their impact in real world settings lags behind.1-4 As new and advanced 
imaging modalities that assist with diagnosing, staging, and treating cancer are introduced 
into clinical practice, it is important to examine their impact on treatment planning and to 
develop evidence about their influence on short- and long-term outcomes. This evidence 
can be used, in turn, to determine their appropriateness and to inform dissemination into 
clinical practice.  Breast magnetic resonance imaging (MRI) is one type of advanced 
imaging that is being used to a greater extent in practice with limited evidence 
demonstrating its benefit.  
During the past ten years, breast MRI has been used increasingly as part of 
preoperative planning for patients with early stage invasive breast cancer.1,2,5-16 The 
percentage of elderly breast cancer patients with preoperative breast MRI increased from 
1.2% in 2002 to 18.8% in 2007.13 Breast MRI has been used in addition to conventional 
assessment, which includes clinical examination of the breasts, mammography and 
ultrasound, and pathological assessment of suspicious lesions, to measure the extent of 
disease and provide enhanced cancer detection. Preoperative breast MRI is highly sensitive 
and capable of detecting suspicious lesions not visible with mammography or ultrasound, 
but is limited in its specificity.17-19  Despite routine use, evidence suggests that breast MRI 
may not provide as much benefit as expected, resulting in more extensive surgeries17,18,20-22!
and treatment delay5,15,23 without any measurable differences in re-excision17,18,20-22!or breast 
cancer recurrence rates.10,20,24-27  Furthermore, the effect that breast MRI has on initial 
surgical planning and clinical outcomes remains unknown in the elderly United States (US) 
  2!
population. Additional research is needed to examine the influence of breast MRI on 
outcomes in the real world setting to inform its appropriate use. 
Existing evidence examining the association between breast MRI and surgical 
planning, short-term outcomes, and healthcare costs is limited in several aspects. First, 
much of the evidence is based on multiple studies from single institutions and two 
randomized controlled trials (RCT). To our knowledge, few studies examine the effect of 
MRI on surgical planning, outcomes, and cost in a population comparable to the US elderly 
population. Patients and medical groups participating in the RCTs and single institution 
studies were highly selective and the study populations were not comparable to the US 
elderly population. For example, the median and mean ages for the RCTs were 5720 and 
55.5 years,21 two decades younger than the average age of breast cancer patients enrolled 
in Medicare28 and the average patient in our study (76.1 years).  Second, to our knowledge, 
only one study29 has examined the impact of breast MRI on surgical planning or short-term 
outcomes in older women, a population that is least likely to benefit from breast MRIs 
because older patients are more likely to have less dense breasts and, therefore, fewer 
occult tumors with conventional assessment.30-35 Third, the two randomized controlled trials 
were conducted in the Netherlands21 and the United Kingdom20,36 where physician practice 
patterns, payment and referral structures, health insurance coverage, fiscal considerations, 
and patient preferences for mastectomy over breast conserving surgery (BCS) differ 
significantly from the US.37-39 Fourth, no study, to our knowledge, has examined the 
association between breast MRI and the cost of initial treatment in the US. The only study to 
examine the cost of breast MRI was a randomized controlled trial conducted in the United 
Kingdom.36   
This dissertation addressed this gap in the literature by examining preoperative 
breast MRI used in addition to conventional assessment to measure the extent of disease 
as part of the preoperative work-up. We examine breast MRI’s impact on surgical planning, 
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short-term outcomes, and Medicare costs in older, newly-diagnosed breast cancer patients 
using a large, population-based dataset. It is worth noting that, although breast MRI is used 
for other, non-preoperative indications such as screening high-risk women12,40-47 or 
monitoring the response to neoadjuvant therapy,48-54 these indications for breast MRI are not 
the focus of this study.  
Our central hypothesis was that preoperative breast MRI would be associated with a 
surgical treatment delay and an increased likelihood of a mastectomy as the initial surgery 
without evidence for improved short-term outcomes. Additionally, we hypothesized that 
breast MRI would be associated with increased costs to treat the incident breast cancer.  
Specific aims include: 
1. Examine the association between preoperative breast MRIs and surgical 
planning: 
a. Examine the association between preoperative breast MRI and the time 
elapsed from the date of the first claim for a suspected breast disorder 
to the date of complete surgical treatment; and 
b. Examine the association between of preoperative breast MRI and initial 
type of breast surgery (i.e., mastectomy vs. breast conserving surgery). 
2. Examine the association between preoperative breast MRIs and short-term 
outcomes: 
a. Examine the association between preoperative breast MRI and whether 
a patient had a re-excision; and  
b. Examine the association between preoperative breast MRI and whether 
a patient had a second breast cancer event. 
3. Examine the costs associated with breast MRI during the initial treatment phase 
from the perspective of Medicare. 
  4!
Aim 1a examined the time elapsed from the date of the first claim for a suspected 
breast disorder (e.g., lump or mass in breast or abnormal mammogram) until the date of 
complete surgical treatment for women with and without breast MRI. Examining the time to 
complete surgical treatment is important because a surgical delay of 3 - 8 months may have 
detrimental effects on breast cancer outcomes.55,56 Moreover, any delay in treatment may be 
anxiety-provoking for patients, lead to uncertainties related to the interpretation and 
management of additional findings, and delay the start of adjuvant therapy.57 Previous single 
institution studies have found that breast MRI was associated with a 22- to 41-day 
delay.5,15,23 
Aim 1b examined the association between breast MRI and initial type of breast 
surgery (i.e., BCS vs. mastectomy). Recent studies have reported that mastectomy rates for 
early-stage breast cancer patients have increased, and more patients with early-stage 
breast cancer are undergoing aggressive surgical treatment.11,58-62 Although evidence has 
shown that breast conserving therapy (BCT), or BCS followed by radiation, and mastectomy 
yield equivalent survival outcomes63-65 and the decision regarding the type of initial surgery 
has been considered a “preference-sensitive decision,”66,67 it is important to examine what 
other factors, such as breast MRI, may influence the likelihood of a mastectomy over BCT.  
In multiple recent single institutional studies,10,23,26,68-77 meta-analyses,17,18,22 and two 
European RCTs,20,21  breast MRI was found to be associated with an increased likelihood of 
mastectomy compared to breast conserving surgery due to additional lesions detected by 
MRI that were occult with conventional assessment. However, there is a dearth of literature 
examining the association between breast MRI and surgical planning on a sample 
comparable to the US elderly population.  
In the observational, retrospective analyses for Aim 1, we identified women 
diagnosed with early stage (I-IIB), operable breast cancer from 2004-2007 whose data 
comprise a subset of the Surveillance, Epidemiology, and End Results (SEER) registry and 
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was linked to Medicare claims.  Cancer treatment and breast MRI receipt were identified 
from the Medicare claims. Time from the first claim for a suspected breast disorder to 
complete surgical treatment was defined as the number of days from the first claim for a 
suspected breast disorder diagnosis to the last surgical procedure in the initial treatment 
phase. The first surgical procedure was defined as the first surgery that was either a BCS 
(partial mastectomy or a breast excision) or a full mastectomy. To control for measured 
confounders, we used propensity score methods.78,79 Based on previous findings,13,17-22 we 
hypothesized that women who received preoperative breast MRI would be associated with: 
(a) a longer time to complete surgery; and (b) more extensive initial surgeries (i.e., 
mastectomy) than those women who did not receive a breast MRI.  
In Aims 1a and 1b, we used multivariate logistic regression to determine each 
patient’s propensity for receipt of preoperative breast MRI on the basis of observed patient 
and surgical facility characteristics.80 We selected variables based on their hypothesized 
relationship with breast MRI receipt and the outcome (either time to surgery or type of first 
surgery). Patient-level covariates included year of diagnosis (2004-2007), age group at 
diagnosis (in five-year intervals), marital status, Medicare state buy-in coverage status, race, 
and co-morbidities using the National Cancer Institute (NCI) combined index.81 We included 
person-level tumor characteristics such as stage, grade, histology, and tumor size as well as 
hormone receptor status. Surgical provider variables were included, such as whether or not 
the surgical facility was affiliated with NCI Cooperative Groups with breast cancer research 
portfolios, a designated NCI Cancer Center, a teaching hospital, or had high breast cancer 
surgical volume. We also included indicators for SEER region and education level as the 
percentage of high school graduates in the patient’s zip code of residence.  
Aim 2a examined the association between breast MRI and the likelihood of re-
excision after a patient’s initial surgery. Re-excision rates after initial breast conserving 
surgery are an important clinical issue. Re-excisions have been found to occur after 17% to 
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60% of breast conserving surgeries.82-86 Re-excisions have multiple negative consequences, 
including a worsened cosmetic outcome, delay in adjuvant therapy, and higher cost 
associated with additional treatment.84,85,87-89 Reoperation rates are also an important clinical 
issue in the elderly population. Operations and re-excisions are more problematic for elderly 
women who are more likely to have co-morbidities and for whom it is riskier to undergo 
anesthesia. Furthermore, recovery from surgery is much more difficult for these women. 
Because of its sensitivity and enhanced imaging, researchers and clinicians have begun to 
investigate whether or not breast MRI can increase the likelihood of identifying clear margins 
after the initial surgery and reduce the need for re-excisions. Multiple single institution 
studies, meta-analyses, and two RCTs found no difference in re-excision rates between 
patients with and without preoperative breast MRI.10,17,18,20-23,26,27,68   
Aim 2b examined the likelihood of whether the women had a second breast cancer 
event, either a recurrence or a second cancer in the contralateral breast. Studies have 
shown that recurrence rates after the completion of adjuvant therapy are 6–13%,90-92 and the 
likelihood of recurrence has been reported to peak within the first five years after primary 
treatment.93-95 A second breast cancer event is an important short-term outcome due to its 
effect on overall survival96 as well as the physiological and physical distress of additional 
cancer treatments. Additionally, anxiety from fear of recurrence or a second breast cancer is 
one of the most prevalent long-term psychological consequences of breast cancer.97-99 
Because of breast MRI sensitivity and enhanced imaging, researchers and clinicians have 
examined whether or not breast MRI can reduce the likelihood of a second breast cancer 
event. One RCT from United Kingdom20 found no significant difference in one-year, local 
recurrence-free interval rates, which is consistent with other retrospective, single institution 
studies reporting that preoperative breast MRI was not associated with reduced local 
recurrence rates.10,24-27 Despite existing evidence examining the effectiveness of 
preoperative breast MRI, there is a dearth of evidence examining the association between 
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breast MRI and the likelihood of a re-excision or second breast cancer event in a sample 
comparable to the US elderly population. 
Aims 2a and 2b used a similar cohort of elderly women described in Aim 1. However, 
for Aim 2a, we limited our sample to women eligible for re-excision by including only women 
with BCS as their initial surgery. Cancer treatment and breast MRI receipt were again 
identified from the Medicare claims. A re-excision was defined as a claim for a breast 
surgical procedure (a breast excision, partial mastectomy, or conversion to mastectomy) 
after the initial surgery but during the initial treatment phase, which ended on the last day of 
treatment before a treatment gap of 90 days. Second breast cancer events were identified 
through an algorithm validated in breast cancer patients using information regarding 
secondary cancers and surgical procedures from claims data and SEER registries.100 To 
control for measured confounders, we used propensity score methods78,79 to estimate the 
association of breast MRI on the likelihood of a re-excision and the hazard of a second 
breast cancer event. Based on previous findings,10,17,20-22,24-27 we hypothesized that the 
group of women who received a preoperative breast MRI would have a similar likelihood of 
a re-excision (Aim 2a) and a second breast cancer event (Aim 2b) as the group of women 
who did not have a preoperative breast MRI. 
As with Aim 1, we used multivariate logistic regression in the analyses for Aim 2 to 
determine each patient’s propensity for receipt of preoperative breast MRI on the basis of 
observed patient and surgical facility characteristics.80 Again, we selected from the 
previously mentioned variables based on their hypothesized relationship with breast MRI 
receipt and outcome (re-excision or second breast cancer event). 
The third study aim focused on the costs associated with breast MRI for elderly 
breast cancer patients in the US from the perspective of Medicare. Funds spent on breast 
cancer, the most expensive cancer diagnosis, are estimated at $16.5 billion, which comprise 
13.3% of total healthcare spending. Based on US population changes alone, it has been 
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estimated that national expenditures for breast cancer will increase by 24.2% and reach 
$20.5 billion by 2020.101 Spending on breast cancer is not only growing due to increased 
prevalence, but also due to escalating treatment costs per patient.102-104 Studies also have 
estimated that the inflation-adjusted cost of initial care for each breast cancer patient 
increased by 25% from $16,775 in 1991 to $20,964 in 2002.105 Stakeholders view the 
increasing cost of cancer care as a major societal issue that may impact the health of the 
US population and exacerbate disparities in care and outcomes.106 Rising costs have 
prompted the American Society of Clinical Oncology (ASCO) to create a task force on the 
cost of cancer care to examine the drivers of increasing cancer costs, their impact, and 
strategies to modulate them in order to sustain progress against cancer and universal 
access to high-quality care.106,107 
The rising cost of breast cancer treatment has been attributed to changes in 
treatment patterns and the increased use of targeted therapies and supportive medicine.102-
104 Additionally, it has been estimated that the growing use of advanced imaging contributes 
to the accelerating cost of breast cancer care, with the costs of advanced imaging 
increasing at a greater rate than total costs among Medicare beneficiaries with cancer.2,3 
Preoperative breast MRI is an example of an advanced imaging modality that is being 
rapidly adopted, and research has shown that breast MRI may change treatment patterns in 
ways that may affect the cost of the initial treatment phase through additional diagnostic 
work-up21,108,109 and lead to extensive surgical treatment without reducing the likelihood and 
cost of re-excision surgeries.17,18,20-22 Because of breast MRI’s influence on treatment 
patterns and limited evidence for improved outcomes, it is important to examine the effect 
this imaging has on the overall cost to care for women with breast cancer. No study, to our 
knowledge, has examined the association between breast MRI and the cost of initial 
treatment in the US. The only study to examine the cost of breast MRI was a RCT 
conducted in the United Kingdom.36  
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For the third study aim, we used the same patient sample from Aim 1, or women 
diagnosed with early stage (I-IIB), operable breast cancer from 2004-2007 in the SEER 
registries. Using claims from 2004 through 2009, we identified Medicare payments during 
the initial treatment phase, which we defined to include the diagnostic, preoperative, 
surgical, and adjuvant therapy stages of care. For women with and without a preoperative 
breast MRI, we examined unadjusted all-cause and breast cancer-attributed Medicare 
payments during the initial treatment phase. Further, we used multivariate generalized linear 
models, controlling for the same independent variables as in Aims 1 and 2, to generate the 
adjusted multiplicative and marginal effects of preoperative breast MRI on all-cause or 
breast cancer-attributed Medicare payments. We hypothesized that the overall cost of care 
for older women with breast cancer would be higher for those women who received a 
preoperative breast MRI than for women who did not.20 
The subsequent chapters are organized as follows: (a) Chapter 2 provides an 
overview of the breast cancer burden and a review of the current standards for diagnosis, 
staging, and treatment, including conventional and breast MRI evaluation of breast cancer; 
(b) Chapter 3 describes the methods used in this dissertation, detailing the conceptual 
framework, research questions and hypotheses, data sources, study population, variables 
and measurement, and statistical analyses employed; (c) Chapters 4, 5, and 6 comprise 
Aims 1, 2, and 3, respectively, and each of these chapters is written as a self-contained 
journal manuscript and, hence, includes an overview, introduction, methods, results, and 
discussion (because they are to be submitted for publication, there are some redundancies 
across papers); and (d) Chapter 7 summarizes this dissertation’s strengths and limitations, 
policy relevance, and future research plans.  
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CHAPTER 2: LITERATURE REVIEW
Breast cancer burden in the United States 
Cancer is a major public health problem in the United States (US), both in terms of 
the number of life-years lost and the cost of treatment.  Presently, one in four deaths in the 
US are attributable to cancer, which is the leading cause of death in adults aged 40 to 79.110 
In 2013, it has been estimated that more than 1.6 million Americans will be newly diagnosed 
with cancer and more than half a million people will die from the disease.110 Additionally, 
cancer prevalence is predicted to increase over the next decade with the number of 
estimated cancer survivors in the US increasing from 13.8 million in 2010 to 18.1 million in 
2020.101 
Over the past twenty years, the medical costs of cancer have nearly doubled.111 The 
overall costs of cancer in 2010 have been estimated at $263.8 billion, with direct medical 
costs, indirect morbidity costs, and interect mortality costs comprising $102.8, $20.9, and 
$140.1 billion, respectively.112 Elements contributing to the rising cost of cancer care include 
increasing cancer incidence rates as the population ages, increasing prices for novel 
techniques and chemotherapy agents, and increasing intensity of cancer care.102,103,105,111,113-
115 Stakeholders view the increasing cost of cancer care as a major societal issue that may 
impact the health of the population and exacerbate disparities in care and outcomes.106 
Rising costs have prompted the American Society of Clinical Oncology to create a task force 
on the cost of cancer care to examine drivers of increasing cancer costs, their impact, and 
strategies to modulate them in order to sustain progress against cancer and universal 
access to high quality care.106,107  
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 Breast cancer is the most common cancer among women, with an estimated 3.5 
million breast cancer survivors in the US in 2010,101 and is the second most fatal cancer 
site.110  In 2013, an estimated 234,580 women have been diagnosed with breast cancer and 
an estimated 39,620 are expected to die from the disease.110 Elderly women are most at risk 
for developing breast cancer. The incidence among women age 65 or older is approximately 
five times greater than the incidence among women younger than 65, and risk increases at 
all ages until age 80.116 Breast cancer has a high treatment burden and, as a result of the 
disease and its treatments, health-related quality of life in breast cancer patients is 
significantly diminished through compromised physical, psychological, and social 
functioning.117 In addition, breast cancer presents a significant cost burden in national 
expenditures, which were estimated at $16.5 billion in 2010. This figure constitutes 13.3% of 
total healthcare spending on cancer, more than any other cancer site.112,118 Based on US 
population changes alone, it has been estimated that national expenditures for breast 
cancer will increase by 24.2% and reach $20.5 billion by 2020.101  Spending on breast 
cancer is not only growing due to increased prevalence, but also to escalating treatment 
costs per patient.102-104 It has been estimated that the inflation-adjusted cost of initial care for 
each breast cancer patient increased 25% from 1991 ($16,775) to 2002 ($20,964).105 Thus, 
the significant morbidity, mortality, and cost of treating breast cancer patients result in a 
considerable breast cancer burden in the US. 
Overview of breast cancer diagnosis, staging, and treatment 
After breast cancer is detected, patients have the best chance of a successful 
outcome if the extent of the cancer is accurately identified, diagnosed, staged, and treated 
accordingly. The cancer stage at diagnosis determines the type and extent of disease in the 
body and the type of surgical and/or systemic treatment the patient will receive.119,120  The 
American Joint Committee on Cancer (AJCC) staging system is used by patients and 
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providers to determine prognosis and treatment options.121 The AJCC system (Table 2.1), 
also referred to as the Tumor, Node, Metastasis (TNM) system, is used to ascertain whether 
a cancer is invasive or non-invasive, the size of the tumor (T), how many lymph nodes are 
involved (N), and if the cancer has spread to other parts of the body (M). Patients have a 
better prognosis if cancer is diagnosed at an early stage. Five-year survival rates for women 
diagnosed between 2000-2007 with localized (i.e., confined to primary site), regional (i.e., 
spread to regional lymph nodes), and distant (i.e., metastasized) tumors were 98.6%, 
83.8%, 23.3%, respectively.122 In addition to staging, other tumor factors can influence 
treatment decisions and patient outcomes.  Hormone receptor tests determine whether or 
not the tumor is estrogen receptor (ER) or progesterone receptor (PR) positive. ER/PR 
positive tumors are dependent on estrogen and progesterone to grow and, thus, hormone 
therapy is often recommended to block the cancer cell from using these hormones. Testing 
is available to determine the amount of Human Epidermal Growth Factor Receptor 2, also 
known as HER2/neu, which is a protein that stimulates the growth of breast cancer cells in 
cancerous tissue.  If cancerous tissue has excessive amounts of the protein, the patient 
might be eligible for a targeted therapy that blocks growth of HER2/neu.47 Additionally, the 
nature of the tumor, such as whether or not it is multifocal (i.e., smaller cancer spots 
occurring in the same quadrant of the breast as the main tumor) or multicentric (i.e., smaller 
cancer spots in other quadrants than the one containing the main tumor), can influence 
treatment decisions. ! Multiple treatment guidelines and practice standards exist for the management of 
patients with breast cancer, each with different treatment risks, costs, and outcomes. For 
most women with operable breast cancer, treatment involves local therapy, such as surgery 
and radiation, to remove or destroy the breast cancer, and/or systemic therapy, such as 
hormone therapy, chemotherapy, and targeted therapy.47 Women with early-stage, invasive 
breast cancer may receive a combination of treatments (Figure 2.1). Most women will either 
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undergo BCS or a mastectomy and may possibly have the lymph nodes under an arm 
removed. After the initial surgery, a pathologist examines the excised tumor to see if 
cancerous tissue remains at the margins. If the margins are positive, the patient may need a 
re-excision to obtain negative tumor margins.  
After surgery, many women receive adjuvant therapy to lower the chance of breast 
cancer recurrence.  The National Comprehensive Cancer Network (NCCN) recommends 
that women who undergo BCS also receive adjuvant radiation therapy, or the combination of 
the two, which is known as breast conserving therapy (BCT).47 Women may also receive 
hormone therapy, chemotherapy, targeted therapy, or a combination of these therapies to 
eliminate any remaining cancer and reduce the risk of recurrence. 
Treatment decision-making by a woman diagnosed with early-stage breast cancer is 
complex. Treatment decisions are based on a wide range of biological, physical, emotional, 
economic, and social factors.123-129 These factors include stage of disease, genetic 
indicators, age, family history, and risk of local recurrence. They also include personal 
experiences, concern about radiation exposure, the inconvenience of adding daily radiation 
to a complicated treatment regimen, social factors, educational status, insurance coverage, 
patient preferences regarding physical appearance, and patient fears of recurrence. 
Geographic location and type of clinical care provider also play a role in treatment 
decisions.122 
Since the early 1990s, evidence has shown that BCT and mastectomy are equally 
effective,130 and trials reporting long-term survival have found equivalent outcomes for both 
surgeries.63,131-135 Additional research reported improved quality of life with BCT, which is 
often associated with improved psychosocial health in terms of body image, sexuality, and 
short-term physical functioning.64,65,135-140 In 1990, NCI reported that BCS “is preferable 
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because it provides survival equivalent to total mastectomy while preserving the breast,” and 
professional consensus began to favor the less-invasive surgery.64,132,140 
 After NCI’s 1990 publication, mastectomy rates for early-stage breast cancer 
patients markedly decreased in the United States.141-144 However, recent studies have 
reported that this trend is changing and more patients with early-stage breast cancer are 
undergoing more aggressive surgical treatment. Single institution studies indicate that 
mastectomy rates for early-stage breast cancer patients increased from 35% in 2004 to 60% 
in 2007 at Moffitt Cancer Center,58 from 35% of in 2004 to 60% at the Magee-Women’s' 
Hospital at the University of Pittsburgh,59 and from 31% in 2003 to 43% in 2006 at the Mayo 
Clinic.11  Additional studies using SEER registry data (Figure 2.2) showed that mastectomies 
for elderly women decreased from 2000-2005, but then increased in 2006-2008.38,61  
Research using SEER registries and single institution data145-147 has also documented a 
trend toward more aggressive surgical treatment, which was exhibited by contralateral 
prophylactic mastectomy rate in the US that more than doubled from 1998 to 2003.  
These results have generated significant discussion in the lay press and medical 
literature about how to explain these trends.39,148-151 Some authors have suggested that 
recent changes in preoperative management may explain the changing trend, such as 
genetic testing for BRCA1 and BRCA2 mutations, increased education regarding surgical 
treatment options, concern over the long-term side effects of radiation, and the introduction 
of new or improved imaging modalities (e.g., MRI or digital mammography).11,152-157 
Increased mastectomy rates could also be due to improvements in mastectomy techniques 
and reconstruction options,125,151,158,159 however, this explanation may be more likely in 
younger populations. The findings also suggest a possible global shift in breast surgical 
treatment preferences toward mastectomy, and may reflect a growing patient choice for a 
preventive surgical approach against local recurrence and new primary breast cancers.11 
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 Conventional evaluation of breast cancer 
Breast cancer can be discovered through screening mammograms, routine clinical 
breast exams, breast self-exams, breast symptoms, or routine screening of high-risk 
individuals with breast MRI.47 If a screening mammogram shows an abnormal area of the 
breast or the patient experiences unusual breast changes, such as a lump, pain, tissue 
thickening, nipple discharge, or a change in breast size or shape, it is recommended that the 
patient undergo a diagnostic mammogram. NCCN recommends that all women diagnosed 
with breast cancer be evaluated using standard breast imaging with mammography and, 
when indicated, diagnostic breast ultrasound.47 Suspicious lesions should then be biopsied 
and the presence of malignant cells confirmed by a pathologist.  
 Once the patient has a confirmed diagnosis, the cancer is then staged. According to 
NCCN guidelines, clinical staging includes a physical examination of the skin of the breast, 
mammary glands, and lymph nodes, as well as imaging and pathologic examination of the 
breast or other tissues.47 Based on the physical examination and imaging results, the cancer 
is then staged based on the size of primary tumor, chest wall invasion, and presence or 
absence of regional or distant metastasis according to the AJCC staging system described 
earlier.  
Breast MRI evaluation of breast cancer  
Although the diagnostic mammogram has been the imaging gold standard to 
determine the extent of disease, MRI has been used increasingly in the preoperative 
evaluation of women with newly diagnosed breast cancer to provide enhanced cancer 
detection during the past ten years.1,2,5-16 There is strong evidence demonstrating that breast 
MRI has improved sensitivity over mammography to detect additional cancerous 
disease;17,19,160 however, it has not been shown that breast MRI improves patient outcomes, 
such as re-excision rates17,18,20-22 or local recurrence.10,20,24-27   Thus, the use of preoperative 
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breast MRI to detect additional disease in the absence of evidence for improved patient 
outcomes has become a controversial issue in breast cancer management.12,17-19,24,160-174    
Several consensus-based guidelines state that the use of preoperative breast MRI to 
evaluate the extent of disease for surgical planning is optional and may be used in addition 
to conventional assessment.47,49,175,176 For example, NCCN does not advocate for or against 
the use of routine preoperative breast MRI for the assessment of ipsilateral breast cancer, 
but instead, recommends that decisions to use MRI are made in concert with the 
multidisciplinary treatment team and any alteration in surgical management should be 
considered after the MRI-detected lesion is biopsied due to the high rate of false positive 
findings.47 NCCN also recommends that breast MRI should “generally be considered” in the 
staging of breast cancer for patients whose breasts were inadequately imaged with 
mammography and ultrasound (e.g., women with dense breast tissue or positive axillary 
nodal status and occult primary tumor presumed to originate in the breast). Further, the 
guidelines state that breast MRI may be useful for detecting additional disease in women 
with mammographically dense breasts, but the evidence does not show differential detection 
rates for any subset by breast pattern (breast density) or disease type (e.g., ductal 
carcinoma in situ (DCIS), invasive ductal cancer, or invasive lobular cancer). The European 
Society of Breast Cancer Specialists (EUSOMA) working group provides additional selection 
criteria for preoperative MRI, including women with lobular cancer, patients under 60 years 
of age with a tumor size discrepancy greater than one centimeter between mammography 
and ultrasound, and patients at high risk for breast cancer.49 The EUSOMA group also 
recommends that women newly diagnosed with breast cancer should always be informed of 
the potential risks and benefits of preoperative MRI before undergoing the test. 
It is worth noting that evidence exists for the use of breast MRI in a limited number of 
other clinical settings. For example, breast MRI has been recommended to screen high-risk 
women,12,40-47 to investigate an occult primary breast cancer in patients presenting with 
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metastatic cancer in axillary nodes,12,47 to examine patients considering partial breast 
irradiation,12,49 and to evaluate tumor response to neoadjuvant chemotherapy.48-54 These 
indications are beyond the scope of this study, which focuses on the use of breast MRI to 
preoperatively evaluate the extent of disease for surgical planning.  
Strong evidence demonstrates that breast MRI is highly sensitive and has the ability 
to detect suspicious lesions not visible with mammography or ultrasound. Numerous articles 
have been published summarizing the sensitivity and specificity of breast 
MRI,17,31,69,162,163,166-169,177,178 including three meta-analyses.17-19 One meta-analysis of 19 
published studies, including 2,610 breast cancer patients undergoing preoperative MRI, 
reported that MRI detected additional disease in 16% of women.18 However, the authors 
found that breast MRI had limited specificity with a summary positive predictive value of 
66%.  An additional meta-analysis of women with newly diagnosed breast cancer showed 
that MRI detected abnormal contralateral lesions not seen on conventional imaging in 9.3% 
of women.19 However, more than half of these lesions were false positives, and the authors 
found a true-positive to false-positive ratio of 0.92, indicating that MRI does not reliably 
distinguish benign from malignant findings.19 Consistent with previous data, a third meta-
analysis, including 50 articles and 10,881 women, found that MRI detected additional 
disease in 20% of women, but had limited specificity with a summary positive predictive 
value of 67%.17 
Because of its increased sensitivity, research has shown that the use of breast MRI 
may influence surgical planning and treatment patterns for newly diagnosed breast cancer 
patients. Numerous studies have shown that patients with a preoperative breast MRI have 
an increased likelihood of more extensive surgery compared to those patients without 
preoperative breast MRI. A recent meta-analysis of newly diagnosed breast cancer 
patients,22 including two randomized controlled trials20,21 and four comparative cohort 
studies10,23,26,68 that included a total of 3,112 subjects, demonstrated consistent evidence 
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that preoperative MRI significantly increased the odds of having mastectomy, either as initial 
surgery [OR, 2.22 (P < 0.001); adjusted OR, 3.06 (P < 0.001)] or as a complete surgery 
[OR, 1.54 (P < 0.001); adjusted OR, 1.51 (P < 0.001)]. These findings are consistent with 
previous meta-analyses17,18 and recently published single institution studies,69-77 which found 
that preoperative breast MRI leads to more extensive surgeries based on additional findings 
from the MRI. Some findings suggest that the changes in surgical management were not 
always beneficial and some modifications toward more extensive surgery were based on 
false-positive results.17,18,33,179,180 In their meta-analysis, Houssami and colleagues found 
that, based on true-positive MRI findings, 8.1% of women were converted from wide local 
excision to mastectomy and 11.3% from wide local excision to more extensive surgery, such 
as wider/additional excision or mastectomy.18 Based on false-positive MRI results, 1% of 
patients converted to mastectomy and 5.5% converted from wide local excision to more 
extensive surgery. Authors of an additional meta-analysis reported similar results with true-
positive MRI findings, prompting conversion to more extensive surgery in 12.8% of women, 
however, this conversion was based on false-positive findings in 6.3% of these women.17 
Although one randomized, prospective clinical trial examining the impact of breast MRI 
(MONET) found that the BCS rate did not significantly differ between groups with and 
without breast MRI,21 another randomized, prospective clinical trial (COMICE) observed that 
7% of the breast MRI group underwent a mastectomy at the initial operation compared to 
1% of the no MRI group, and 2% of all MRI patients had a pathologically avoidable 
mastectomy.20,36 
Existing evidence also suggests that the receipt of breast MRI may delay initial 
treatment. This delay could be due to additional diagnostic work-up needed for a breast 
MRI, including managing breast MRI findings that may require MR-guided needle 
biopsy.21,108,109 One study by Bleicher and colleagues found that women who underwent 
breast MRI experienced a 22-day increase in the time period from diagnosis to initial surgery 
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when compared to women who did not receive a breast MRI.23 Another study by Krishnan 
and colleagues reported a delay for patients receiving a breast MRI of 27-41 days.5 A third 
study found that patients with breast MRI had a longer median time to treatment (43 days) 
than those who did not (32 days).15  The authors suggest that these delays were possibly 
related to the fact that imaging and biopsy prompted by MRIs were sometimes performed 
outside their breast center. Though these results are worthy of note, they were single 
institution studies and do not reflect nationwide treatment patterns.  
Because breast MRI is a sensitive imaging technology that may be associated with 
more extensive surgeries and treatment delay, it is important to examine whether MR breast 
imaging offers clinical benefit.  One assumption related to breast MRI is that its use results 
in improved surgical precision by helping to plan resection of the tumor, thus, reducing  re-
excision rates for incomplete excisions, local recurrences, or distant metastases. However, 
based on current literature, documentation of the benefits of breast MRI for improved 
outcomes is limited. Research has shown that the routine rate of positive margins after BCS 
is high, ranging from 17% to 60%.72,82-86 However, evidence suggests that breast MRI does 
not reduce the need for re-excision compared to routine standard of care (Table 
2.2).10,20,21,23,26,27,68 For example, in the COMICE trial, the authors found that there were no 
differences in secondary outcomes between. the groups who did and did not receive breast 
MRIs.20 Nineteen percent of the patients in both the MRI group and the non-MRI group 
needed re-excision. In the MONET randomized trial, the number of re-excisions after initial 
breast conserving surgery was greater in the MRI group compared to the control group 
(34% versus 12%).21 Furthermore, a meta-analysis including 3,112 newly diagnosed breast 
cancer patients reported no differences in the odds of having positive margins or re-excision 
surgery for women with and without preoperative breast MRI.22 
Studies have also shown that recurrence rates are similar for patients with and 
without breast MRI (Table 2.3).10,20,24-27 For example, in the COMICE trial, the local 
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recurrence-free interval rate at one year was 99.87% for patients randomized to the MRI 
group when compared with 99.73% for patients randomized to the non-MRI group.20,36 Four 
additional, single institution studies10,24-27 showed that recurrence rates did not differ 
significantly between groups. Only one study25 reported that patients with preoperative 
breast MRI had fewer local recurrences than patients without breast MRI (1.2% vs. 6.8%, 
respectively; p-value <0.001), but it is worth noting that this study did not control for 
differences between the groups. 
The juxtaposition of breast MRI’s superior sensitivity to detect additional breast 
cancer tumors over conventional imaging and the lack of evidence for improved clinical 
outcomes has led some researchers to suggest that the majority of additional cancer 
detected by breast MRI may not be of clinical relevance.12,20,23,85,164,171,172 Rather, these 
additional cancer tumors may be adequately managed by radiotherapy or systemic 
therapy12,23,39,171,172,181 and, therefore, the increased rate of mastectomy, possible treatment 
delay, and additional work-up procedures following MRI may not always be justified.  
Current breast MRI utilization  
Despite uncertainty surrounding the clinical benefits of routine use of breast MRI in 
women with a new cancer diagnosis, breast MRI has been increasingly adopted in practice.  
One recent study found that the percentage of early-stage breast cancer patients 
undergoing a breast MRI from 2003 to 2006 by stage were: a) ductal carcinoma in situ, 7%; 
b) stage I, 15%; and c) stage II, 22%.  The percentage of all patients receiving a breast MRI 
increased from 10% in 2003 to 23% in 2006.11  Additionally, the proportion of older patients 
with newly diagnosed, invasive breast cancer receiving breast MRI increased from 1.2% in 
2002 to 18.8% in 2007 (Figure 2.3).13  
Recent publications have suggested ways to optimize the benefits of breast MRI as a 
preoperative tool.47,166,182 Patients with the potential for greater benefit include women: a) 
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with mammographically dense breasts; b) with a unilateral multifocal/ multicentric cancer; c) 
with synchronous bilateral cancer already diagnosed at mammography and ultrasound; d) 
with invasive lobular carcinoma; e) at high-risk for breast cancer based on a BRCA mutation!
or family history; f) with a cancer that shows a discrepancy in size of >1 cm between 
mammography and ultrasound; or g) who are under consideration for partial breast 
irradiation.47,166,182  
Despite these recommendations, evidence suggests that breast MRI is being 
differentially adopted and the variation is unlikely to be related to differing patient clinical 
characteristics alone.  One study of radiologists found that academic practices were more 
likely to perform screening breast MRI than nonacademic practices (83.2% vs. 58.5%).8 This 
finding is consistent with previous results showing that the adoption of medical technologies 
is associated with teaching status, academic affiliation, case volume, research activity, 
medical/training culture, institutional characteristics, specific attributes of the technology, 
and the political and economic climate.183,184 Sommer and colleagues found that women 
were more likely to receive an MRI if they were recently diagnosed, younger, white, or 
Hispanic.1 This unequal adoption is consistent with studies documenting racial disparities in 
treatment patterns in women with breast cancer.185-187 Additionally, these authors found that 
diagnostic breast MRI use was associated with geographic variation.  Women living in more 
urban areas, areas of higher income, and areas with a greater proportion of high school 
graduates were most likely to receive breast MRI. Significant differences also were found in 
the overall utilization rate of MRI between SEER regions. The percentage of women 
receiving MRI ranged from 0.85% in the Hawaii SEER region to 18.0% in New Mexico. 
These findings are consistent with previous literature documenting regional variations in 
care among the Medicare population.64,188 The variability in the adoption of breast MRI is 
also consistent with research showing that test or treatments with uncertain evidence to 
support their utility are more likely to be inconsistently adopted into practice.189  
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 Medicare covers diagnostic breast MRI scans that are considered reasonable and 
necessary if they are performed with FDA-approved MRI equipment. Local Medicare 
contractors have the ability to determine the circumstances under which an MRI scan is 
covered. Some contractors have selective coverage for MRI breast imaging, depending on 
the patient’s diagnosis. The amount paid for MRI scans ranges from $800 to $2,000 
compared to $85 to $150 for mammograms. The amount that a patient may pay for these 
screenings can vary considerably across the United States.190 
Limitations of current breast MRI research 
The current breast MRI literature is limited in several aspects. First, much of the 
evidence is based on multiple studies from single institutions and two randomized controlled 
trials. There is a dearth of evidence examining the effect of MRI on surgical planning, 
outcomes, and cost in a population comparable to the US elderly population. The patients 
and medical groups participating in the RCTs and single institution studies were highly 
selective and the study populations were not comparable to the US elderly population. For 
example, the median and mean ages for the RCTs were 5720 and 55.5,21 two decades 
younger than the average age of breast cancer patients enrolled in Medicare28 and the 
average patient in our study (76.1 years).  
Second, to our knowledge, there is a dearth of evidence examining the impact of 
breast MRI on surgical planning or short-term outcomes in older women. Elderly women are 
least likely to benefit from breast MRIs because they are more likely to have less dense 
breasts and fewer occult tumors with conventional assessment.30-33 Despite the perceived 
lack of benefit, as much as 20% of elderly women with newly diagnosed breast cancer may 
be receiving breast MRI.13 Thus, examining the risks and benefits of preoperative breast 
MRI in this subset of the population is warranted. 
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Third, the two randomized controlled trials mentioned previously were conducted in 
the Netherlands21 and the United Kingdom20,36 where physician practice patterns and patient 
preferences for mastectomy over BCT differ significantly from those in the US.37-39 Thus, the 
effect of preoperative breast MRI on surgical planning and outcomes in the US may be 
different than results from European studies. 
Fourth, to our knowledge, no study has examined the association between breast 
MRI and the cost of initial treatment in the US. The only study to examine the cost of breast 
MRI was a randomized controlled trial conducted in the United Kingdom36 where payment, 
referral structures, health insurance coverage, and fiscal considerations are different than 
those in the US. 
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Table 2.1.  American Joint Committee on Cancer breast cancer staging definitions  
In Situ Breast Cancer 
Stage 0 Ductal carcinoma in situ and lobular carcinoma in situ and has not spread to 
lymph nodes 
Early-stage Invasive Breast Cancer 
Stage I Tumor measures 2 cm or less and has not spread to lymph nodes 
Stage IIA No evidence of a tumor but cancer has spread to lymph nodes under arm on 
the same side as the cancer; OR 
Tumor is 2 cm or less and has spread to lymph nodes under arm but no other 
lymph node involvement; OR 
Tumor is between 2-5 cm and has not spread to any lymph nodes 
Stage IIB Tumor measures between 2-5 cm and has spread to only lymph nodes under 
the arm on the same side as the cancer; OR 
Tumor is >5 cm but has not spread to any lymph nodes 
Advanced-stage Invasive Breast Cancer 
Stage IIIA Tumor is any size and cancer has spread to lymph nodes under arm on the 
same side as the cancer and possibly other lymph nodes as well 
Stage IIIB Tumor is any size and has spread to breast skin or chest wall and possibly 
lymph nodes 
Stage IIIC Tumor is any size and may have spread to lymph nodes near the sternum or 
collarbone, but not other parts of body 
Metastatic Breast Cancer 
Stage IV Tumor is any size and has spread to other parts of body 
Note:  Created using information from American Joint Committee on Cancer (AJCC) with permission.  Breast.  In:  
AJCC on Cancer: AJCC Cancer Staging Manual, 6th edition.  New York, NY:  Springer, 2002, pp. 227-228. !
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HER2, Human Epidermal Growth Factor Receptor 2. 
*Excluding women with large tumors eligible for neoadjuvant chemotherapy 
** With possible lymph node procedure 
Created using information from NCCN Guidelines National Comprehensive Cancer Network. (2009). "NCCN Clinical 
Practice Guidelines in Oncology." nccn.org,  
  from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp and with the input of oncologists (Muss, Reeder-
Hayes) and breast surgeon (Amos) 
 
  
Figure 2.1.  Initial tests and treatment pathways for early-stage, invasive breast  
   cancer  !
Diagnostic work-up 
•  Medical history and physical exam to assess general health and symptoms 
•  Complete blood count and chemical tests 
•  Diagnostic bilateral (both breasts) mammogram, ultrasound as needed  
•  Pathology review of biopsy sample  
•  Determination of tumor estrogen/progesterone receptor status and HER2 status  
•  Genetic counseling if patient is high risk for hereditary breast cancer  
Other studies for breast imaging:  
•  Breast MRI  
Positive margin? 
Mastectomy**  
Primary surgical treatment options  
for Stages I-llB* 
 
Breast conserving surgery (BCS)** 
Follow-up care,  
including monitoring for a second breast cancer event 
Depending on lymph node involvement, possible 
chemotherapy, and/or radiation therapy to the chest 
wall, supraclavicular area and/or the lymph nodes next 
to the breast bone and endocrine therapy for hormone 
receptor positive women 
 
Negative margin? 
Re-excision 
(either BCS or mastectomy) 
Radiation therapy to the entire breast with or without 
added boost to tumor site and clavicle area 
Chemotherapy if needed based on stage, hormone 
receptor status and HER2 status  
Endocrine therapy for hormone receptor positive women 
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Figure 2.2. Mastectomy rates by age at diagnosis, 2000–2008 !
Reprinted with permission from Mahmood U et al. Ann Surg Oncol 2012 Nov 8. [Epub ahead 
of print] !
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Figure 2.3. Percent MRI use among elderly women diagnosed with ductal carcinoma in 
situ or locally invasive breast cancer from SEER-Medicare, 2002–2007 
Reprinted from Tuttle, T. M., S. Jarosek, et al. Use of Preoperative MRI Among Older Women with Ductal 
Carcinoma in Situ (DCIS) and Early Invasive Breast Cancer: Use of Preoperative Breast MRI (2012), AHRQ 
public domain publication No. 12-EHC086-EF.!
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CHAPTER 3: METHODS OVERVIEW
Overview and study design 
The goal of this dissertation was to examine the effects of preoperative breast MRI 
on secondary outcomes and costs for elderly women with breast cancer. This retrospective 
analysis included women aged 66 or older with early-stage (I-IIB), operable breast cancer 
diagnosed between January 1, 2004 and December 31, 2007 from SEER-Medicare data. 
The independent variable of interest for all three study aims was whether or not the patient 
received a preoperative breast MRI. In Aim 1, the dependent variables of interest were: (a) 
the time elapsed from the date of the first claim for a suspected breast disorder to the date 
of complete surgical treatment; and (b) whether or not the initial type of surgery was a 
mastectomy or breast conserving surgery (BCS). In Aim 2, the dependent variables of 
interest were: (a) whether or not the patient had a re-excision after her initial breast cancer 
surgery; and (b) whether or not the patient experienced a second breast cancer event. In 
Aim 3, the dependent variables of interest were total all-cause and total breast cancer-
attributable Medicare payments per patient during the initial treatment phase. We controlled 
for tumor, demographic, and provider characteristics in our multivariate analyses and, for 
Aims 1 & 2, used propensity score methods to control for measured confounders associated 
with the initial receipt of breast MRI based and our outcomes of interest. 
Conceptual framework: Cancer Care Continuum 
We examined our three aims using a framework adapted from Zapka and 
colleagues’ cancer care continuum.119,120 This framework (Figure 3.1) provided us with a 
systematic approach for assessing factors that influence cancer outcomes across the span 
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of care, including risk assessment, primary prevention, screening, detection, diagnosis, 
treatment, recurrence surveillance, and end-of-life care. Potential failures during the process 
of care are manifested in two ways: (a) first, as breakdowns in specific types of care 
delivered to individuals at different points in the history of their cancer (short vertical arrows); 
and (b) second, as breakdowns during the transitions between these types of care (long 
vertical arrows).  Specifically, this study focused on the diagnosis, treatment, recurrence, 
and surveillance phases of care (Figure 3.1a).   
For the present study, our main independent variable of interest was whether or not 
the patient received a breast MRI in the diagnosis phase. The outcomes of interest were the 
timing and type of initial surgery (Aims 1a & b), re-excisions in the treatment stage (Aim 2a), 
and a second breast cancer event in the surveillance stage (Aim 2b). Procedures and 
treatments in the diagnosis and treatment stage influence the cost of care during the initial 
treatment phase (Aim 3 outcome of interest). As Figure 3.1 illustrates, characteristics of the 
patient and the cancer itself contribute to the various outcomes. Thus, it was important to 
control for cancer characteristics such as tumor size, nodal involvement, tumor histology, 
hormone receptor status, and patient characteristics, including age, in our models. 
Factors at many levels affect the process of cancer (Figure 3.2). These factors 
influence: (a) the receipt of breast MRI; (b) the delivery of high quality cancer care; and (c) 
short- and long-term outcomes and costs.119 Elements in the immediate practice setting that 
can affect cancer care include clinician/team characteristics, such as professional group 
affiliation or medical training, as well as patient characteristics, such as their social support 
system. Clinician/team level factors could include whether or not the medical group is 
affiliated with an academic medical center or the group’s culture of routine preoperative 
breast MRI utilization. At the community level, factors may consist of the availability of 
radiation facilities and healthcare, or MRI utilization practices in a given metropolitan 
statistical area (MSA).  Given that these factors may influence both the receipt of 
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preoperative breast MRI and short-term outcomes as well as cost, it was important to control 
for them in our analyses. Because our study focused on the association between 
preoperative breast MRI, surgical planning, and outcomes, we considered the surgical 
provider as the provider of interest. 
Research questions and hypotheses 
Aim 1: To examine the association between preoperative breast MRIs and surgical 
planning.  Specifically, to determine: (a) the time elapsed from the date of the first 
suspected breast disorder to the date of complete surgical treatment; and (b) the 
initial type of breast cancer surgery. 
H1a: Older women with breast cancer who received a preoperative breast MRI will 
be more likely to experience a delay in surgical treatment surgery than those women who 
did not have a breast MRI. 
H1b: Older women with breast cancer who received a preoperative breast MRI will 
be more likely to have a mastectomy as their initial surgery than those women who did not 
have a breast MRI. 
Aim 2: To examine the effect of preoperative MRI on the likelihood of a re-excision 
(2a) and a second breast cancer event (2b). 
H2: Elderly women with breast cancer who received a preoperative breast will have 
the same likelihood of a re-excision (Aim 2a) and a second breast cancer event (Aim 2b) as 
those women who did not have a breast MRI. 
Aim 3: To examine the effect of preoperative MRI on the costs to Medicare during the 
initial treatment phase. 
H3: The total all-cause and total breast cancer-attributable Medicare payments per 
patient during the initial treatment phase will be higher for those patients who received 
breast MRI than for those patients who did not. 
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Data  
This retrospective study used data from the Surveillance, Epidemiology, and End 
Results (SEER)-Medicare linked dataset.191 The SEER-Medicare dataset comes from a 
consortium of population-based cancer registries across the United States linked to 
Medicare administrative data and healthcare claims. The SEER-Medicare data have been 
used to examine various factors across the cancer care continuum, including 
sociodemographics, physician and hospital characteristics, surgery, chemotherapy, 
radiation, comorbidities, complications, screening, relapse, and costs (See Medical Care 
2002 Medicare Supplement;40 (8S):IV).  
The SEER data comprise 17 registries nationwide and cover approximately 25% of 
the incident US cancer population. The data contain demographic and incident cancer 
characteristics, including histology, grade, and stage, as well as treatment information and 
vital statistics for people living in Connecticut, Detroit, Hawaii, Iowa, New Mexico, Utah, 
Alaska, California, Kentucky, Louisiana, New Jersey, metropolitan areas of Atlanta, San 
Francisco-Oakland, Los Angeles, San Jose-Monterey, Seattle-Puget Sound, and rural 
Georgia. The SEER data also contain ecological measures of income, education, and other 
characteristics at each patient’s census tract and zip code of residence. The population 
covered by the program is comparable with the US general population with regard to 
measures of poverty and education.191 
Medicare covers hospital services, physician services, some drug therapy, and other 
medical services for more than 97% of Americans aged 65 and older. Medicare data include 
information about the use and cost of health care services and co-morbid health conditions. 
The National Cancer Institute (NCI) hospital file contains hospital-level information, including 
staffing, structure, research network affiliation, and information on accreditation.192 
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Study population and inclusion/exclusion criteria 
The present study included women with a primary diagnosis of unilateral, 
pathologically confirmed breast cancer identified from SEER-Medicare data (American Joint 
Committee on Cancer [AJCC] sixth edition, International Statistical Classification of 
Diseases and Related Health Problems, 9th revision, clinical modification [ICD-9-CM] code 
147) (Table 3.1). Women were included if they were diagnosed with their first primary, 
unilateral breast cancer between January 1, 2004 and December 31, 2007, and had no 
previous cancers. Focusing on elderly breast cancer patients, we excluded women who 
were younger than 66 at diagnosis and women enrolled in Medicare for renal disease or 
disability. We excluded women who were diagnosed at autopsy or death. We also excluded 
women who were not continuously enrolled in Medicare Part A and Part B, and women who 
were enrolled in a health maintenance organization (HMO) during the study period because 
these beneficiaries had incomplete claims in the SEER-Medicare dataset. As a result, we 
were unable to examine their healthcare utilization in its entirety. The NCI comorbidity index 
was calculated based on 12 months of claims. Thus, women not enrolled 12 months prior to 
diagnosis were excluded.  
Additional exclusion criterion (Figure 3.3) included limiting our analysis to women 
with stage I-IIB operable breast cancer whose first definitive treatment was surgery, thus 
excluding women who received neoadjuvant chemotherapy prior to surgery (n=435). These 
women were eliminated because breast MRI can also be used to measure tumor response 
to neoadjuvant chemotherapy,50-54 which is not the focus of the present study. We also 
excluded patients who had conflicting claims for mastectomy and partial mastectomy on the 
same day in the Medicare outpatient setting, inpatient setting, and physician files (n=647). 
We excluded these women because we were unable to determine the type of initial surgery. 
Data from this sample of women (n=25,038) was utilized for analyzing the time to surgery 
(Aim 1a). 
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Aim 1b & 2b. In the analyses examining the initial type of surgery (Aim 1b) and 
second breast cancer event (Aim 2b), we excluded women who had their first biopsy or 
breast surgical procedure more than four months before or after the SEER diagnosis month 
(n=599) because we were concerned that those surgical claims did not correspond to the 
first primary breast cancer identified from the SEER registry.  
Aim 2a. For the analysis examining re-excision (Aim 2a), we excluded those women 
who had a mastectomy as their first surgical procedure (n=4,631) because re-excisions after 
mastectomies are rare and unlikely.83 In our sample of women who had a mastectomy as 
their first surgery, only 2.0% had a re-excision. We excluded women who died within a year 
of diagnosis in order to have enough time to observe if the women underwent a re-excision.  
We also excluded women who were diagnosed with a second primary cancer identified in 
SEER within 12 months of diagnosis because we would not have been able to determine 
whether the surgery was a re-excision or a surgical treatment for the second primary tumor. 
Aim 3. In the analysis examining costs to Medicare (Aim 3), the sample of women 
was identical to those included in the assessments for Aims 1b and 2b, however, we 
excluded those women who did not have a breast surgical procedure within a year of the 
first suspected breast disorder (n=846) in order to ensure we were capturing the correct 
initial treatment period. We also excluded women died within a year of diagnosis or while in 
active treatment (n=629). We eliminated these women and because research has shown 
that healthcare utilization and cost is significantly different in the terminal phase of care than 
in the initial phase of care,192-198 which is the focus of this study. The final analytic sample for 
Aim 3 was 22,947 women. 
Variables and measures 
Initial treatment phase. We examined all claims during the initial treatment phase 
(Table 3.2) from 2004 through 2009. We defined the initial treatment phase to capture the 
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diagnostic, preoperative, and initial treatment stages and to include healthcare utilization 
from when the patient was first suspected of having breast cancer up through the end of 
each patient’s initial treatment. The start of the initial treatment phase began on the date of 
the first claim for a suspected breast disorder (e.g., lump or mass in breast, or an abnormal 
mammogram) one year prior to the SEER diagnosis month. We defined the end of the initial 
treatment phase as the last day of breast cancer treatment before a treatment gap of more 
than 90 days,93,95,199 the patient’s death, or the end of the study period, which was 
December 31, 2009. We identified healthcare utilization, breast cancer events, and 
Medicare payments during the initial treatment phase by reviewing the Medicare outpatient, 
carrier, and Medicare Provider Analysis And Review (MEDPAR) files using the following 
coding systems: (a) American Medical Association Current Procedural Terminology (CPT); 
(b) Healthcare Common Procedure Classification System (HCPCS); and (c) ICD-9-CM 
codes. 
For each aim, our independent variable of interest was a binary indicator for whether 
or not the patient received a preoperative breast MRI. Patients were classified as having a 
preoperative breast MRI if they had a claim for a breast MRI (CPT: 76093-94, 77058-59,!
HCPCS: C8903-C8908) on or after the first day of suspected breast disorder but before the 
date of their first surgical procedure. Though this approach may capture breast MRIs that 
were ordered for screening purposes, we are not concerned about including these breast 
MRIs as “preoperative” because breast images taken during the initial treatment phase, 
even for screening purposes, would most likely be used as a part of the surgical planning 
process (Dr. Keith Amos. Personal communication. May 23, 2012). 
Outcome variables. The outcome variables in our study are defined in Table 3.4. We 
examined the association between breast MRI and surgical planning (Aim 1) with the time to 
complete surgery (Aim 1a) and whether or not the initial surgery was a mastectomy (Aim 
1b). We examined whether or not the patient had a re-excision (Aim 2a) and the time to a 
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second breast cancer event (Aim 2b) when assessing short-term outcomes (Aim 2). We also 
examined the association between breast MRI and all-cause and breast cancer attributable 
payments during the initial treatment phase (Aim 3). 
Control Variables and Measures. Based on the cancer care continuum (Figure 3.1) 
and factors that impact the processes of care, we included patient (Table 3.5), medical 
group, and community-level factors (Table 3.6) to control for these variables’ association 
with whether or not the patient received an MRI and their impact on health outcomes. 
Patient-level covariates (Table 3.5) included year of diagnosis (2004-2007) and age at 
diagnosis. Because social support has been associated with improved outcomes, we 
controlled for marital status.200,201 As an indicator of the patient’s financial resources, we 
controlled for Medicare state buy-in coverage status. We controlled for race because 
research has shown that race may be associated with treatment selection and outcomes. 
We also controlled for co-morbidities using the NCI Combined Index81 to address competing 
health demands and risks of complications that may affect treatment selection. Person-level 
tumor characteristics included stage, grade, histology, and tumor size as well as hormone 
receptor status identified from SEER data. These tumor and biological characteristics are 
important measures of cancer severity.  
We controlled for several surgical facility characteristics (Table 3.6) that could be 
associated with breast MRI receipt and affect breast cancer outcomes. We identified the 
facility where the first surgical procedure took place and linked it to the NCI Hospital file, 
which includes measures for whether or not the facility was a teaching hospital, a 
designated NCI Cancer Center, and had on-site radiation facilities.  We also examined 
facility ownership type (i.e., for-profit vs. not-for-profit) and constructed a variable for whether 
or not the facility was affiliated with NCI Cooperative Groups having breast cancer research 
portfolios, including the American College of Surgeons Oncology Group, Eastern 
Cooperative Oncology Group, Cancer and Leukemia Group B, Southwest Oncology Group, 
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and the National Surgical Adjuvant Breast and Bowel Project.183 We also included a variable 
measuring breast cancer surgical volume (low volume vs. high volume). To construct this 
variable, we used the number of breast cancer surgeries (partial/full mastectomy) for each 
surgery site from 2004-2009. 
To measure resource availability within the community, we used ecological variables, 
including median income and percentage of high school graduates at the zip code level, 
unique to each patient for their zip code of residence at diagnosis. Since geographic region 
and health services area may influence breast MRI practices and availability, we also 
included SEER registry region as a variable. 
Analyses 
Aims 1 & 2. For each aim, we compared unadjusted baseline characteristics 
between the groups of women with and without a preoperative breast MRI using Pearson 
chi-squared tests for categorical variables and Student’s t-tests for continuous variables. To 
estimate the association of each covariate on the likelihood of receiving breast MRI, we 
used multivariate logistic regression. We calculated odds ratios, 95% confidence intervals 
(CI), and two-sided p values for each predictor.  
Because baseline characteristics for elderly women who receive a preoperative 
breast MRI may systematically differ from women who do not, in Aims 1 and 2 we used 
propensity score methods80 to balance the groups of women with and without breast MRI on 
measured covariates and to control for potential confounders. Propensity score methods 
have been previously used when examining SEER-Medicare data.202-206  
First, we developed propensity scores to estimate the probability, on the basis of 
observed patient and surgical facility characteristics described above, that patients would 
have a breast MRI using multivariate logistic regression.80 We selected covariates to include 
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in the logistic regression based on their hypothesized relationship with breast MRI receipt 
and the outcome of interest (either time to complete surgery or initial type of surgery).207  
Second, we adjusted for differences between the groups that did and did not receive 
a breast MRI using inverse probability weighting.78,79 To create balance, each patient with a 
breast MRI was weighted by the inverse of the probability that she would be selected for a 
breast MRI based on her covariates, and each patient without a breast MRI was weighted 
by the inverse of the probability that she would not have a breast MRI. We then stabilized 
these weights by multiplying the inverse probability weights by the marginal prevalence of 
the breast MRI receipt.208,209 
To assess balance and the performance of the propensity model, we examined the 
distribution of propensity scores and covariates between the two groups (MRI vs. no MRI), 
examining balance by decile of propensity score.210 We also used standardized differences 
to compare the distribution of baseline covariates between the two groups before and after 
inverse probability weighting.211 We examined excluding women with non-overlapping 
propensity score distributions (i.e., women without a preoperative breast MRI who had a 
propensity score higher than the maximum or lower than the minimum propensity score of 
women with preoperative breast MRI).210 To reduce bias due to unmeasured confounders, 
we also assessed asymmetrically trimming patients who were treated most contrary to 
prediction.208 We examined trimming patients at three different cut points corresponding to 
the 1st and 99th percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles 
at the tails of the propensity score distribution in the treated (i.e., breast MRI) and untreated 
(i.e., no breast MRI) patients, respectively.  
In the analyses examining the time until complete surgery (Aim 1a) and the time to a 
second breast cancer event (Aim 2b), we generated unadjusted survival curves using the 
Kaplan-Meier method.56 We estimated adjusted survival curves using inverse-probability 
weighting approach from Cole and Hernan.212 The adjusted curves represent the expected 
 !
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rate of the event (i.e., surgery or a second breast cancer event): (1) if all study patients had 
a MRI; and (2) if all study patients did not have an MRI.  We estimated the median time to 
the event for both groups after adjusting for the inverse-probability weights and used 
bootstrap methods to obtain 95% confidence intervals. We estimated hazard ratios using the 
Cox proportional-hazards model,213 generating unadjusted estimates and estimates (a) 
adjusted for covariates and (b) adjusted using inverse-probability weighting. We evaluated 
the proportional hazards assumption by graphical methods using Schoenfeld residuals.214 
In the analyses estimating the likelihood of a mastectomy as the first surgical 
procedure (Aim 1b) and the likelihood of a re-excision (Aim 2a), we used multivariate logistic 
regression weighted with the inverse probability weights and robust standard errors.78,215  Z-
test statistics and 95% confidence intervals were used to examine the difference in the 
likelihood of a re-excision between those women with and without a breast MRI. 
Aims 3. Descriptive statistics were calculated for patients with and without a 
preoperative breast MRI.  We tested for differences in the clinical, demographic, and 
treatment characteristics across patients with and without breast MRI using the Pearson chi-
squared test for categorical variables and the Student’s t-test for continuous variables. We 
also used t-tests in our bivariate analyses of breast MRI receipt and different measures of 
healthcare utilization and cost.  
In our multivariate analyses examining the association between breast MRI and cost, 
we fitted a generalized linear model with a log-link and gamma distribution variance function 
with robust standard errors.216,217  We used a log transformation to normalize the cost 
distribution, which is typically highly skewed.44 Because all of the women in our sample had 
surgery within our study’s timeframe, almost all women had Medicare payments during the 
initial treatment phase and two-part models were not required.218,219  
Diagnostic and procedure codes were identified and verified using medical literature, 
coding experts, EpiCoder (Yost Engineering Inc., Ohio) and the Integrated Cancer 
 !
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Information and Surveillance System coding references.220 Analyses were performed using 
Stata version 12.0 (Stata Corporation, College Station, Texas). All tests were conducted 
using a minimum significance level of 0.05. 
 !!!! !
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Table 3.1. SEER-Medicare inclusion/ exclusion criteria 
Inclusion Criteria Included Excluded 
Breast cancer diagnosis in SEER 260,079  
Diagnosed between 2003 and 2007 (inclusive) 143,757 116,322 
First or primary cancer 131,974 11,783 
Age 66 or older at diagnosis 86,127 45,847 
Female 85,367 760 
Reporting source not autopsy or death certificate 84,466 901 
Laterality is not bilateral or unknown 83,659 807 
Original reason for Medicare entitlement not disability or ESRD 79,355 4,304 
Has valid month of diagnosis 79,114 241 
Has no HMO enrollment during study period* 56,652 22,462 
Has continuous enrollment in Part A&B during the study period* 52,038 4,614 
Has comorbidity score and was able to be matched to claims during the 
study period* 48,283 3,755 
Diagnosed between 2004 and 2007** 39,652 8,631 
*Study period is 12 months prior to diagnosis month until the end of data or death 
ESRD, end stage renal disease; HMO, Health Maintenance Organization; SEER, Surveillance, Epidemiology 
and End Results  **!We excluded patients diagnosed in 2003 because few patients (n=148) had a breast MRI, and were unable 
to be balanced using propensity scores. 
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SEER, Surveillance, Epidemiology and End Results 
* Meeting SEER-Medicare inclusion requirements of aged 66 or older at diagnosis, reporting source 
not autopsy or death certificate, laterality not bilateral or unknown, original reason for Medicare 
entitlement not disability or end stage renal disease, valid month of diagnosis, no health maintenance 
organization enrollment during study period, continuous enrollment in Parts A & B during the study 
period, comorbidity score and was able to be matched to claims during the study period. Study period 
is defined here as the 12 months prior to diagnosis month till the end of data or death 
** The sample for Aim 3 also excluded those women who did not have a breast surgical procedure 
within a year of the first suspected breast disorder (n=846) or died within a year of diagnosis or while 
in active treatment (n=629) for a sample of 22,947 women 
† Breast surgical procedure includes breast excision, partial/subtotal mastectomy and mastectomy 
‡ Breast conserving surgery is defined as breast excision or partial/ subtotal mastectomy 
 
!!  
Figure 3.3. Inclusion/exclusion criteria schematic, all study aims 
 Women diagnosed with their first primary breast cancer in SEER in 2004-2007* 
n= 39,652  
INCLUDED EXCLUDED 
Medicare claims identified conflicting surgical  
procedures on the same day;  
receipt of cancer treatments prior to surgery 
n=1,082 
Known Stage I-IIIA disease, tumor size <5cm, 
histology codes indicating malignant breast cancer 
N=26,751   
Stage 0 or IV disease, stage unknown; tumor size 
greater than 5cm; histology codes indicating in situ/
non-malignant disease or non-breast primary tumors 
n=12,901 
Able to determine the first definitive surgical treatment 
and have no prior cancer treatments before surgery 
n= 25,669   
Patients with a breast surgical procedure 
Linkable to their surgical provider  
n= 25,038  
Unable to link patient to her surgical provider  
n= 631  
Sample for the analysis examining time to surgery (Aim 1a)  
n= 25,038  
INCLUDED EXCLUDED 
INCLUDED EXCLUDED 
Did not have a second primary cancer identified  
in SEER  
n= 22,348  
Had a second primary cancer identified in SEER  
within 12 months of diagnosis 
n= 2,091  
Alive 12 months after diagnosis  
n= 21,830  
Died within 12 months of diagnosis 
n= 518  
Had breast conserving surgery‡  as the 
first surgical procedure 
n= 17,199  
Had mastectomy as the first surgical procedure  
n= 4,631  
Sample for the analysis examining the likelihood of a re-excision (Aim 2a) 
n= 17,199  
Had a first biopsy or breast surgical procedure†  
Within 4 months of SEER diagnosis month 
n= 24,439  
First breast breast biopsy or surgical procedure† claim  
more than 4 months from SEER diagnosis month   
n= 599  
Sample for the analysis examining the likelihood of a mastectomy as the initial surgery (Aim 1b),  
the hazard of a second breast cancer event (Aim 2b), and cost (Aim 3**) 
n= 24,439  
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Table 3.2 Definition of study timeframe 
Construct Definition 
Suspected breast 
disorder diagnosis 
codes 
174.*     Malignant neoplasm of female breast 
217.      Benign neoplasm of breast 
233.0    Carcinoma in situ of breast 
238.3    Neoplasm of uncertain behavior of breast 
239.3     Neoplasms of unspecified nature breast 
610.0     Solitary cyst of breast 
610.1     Diffuse cystic mastopathy 
610.2     Fibroadenosis of breast 
610.3     Fibrosclerosis of breast 
610.9     Benign mammary dysplasia, unspecified 
611.0     Inflammatory disease of breast 
611.1     Hypertrophy of breast 
611.3     Fat necrosis of breast 
611.8     Other specified disorders of breast 
611.9     Unspecified breast disorder 
611.71   Signs and symptoms in breast 
611.72   Lump or mass in breast 
611.79   Signs and symptoms in breast 
793.80   Abnormal mammogram, unspecified 
793.81   Mammographic microcalcification 
793.89   Other (abnormal) findings on radiological examination of 
breast 
V711      Observation for suspected malignant neoplasm 
First suspected breast 
disorder date 
The day of the first breast diagnosis code listed above within one year 
prior to the SEER diagnosis month 
Initial treatment phase 
All claims from the first claim with a breast diagnosis code to the end 
of the initial treatment as defined as the last day of treatment before a 
gap in treatment of 90 days or more or the end of the study period 
(December 31, 2009) or patient’s death. 
SEER, Surveillance, Epidemiology and End Results !
  69!
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Table 3.3. Identification of breast magnetic resonance imaging  
Treatment Primary means of identification Years Effective 
Unilateral 
without and/or with contrast material(s); CPT Code: 76093 1/1/2007-Present 
without and/or with contrast material(s); CPT Code: 77058 1/1/1995-12/31/2006 
with contrast HCPCS Code: C8903 10/1/2001-Present 
without contrast HCPCS Code: C8904 10/1/2001-Present 
without contrast followed by with contrast HCPCS Code: C8905 10/1/2001-Present 
Bilateral 
without and/or with contrast material(s); CPT Code:76094 1/1/2007-Present 
without and/or with contrast material(s); CPT Code: 77059 1/1/1995-12/31/2006 
with contrast HCPCS Code: C8906 10/1/2001-Present 
without contrast HCPCS Code: C8907 10/1/2001-Present 
without contrast followed by with contrast HCPCS Code: C8908 10/1/2001-Present 
Notes:  HCPCS:  Healthcare Common Procedure Classification System; CPT:  Current Procedural 
Terminology. 
 
Table 3.4. Outcome by aim 
Aim Outcome Definition 
Aim 1a Time to complete surgery 
Time in days from the date of the first claim for a 
suspected breast disorder until the date of last surgical 
procedure (i.e.!partial or full mastectomy) in the initial 
treatment phase 
Aim 1b Initial surgery a mastectomy 
First surgical procedure a mastectomy as compared to 
breast conserving surgery (i.e. breast excision or partial 
mastectomy) 
Aim 2a Re-excision 
Additional breast surgical procedure (i.e. breast excision, 
partial mastectomy, or full mastectomy) after the initial 
surgery during the initial treatment phase 
Aim 2b Time to 2
nd breast cancer 
event 
Time in days from the date of the first claim for a 
suspected breast disorder until the date of the second 
breast cancer event identified through a validated 
algorithm (Chubak et al. 2012) 
Aim 3 
 
All-cause Medicare payments 
 
The sum of Medicare payments from all claims during 
the initial treatment phase from the outpatient, carrier, 
and MEDPAR files (including claims for ED, long and 
short-term inpatient, and skilled nursing facility stays) 
Aim 3 Breast cancer-attributable payments 
The sum of Medicare payments from claims with breast 
biopsy, breast surgery, chemotherapy, radiation, 
mammogram, ultrasound, breast MRI or from a claim 
with a breast diagnosis code within the claim’s first four 
diagnosis codes during the initial treatment phase. 
Claims from the outpatient, carrier, and MEDPAR files 
were included. 
MRI, Magnetic resonance imaging; ED, emergency department; MEDPAR, Medicare Provider 
Analysis And Review !
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Table 3.5. Patient characteristics 
Construct Dimension Measure/Variable Data Source 
Patient 
characteristics 
Age Age at diagnosis PEDSF-SEER 
Residential area Rural/urban residence PEDSF-ARF 
Medicaid 
enrollment 
Any indication of dual Medicaid coverage PEDSF-EDB 
Social/familial 
support 
Marital status PEDSF-SEER 
Race/ethnicity White PEDSF-SEER 
Non-white PEDSF-SEER 
Tumor/biological 
characteristics 
Extent of 
disease 
Stage PEDSF-SEER 
Cellular 
differentiation 
Histologic grade PEDSF-SEER 
Molecular 
subtypes 
Estrogen receptor status PEDSF-SEER 
Progesterone receptor status PEDSF-SEER 
Tumor size Tumor size in cm PEDSF-SEER 
Heath status/ 
healthcare 
utilization  
Co-morbid 
conditions 
NCI- co-morbidity index  MEDPAR; carrier claims; 
outpatient claims 
Time  Time Year of diagnosis SEER – PEDSF 
Notes: AHA, American Heart Association; ARF,!Area Resource File; EDB, Enrollment Data Base; MEDPAR, 
Medicare Provider Analysis and Review; PEDSF, Patient Entitlement and Diagnosis Summary File; SEER, 
Surveillance, Epidemiology and End Results; NCI, National Cancer Institute !!
Table 3.6. Surgical facility and community characteristics 
Dimension Measure/Variable Data Source 
Surgical facility-level 
factors  
High routine preoperative breast MRI utilization PEDSF-SEER 
Bed size of surgical facility NCI Hospital file 
ACOSOG group affiliation of surgical facility NCI Hospital file  
Teaching status of surgical facility NCI Hospital file  
On-site radiation at surgical facility NCI Hospital file  
Surgical facility type/ownership NCI Hospital file 
NCI affiliation of surgical facility NCI Hospital file 
Surgical hospital location (rural/urban) NCI Hospital file 
Area/ aggregate 
socioeconomic 
status 
Percent of census tract (2000) with less than high 
school education 
PEDSF-Census 
Median census tract (2000) income PEDSF-Census 
Geographic region SEER registry PEDSF-SEER 
Notes: ACOSOG, American College of Surgeons Oncology Group; ARF, Area Resource File; PEDSF, 
Patient Entitlement and Diagnosis Summary File; MRI, Magnetic Resonance Imaging; MSA, Metropolitan 
Statistical Area; NCI, National Cancer Institute; SEER, Surveillance, Epidemiology and End Results. !
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CHAPTER 4: THE ASSOCIATION BETWEEN PREOPERATIVE BREAST MRI, SURGICAL DELAY, AND 
TYPE OF INITIAL SURGERY IN ELDERLY BREAST CANCER PATIENTS
 
Overview 
Magnetic Resonance Imaging (MRI) has been used increasingly in the preoperative 
evaluation of women with newly diagnosed breast cancer in addition to conventional 
assessment. Despite its increasing utilization, some research suggests that using MRI for 
preoperative planning leads to more extensive surgeries and treatment delay with limited 
evidence of clinical benefit. This study examines the relationship between preoperative 
breast MRI and: (a) time from the first date of suspected breast disorder to complete surgical 
treatment; and (b) the type of first surgical procedure in a large, population-based cohort of 
older women with early-stage breast cancer.  
In this observational, retrospective analysis, we identified women diagnosed with 
early-stage (I-IIB), operable breast cancer from 2004-2007 in the Surveillance, 
Epidemiology, and End Results registry data linked to Medicare claims. Cancer treatment 
and breast MRI receipt were identified from the Medicare claims. Time from the first the 
suspected breast disorder (e.g., lump or mass in breast or abnormal mammogram) to 
complete surgical treatment was defined as the number of days from the first breast-related 
diagnosis code claim to the last surgical procedure before a gap in treatment claims of at 
least 90 days. The first surgical procedure was defined as the first surgery that was either a 
breast conserving surgery (partial mastectomy or a breast excision) or a full mastectomy. To 
control for measured confounders, we used propensity score methods. 
We identified 25,038 women who meet our inclusion criteria for the time to surgery 
analysis and 24,439 women who meet our inclusion criteria for the type of initial breast 
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surgery analysis. Twelve percent of women in both samples received a preoperative breast 
MRI. The unadjusted median time to complete surgery was 53 days for patients without a 
breast MRI and 63 days for patients with a breast MRI (p<0.001). Using inverse probability 
weighting, having a preoperative breast MRI was associated with a median 15-day delay in 
the time to complete surgery (95% CI: [11, 19]; HR: 0.90, 95% CI: [0.85, 0.95]). More than 
one-fifth (22.3%) of women in our sample had a mastectomy as their first surgical procedure 
(22.0% of no MRI group; 24.1% MRI group). After adjustment using inverse probability 
weighting, having a breast MRI was associated with a significant increase in the odds of 
having a mastectomy (OR: 1.30, 95% CI [1.12, 1.50]). 
Given that preoperative breast MRI was associated with a slight delay in the time to 
complete surgery and an increased likelihood of mastectomy, healthcare providers and their 
patients should consider these factors when making informed decisions about the use of 
breast MRI for elderly women with breast cancer. Further research should examine the 
impact of preoperative MRI on outcomes such as reoperation rates, recurrence, and 
survival.  
Introduction 
During the past ten years, breast magnetic resonance imaging (MRI) has been used 
increasingly in the preoperative evaluation of women with newly diagnosed breast cancer, 
providing enhanced cancer detection and supplementing conventional assessment, which 
includes clinical examination of the breasts, mammography and ultrasound, and 
pathological assessment of suspicious lesions.1-8 Breast MRIs used as a part of 
preoperative surgical planning to measure the extent of disease are reported to be highly 
sensitive and capable of detecting suspicious lesions not visible with mammography or 
ultrasound, but are limited in their specificity.9-19 Two European randomized controlled trials 
(RCT) and multiple retrospective single institution studies have suggested that breast MRI 
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may not provide as much benefit as expected, resulting in treatment delay and more 
extensive surgeries without clear evidence of clinical benefit.12,18-21 However, despite use, 
the effect that breast MRI has on initial surgical planning and surgical delay remain unknown 
in the elderly US population. 
Research has shown that the use of preoperative breast MRI may influence 
treatment patterns for newly diagnosed breast cancer patients. First, the receipt of breast 
MRI has been associated with a delay in surgical treatment. Single institution studies report 
a 22- to 41-day increase in the time period from diagnosis to surgery for women with breast 
MRI when compared to those women without breast MRI.22-24 Second, breast MRI has been 
associated with an increased likelihood of mastectomy compared to breast conserving 
surgery (BCS).12,18,25-30 In two meta-analyses, true-positive MRI findings prompted 
conversion to more extensive surgery in 11-13% of women, however, changes in surgical 
management were not always beneficial as 5-6% of women converted from wide local 
excision to more extensive surgery based on false positive results.12,18 Two European 
randomized, prospective clinical trials have examined the efficacy of breast MRI.20,21,31 One 
trial from the Netherlands (n=149) found that the type of initial surgery did not significantly 
differ (p = 0.776) between the groups with (32% received mastectomy) and without breast 
MRI (34% received a mastectomy).21 Conversely, the other randomized trial from the United 
Kingdom (n=1,623) found that significantly more patients underwent a mastectomy at the 
initial operation in the MRI group (7%) compared to the patients in the group without an MRI 
(1%).20,31  
Existing evidence examining the association between breast MRI with treatment 
delay and the type of initial surgery is limited in several aspects. First, much of the evidence 
is based on studies from single institutions rather than nationally representative populations. 
The patients and medical groups in the RCTs and single institution studies were highly 
selective and not generalizable to US elderly population. For example, the median and 
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mean ages for the RCTs were 5720 and 55.5 years,32 two decades younger than the average 
age of breast cancer patients enrolled in Medicare33 and the average patient in our study 
(76.1 years).  Second, to our knowledge, there is a dearth of evidence examining the impact 
of breast MRI on surgical planning in older women, a population that is least likely to benefit 
from breast MRIs because older patients are more likely to have less dense breasts and, 
therefore, fewer occult tumors with conventional assessment.27,34-36 Third, the two 
randomized controlled trials were conducted in the Netherlands21 and the United 
Kingdom20,31 where physician practice patterns, payment and referral structures, fiscal 
considerations, and patient preferences for mastectomy over BCT differ significantly from 
the United States (US).37-39  
The present study examined the association between preoperative MRI with time 
from the date of first suspected breast disorder (e.g., lump or mass in breast, or abnormal 
mammogram) to complete surgery and the likelihood of a mastectomy as the first surgical 
procedure in a population-based sample of newly diagnosed, elderly breast cancer patients 
in the US. Since evidence suggests that elderly women who receive breast MRI differ from 
women who do not receive breast MRI on baseline characteristics such as age, race, and 
health service area resources,2 we attempted to balance the groups of women with and 
without breast MRI on measured covariates and to control for potential confounders using 
propensity score methods. Thus, this observational analysis generates estimates about the 
association of breast MRI with breast cancer treatment patterns that may reflect real world 
practice in the US elderly population. The evidence generated by this study is intended to 
inform the decision-making process regarding the benefits and drawbacks of breast MRI 
and help determine its appropriateness for routine utilization.  
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Methods 
Data 
We conducted a retrospective study using data from the Surveillance, Epidemiology, 
and End Results (SEER)-Medicare linked dataset. The SEER-Medicare dataset comes from 
a consortium of population-based cancer registries across the United States linked to 
Medicare administrative data and healthcare claims.40 The SEER dataset comprises 17 
registries nationwide and cover approximately 25% of the incident US cancer population, 
and the population covered by the program is comparable to the overall US population with 
regard to measures of poverty and education.40 The data contain demographic and incident 
cancer characteristics, including histology, grade, and stage as well as treatment information 
and vital statistics. The SEER data also contain ecological measures of income, education, 
and other characteristics at each patient’s census tract and zip code of residence.  
Medicare covers payment for hospital services, physician services, some drug 
therapy, and other medical services for more than 97% of Americans aged 65 and older.41  !
The Medicare claims provide information about the use and cost of health care services and 
co-morbid health conditions. The National Cancer Institute (NCI) hospital file contains 
hospital-level information, including staffing, structure, research network affiliation, and 
information on accreditation.41   
Study Population 
 This study included women aged 66 or older with an initial diagnosis of unilateral, 
pathologically confirmed, stages I-IIB operable breast cancer (American Joint Committee on 
Cancer [AJCC] sixth edition, International Statistical Classification of Diseases and Related 
Health Problems, 9th revision, clinical modification [ICD-9-CM]) code 147). Our sample 
included women diagnosed between January 1, 2004 and December 31, 2007. Since this 
study focused on the effect of breast MRI in elderly patients, we excluded women enrolled in 
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Medicare due to end-stage renal disease or disability since they might differ from those 
women eligible for Medicare on the basis of age. We also excluded women with previous 
cancers, women who were not continuously enrolled in Medicare Part A and Part B, and 
women who were enrolled in a health maintenance organization (HMO) during the study 
period. We were concerned that these beneficiaries would have incomplete claims in the 
SEER-Medicare dataset, and we would be unable to examine their healthcare utilization in 
its entirety. A comorbidity index was calculated based on 12 months of claims, thus, women 
not enrolled 12 months prior to diagnosis were excluded (SEER-Medicare 
inclusion/exclusion table can be found in Appendix Table A.1).       
We limited this analysis to women with operable tumors whose first definitive 
treatment was surgery (Figure 4.1). Thus, we excluded patients with operable breast cancer 
who had large tumors (T3, tumor > 5cm across) (n=2,114) because BCS is generally not 
recommended for these women in the absence of neoadjuvant therapy.42 We also excluded 
women who received neoadjuvant chemotherapy prior to surgery (n=435). We eliminated 
these women because breast MRI also can be used to measure tumor response to 
neoadjuvant chemotherapy,43-47 and our research focuses on the use of preoperative breast 
MRI to measure the extent of disease in the breast as a part of preoperative surgical 
planning.  We also excluded patients who had conflicting claims for mastectomy and partial 
mastectomy on the same day in the Medicare outpatient setting, inpatient setting, and 
physician files because we were unable to determine the type of initial surgery (n=647).  For 
the analysis examining the initial type of surgery, we excluded women who had their first 
biopsy or breast surgical procedure more than four months from the SEER-diagnosis month 
(n=599) because we were concerned that the claims did not correspond to the correct SEER 
registry tumor sequence. Our SEER-Medicare inclusion/exclusion criteria are displayed in 
Figure 4.1. 
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Type of first surgical procedure (main analysis and sub-samples). When examining 
the type of first surgical procedure, we conducted a main and sub-analysis using two 
different definitions of breast conserving surgery (Figure 4.2). In our main analysis, we 
liberally defined BCS as a breast excision or partial mastectomy (for procedure codes, see 
Appendix Table A.2). In our sub-analysis, we conservatively defined BCS as a partial 
mastectomy alone and excluded women whose first surgery was a breast excision 
(n=6,497). We conducted both analyses because our study focuses on the use of 
preoperative breast MRI on therapeutic surgical planning, and previous research has 
classified claims for breast excisions as both a diagnostic procedure48,49 and as breast 
conserving surgical treatment.50-52 Since it is not possible to differentiate between breast 
excisions that were intended to be curative (i.e., BCS) rather than diagnostic (i.e., open 
biopsy) using claims data, we limited our sample to women definitive therapeutic surgeries 
(i.e., partial or full mastectomy) in our sub-analysis.  
Variables and Measures 
We examined all claims in Medicare outpatient, inpatient, and physician claims files 
during each patient’s initial treatment phase from 2004 through 2009. The initial treatment 
phase was defined to capture the diagnostic, preoperative, and initial treatment stages. The 
start of the initial treatment phase began on the date of the first claim for a suspected breast 
disorder53 (e.g., lump or mass in breast, or abnormal mammogram; see Appendix Table A.2 
for codes) 12 or fewer months prior to the SEER diagnosis month. We defined the end of 
the initial treatment phase as the last day of breast cancer treatment (i.e., partial 
mastectomy, mastectomy, radiation, or chemotherapy; for codes, see Appendix Table A.2) 
before a treatment gap of more than 90 days,62-64 the patient’s death, or the end of the study 
period, which was December 31, 2009. We identified breast cancer treatments and surgical 
procedures during the initial treatment phase using the American Medical Association 
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Current Procedural Terminology (CPT) and the Healthcare Common Procedure 
Classification System (HCPCS) codes (See Appendix Table A.2).  
The main independent variable of interest was a binary indicator for whether or not 
the patient received a preoperative breast MRI. Patients were classified as having a 
preoperative breast MRI if they had a claim for a breast MRI (CPT: 76093-94, 77058-59, 
HCPCS: C8903-C8908) on or after the first day of suspected breast disorder but before the 
date of their first surgical procedure. Though this approach may capture breast MRIs that 
were ordered for screening purposes, we are not concerned about including these breast 
MRIs as “preoperative” because breast images taken during the initial treatment phase, 
even for screening purposes, would most likely be used as a part of the surgical planning 
process (Dr. Keith Amos. Personal communication. May 23, 2012). For women in our time to 
surgery analysis without complete surgical treatment, we defined “preoperative” MRI as a 
breast MRI claim after the first day of suspected breast disorder but before their first breast 
excision (n=167) or four months after their SEER diagnosis (n=23) . 
Time to surgery. We measured time to complete surgery as time from the first 
suspected breast disorder date to the last surgical treatment (either a partial or full 
mastectomy) in the initial treatment phase. For several reasons, we used suspected breast 
disorder date, identified by the first claim with a breast-related diagnosis code within one 
year prior to the patient’s SEER diagnosis, rather than diagnosis date. First, SEER registry 
data only include the month and year, thus, the day of diagnosis was not available. Second, 
women can receive preoperative breast MRIs before (as a screening procedure) or after (as 
a diagnostic or preoperative procedure) their date of diagnosis; thus, we were concerned 
with underrepresenting exposure time by using date of diagnosis. Third, we wanted to 
ensure that the start of follow-up did not differ by our exposure of interest (i.e., breast MRI). 
To examine the appropriateness of using the first claim with breast-related diagnosis code 
as the start of follow-up, we examined the distributions and time to breast events for each of 
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the breast-related diagnosis codes (see Appendix Table A.3) and determined it was a 
suitable start date. We used the date of complete surgery as our endpoint to include the 
initial surgery and re-excision to obtain clear margins.  
Type of initial surgery. Using Medicare claims, we constructed a binary variable to 
indicate that a patient had a mastectomy compared to BCS as her first surgical procedure. 
In the main analysis, as previously mentioned (Figure 4.2, Appendix Table A.2 for codes), 
BCS was liberally defined as either a breast excision or partial mastectomy. In the sub-
analysis, BCS was more conservatively defined as a partial mastectomy and women with 
breast excisions as their first surgery were excluded.  
Additional covariates. We examined numerous variables that could potentially be 
associated with breast MRI receipt and/or our outcomes of interest to include in our 
propensity score and multivariate models. We included a variable for tumor histology 
(ductal, lobular, mixed ductal lobular, and other; see Appendix Table A.2 for codes) because 
research has shown that lobular tumors are more likely to be mammographically occult and, 
thus, patients have the potential for greater benefit from breast MRI.17 Other tumor 
characteristics examined included grade (well, moderately, poorly undifferentiated, and 
undetermined), tumor size (<2cm vs. ≥ 2cm & < 5cm), any node positivity (yes vs. no), and 
hormone receptor status identified from SEER data [positive (ER+/PR+, ER+/PR-, ER+/no 
PR data, ER-/PR+, or no ER data/PR+), negative (ER-/PR-), unknown]. We used the NCI 
Comorbidity Index method to address competing health demands and risks of complications 
that may affect treatment selection (0, 0-1, >1).57 Demographic characteristics examined 
included age group (in 5-year intervals) at diagnosis, marital status (married vs. unmarried), 
race (white vs. nonwhite), Hispanic ethnicity (yes vs. no), SEER region (grouping together 
[1] the four California registries, [2] the two Northeast registries, and [3] Atlanta and rural 
Georgia) and urban or rural location (urban vs. rural county).  We included quartiles of the 
percentage of high school graduates in a given zip code of residence, and we included a 
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person-level indicator for Medicare state buy-in coverage (yes vs. no) which identified 
women who had their Medicare premiums and deductibles subsidized by the state during 
the study period owing to their financial status.   
We examined surgical facility characteristics that could be associated with breast 
MRI receipt and affect surgical treatment patterns. We identified the facility where the first 
surgical procedure took place and linked it to the NCI Hospital file, which includes measures 
for whether or not the facility was a teaching hospital  (yes vs. no), a designated NCI Cancer 
Center  (yes vs. no), and had on-site radiation facilities  (yes vs. no).  We also examined 
facility ownership type (for-profit vs. not-for-profit) and constructed a variable for whether or 
not the facility was affiliated (yes vs. no) with NCI Cooperative Groups having breast cancer 
research portfolios, including the American College of Surgeons Oncology Group 
(ACOSOG), Eastern Cooperative Oncology Group (ECOG), Cancer and Leukemia Group B 
(CALGB), Southwest Oncology Group (SWOG), and the National Surgical Adjuvant Breast 
and Bowel Project (NSABP).58 We also included a variable measuring breast cancer surgical 
volume (low volume vs. high volume). To construct this variable, we used the number of 
breast cancer surgeries (partial/ full mastectomy) for each surgery site from 2004-2009.  
Statistical Analysis 
We compared unadjusted baseline characteristics between the groups of women 
with and without a preoperative breast MRI using Pearson chi-squared tests for categorical 
variables and Student’s t-tests for continuous variables. To estimate the association of each 
covariate on the crude likelihood of receiving breast MRI, we used multivariate logistic 
regression. We calculated odds ratios, 95% confidence intervals (CI), and two-sided p 
values for each predictor.  
Propensity score methods. Because baseline characteristics for elderly women who 
receive a preoperative breast MRI may systematically differ from women who do not, we 
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used propensity score methods59 to balance the groups of women with and without breast 
MRI on measured covariates and to control for potential confounders. Propensity score 
methods have been previously used when examining SEER-Medicare data.60-64  
First, propensity scores to estimate the probability, on the basis of observed patient 
and surgical facility characteristics described above, that patients would have a breast MRI 
were developed using multivariate logistic regression.59 We selected covariates to include in 
the logistic regression based on their hypothesized relationship with breast MRI receipt and 
the outcome (either time to complete surgery or initial type of surgery).65  
Second, we adjusted for measured baseline differences between the group that 
received a breast MRI and the group that did not using inverse probability weighting.66,67 
Each patient with a breast MRI was weighted by the inverse of the probability that she would 
be selected for a breast MRI based on her covariates, and each patient without a breast 
MRI was weighted by the inverse of the probability that she would not have a breast MRI. 
We then stabilized these weights by multiplying the inverse probability weights by the 
marginal prevalence of the breast MRI receipt.68,69 
To assess balance and the performance of the propensity model, we examined the 
distribution of propensity scores and covariates between the two groups (MRI vs. no MRI), 
examining balance by decile of propensity score.70 Additionally, we calculated the change in 
standardized difference for each variable before and after inverse probability weighting.71 
We examined excluding patients with non-overlapping propensity score distributions (i.e., 
women without a preoperative breast MRI who had a propensity score higher than the 
maximum or lower than the minimum propensity score of women with preoperative breast 
MRI).70,66 To reduce bias due to unmeasured confounders, we also assessed 
asymmetrically trimming patients who were treated most contrary to prediction.68 We 
examined trimming patients at three different cut points corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles at the tails of the 
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propensity score distribution in the treated (i.e., breast MRI) and untreated (i.e., no breast 
MRI) patients, respectively.  
Analytic Approach. In our first analysis examining the time until complete surgery, we 
generated unadjusted survival curves using the Kaplan-Meier method.56 We estimated 
adjusted survival curves using the inverse-probability weighting approach from Cole and 
Hernan.72 We estimated the median time to surgery for both groups after adjusting for the 
inverse-probability weights and used bootstrap methods to obtain 95% confidence intervals. 
We estimated hazard ratios using the Cox proportional-hazards model,73 generating 
unadjusted estimates and estimates (a) adjusted for covariates and (b) adjusted using 
inverse-probability weighting. We evaluated the proportional hazards assumption by 
graphical methods using Schoenfeld residuals74 and did not find any clear violations of the 
proportional hazard assumption.  
In our second analysis estimating the likelihood of a mastectomy as the first surgical 
procedure, we used multivariate logistic regression weighted with the inverse probability 
weights and robust standard errors.66,75  Z-test statistics and 95% confidence intervals were 
used to examine the difference in the likelihood of a re-excision between those women with 
and without a breast MRI. 
Diagnostic and procedure codes were identified and verified using medical literature, 
coding experts, EpiCoder (Yost Engineering Inc., Ohio), and the Integrated Cancer 
Information and Surveillance System coding references.76 Analyses were performed using 
Stata version 12.0 (Stata Corporation, College Station, Texas). All tests were conducted 
using a minimum significance level of 0.05. 
Results 
 Characteristics of the study population. Of the 26,751 women diagnosed during 
2004-2007 in SEER-Medicare with stages I-IIB breast cancer, 25,038 were included in our 
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analysis examining time to surgery (Figure 4.1). After excluding women who had their first 
breast biopsy or surgical procedure claim more than four months before or after their SEER 
diagnosis, 24,439 women were included in our main analysis examining the likelihood of a 
mastectomy.  Over the five-year study period, the percentage of women receiving 
preoperative breast MRI increased dramatically from 5.7% in 2004 to 20.5% in 2007. 
Baseline characteristics for the sample examining time to surgery and the sample examining 
the likelihood of a mastectomy were similar (Tables 4.1 and 4.2) with 12% of women 
receiving a preoperative breast MRI. In the bivariate analysis before adjustment with the use 
of inverse probability weighting, women who received breast MRI differed significantly from 
women who did not for all baseline characteristics except lymph node involvement.  
In our multivariate logistic regression modeling, significant predictors of MRI receipt 
included the likelihood of preoperative breast MRI to generate propensity scores (Table 4.3), 
younger age, fewer comorbidities, lobular carcinoma, and positive hormone receptor status. 
Also, women living in areas with fewer high school graduates or certain SEER regions such 
as New Mexico, Seattle, and California were significantly more likely to get a breast MRI. 
Women not covered by Medicare state-buy in supplemental insurance or who were 
diagnosed more recently had significantly increased odds of receiving a breast MRI.  
Women getting their surgeries at facilities that were cooperative group- or NCI-affiliated, and 
a higher surgical volume were significantly more likely to have a breast MRI.  Women with 
poorly differentiated tumors compared to well differentiated tumors had significantly 
decreased odds of a preoperative breast MRI. 
After using inverse probability weighting, the observed clinical, sociodemographic, 
and surgical facility variables were well balanced (Tables 4.1 and 4.2). In all analyses, 
adjusting for the propensity scores demonstrated substantial improvement in covariate 
balance across the groups with and without breast MRI. After weighting, the absolute 
standardized differences (Appendix Figures A.1 and A.2) were reduced for all observed 
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covariates below the threshold of 10% in absolute value.77 In all analyses, excluding patients 
with non-overlapping propensity scores or trimming patients at the three different cut points 
did not change the significance of our estimates, and only attenuated the effect of breast 
MRI slightly (See Appendix Table D.1 and D.2). Thus, we report the results without 
trimming. Figure 4.3 shows the propensity score distribution of the samples in our analyses. 
 Time to surgery analysis. Overall, 89.2% of women had surgery, 88.6% of the 
group without a breast MRI and 93.7% of the group with MRI (p<0.001).  Of the women who 
had surgery, The unadjusted median time to complete surgery was 53 days for patients 
without a breast MRI and 63 days for patients with a breast MRI (p<0.001).  Unadjusted time 
to surgery curves and time to surgery curves adjusted with the use of inverse probability 
weighting are shown in Figure 4.4. Adjusting for inverse probability weighting, having a 
preoperative breast MRI was associated with a 15-day delay (95% CI: [11, 19]) in median 
days to complete surgery (No MRI group median:  53 days  [95% CI: 53, 55]; MRI group 
median: 68 days [ 95% CI: 63, 71]).  Using proportional hazard modeling (Table 4.4; for full 
models, see Appendix Table A.4), results were consistent with a delay in treatment for the 
MRI group. All adjusted models demonstrate that the hazard of having surgery was 
significantly lower for women receiving a breast MRI when compared to women not 
receiving a breast MRI. For example in the model with inverse probability weights, the 
hazard ratio was 0.90 (95% CI:[0.85, 0.95]).  
 Type of initial surgery. Overall, in our main analysis, 22.3% of women in our 
sample had a mastectomy as their first surgical procedure compared to those women with 
BCS (No MRI group: 22.0%; MRI group 24.1%).  After adjusting for covariates or using 
inverse probability weighting across all models, MRI was significantly associated with an 
increased likelihood of mastectomy (Table 4.5; for full models, see Appendix Table A.5). 
Having a breast MRI was associated with a 30% increase in the odds of having a 
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mastectomy in the model with inverse probability weights (Odds Ratio [OR]: 1.30 [95% CI: 
1.12, 1.50]).  
We found similar results in our sub-analysis of the association of preoperative breast 
MRI with the likelihood of a mastectomy compared to a partial mastectomy as the first 
surgical procedure. Again, MRI was significantly associated with increased odds of a 
mastectomy across all models when adjusted for covariates or using inverse probability 
weighting (Table 4.6, full models see Appendix Table A.7).  In the model using inverse 
probability weights, women with breast MRI had a 20%-increase in the odds of having a 
mastectomy compared to the women who did not have a breast MRI (OR: 1.20 [95% CI: 
1.02, 1.40]). 
Discussion  
 Preoperative breast MRI is becoming more common for elderly women with breast 
cancer as evidenced by 20.5% of women in our sample diagnosed in 2007 receiving a 
preoperative breast MRI. In this large, population-based observational study of elderly 
women with breast cancer, we found that preoperative breast MRI was associated with a 
15-day delay in the time to complete surgery. Additionally, we found that, when compared to 
women who did not receive a preoperative breast MRI, elderly women who underwent a 
preoperative breast MRI were more likely to have a mastectomy as their first surgical 
procedure. Because baseline characteristics of patients who received breast MRI differed 
from the group that did not receive breast MRI, we used multiple multivariable regression 
modeling techniques and propensity score adjustments to balance the groups with and 
without breast MRI on observed characteristics. Across multiple multivariable models and 
differing propensity score method adjustments, the association between breast MRI and 
treatment delay and the likelihood of a mastectomy persisted and remained significant.   
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Our results showed a significant delay in surgical treatment for those patients with 
breast MRI, however, the 15-day delay we estimated is shorter than the 22- to 41-day delay 
that previous studies have reported.22-24 Our estimates may differ from previous research for 
several reasons. First, the estimated delay due to breast MRI may differ due to inconsistent 
definitions of the follow-up start date. Our study used the first claim with a breast-related 
diagnosis code that differed from studies using the actual date of diagnosis or the 
pathologically confirmed date of diagnosis. Second, the shorter delay we found may be 
attributed to the fact that previous studies were single institution studies that may have 
differing referral and diagnostic follow-up patterns than our national sample.  
Although the delay we estimate is statistically significant, it is unclear how much it 
affects patient outcomes. The estimated delay we found would most likely not impact 
survival directly. Evidence suggests that a much larger delay in initial surgery, specifically, 
between three and eight months, is reported to have detrimental effects on five-year survival 
rates for breast cancer patients.78,79 However, studies have shown that any delay in 
treatment can be anxiety-provoking to patients and leads to uncertainties related to the 
interpretation and management of additional findings.79,80 The timeliness of surgery, 
specifically within 30 days of diagnosis, has been proposed as a quality metric80-83 and, 
although we did not estimate the date of diagnosis, the estimated two-week delay 
experienced by the group with MRI generates concern these women are not having surgery 
in a timely manner. 
Some studies have suggested that the delay in surgery may be due to the additional 
diagnostic work-up necessary for breast MRI.23 Because of the low specificity of breast MRI, 
lesions visible on MRI alone should be followed up with MR-guided needle biopsy with 
pathological assessment and, if needed, pre-surgical localization.20,80 Although not the goal 
of this study (See Chapter 6), we found that women with MRI had a higher proportion of 
biopsies and surgical procedures before their completed surgery than the group without 
 ! 103!
breast MRI. Women in the MRI group had a higher proportion of at least two or more 
biopsies (no MRI group: 2.7%, n=604 vs. MRI group: 10.7%, n=325, p<0.001) and at least 
one breast surgical procedure before complete surgery (no MRI group: 17.1%, n=3,766 vs. 
MRI group: 11.5%, n=349, p<0.001). This is concerning in the elderly population, especially 
if breast MRI is not associated with improved outcomes,4,11,12,21-27  because additional 
biopsies and procedures may cause anxiety, increase complications in frail populations, and 
can be difficult to schedule for women with limited transportation options and access to care.  
We found that the odds of having a mastectomy as a first surgical procedure were 
1.30 times greater in the breast MRI group compared to the group without a breast MRI. 
This is consistent with previous literature showing that breast MRI was associated with an 
increased likelihood of mastectomy compared to breast conserving surgery,12,18,25-30 
including the randomized controlled trial from Great Britan.20,31 Recent studies have reported 
that mastectomy rates for early-stage breast cancer patients have increased, and more 
patients with early-stage breast cancer are undergoing aggressive surgical treatment.8,84-86 
Though our estimates of the proportion of patients with a mastectomy (22.3% main analysis, 
30.3% sub-analysis) may appear lower than estimates in the published literature,8,38,84 it is 
important to note these studies use the complete or most extensive surgery as end points, 
which is what was captured in SEER data or reported in other studies using claims.87 
Conversely, we used the initial surgical procedure to examine the association between 
surgical planning and breast MRI. Though not reported, our estimates of the proportion of 
patients with mastectomy as a complete surgical procedure (33.7% main analysis, 37.4% 
sub-analysis) are consistent with previous estimates of mastectomy rates in the US elderly 
population.  
Since evidence has shown that BCS plus radiation, or breast conserving therapy, 
and mastectomy yield equivalent survival outcomes for those patients who are clinically 
eligible for both treatments,88 the decision regarding the type of initial surgery for early-stage 
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breast cancer has been considered a “preference-sensitive decision.”89,90 Treatment 
decisions can be based on a wide range of biological, physical, emotional, economic, and 
social factors.91-96 Although it is possible that the increased rate of initial mastectomies may 
reflect a shift in patient choice towards an aggressive, preventive surgical approach against 
local recurrence and new initial breast cancers despite any expected survival benefit,8 it is 
also important for providers and patients to be aware of other factors, such as breast MRI, 
that may influence the decision-making process and the choice of initial surgery, especially 
in the absence of evidence of improved psychosocial and outcomes survival. For example, 
evidence suggests that women with multi-focal invasive cancer, a type of cancer that breast 
MRI is highly sensitive in detecting, treated with BCS and adjuvant therapy have an 
equivalent survival and risk of recurrence as those patients treated with mastectomy due to . 
advances in adjuvant systemic treatments and radiotherapy.97-101 Thus, it is concerning if 
patients and providers are basing their decision to have a mastectomy over breast 
conserving surgery on additional lesions found with breast MRI that could have been 
controlled with adjuvant systemic treatments and radiotherapy, and might not affect 
recurrence or survival. 
Our study is limited in several aspects. First, in the analysis evaluating the type of 
first surgery, we were unable to differentiate breast excisions that were used as part of a 
diagnostic work-up, as in the case of open biopsies, and those excisions that were intended 
to be therapeutic lumpectomies using claims data. To address this limitation, we employed 
two definitions of breast conserving therapy: (a) one that defined BCS liberally as a partial 
mastectomy or breast excision; and (b) in a sub-analysis, one that defined BCS 
conservatively as a partial mastectomy. In our main analyses, we used a definition of BCS 
that was more specific than our second definition, but less sensitive because it considered 
women who had open biopsies as having had BCS, regardless of whether they went on to 
have a mastectomy. However, relatively few patients in our sample had a breast excision 
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and subsequent mastectomy in the initial treatment phase (7.2%, n=1,806), and only 6.3% 
(n=112) of them had a preoperative breast MRI. These patients would have been correctly 
classified if they had a breast excision as their planned surgical treatment followed by a re-
excision (a mastectomy) to obtain clear tumor margins, or they might have been incorrectly 
classified as having BCS when they actually had an open biopsy followed by a mastectomy 
as their initial surgical treatment. To address this ambiguity, our second conservative 
definition of BCS was intended to mimic the decision between BCS and mastectomy as first 
surgery in a population in which we can be certain the surgery was intended to be a 
treatment. Despite this limitation, we found that, regardless of how we define BCS, women 
in the breast MRI group were more likely to have a mastectomy as their first surgical 
procedure.  
 Second, we do not know exactly how the MRI results influenced the decision-
making process and course of treatment. As previously mentioned, patient preferences play 
a role in treatment selection and the decision-making process for a woman diagnosed with 
early-stage breast cancer is complex.  We do not know based on claims data if the patient 
and physician decided on a mastectomy based on her MRI results or if the decision was 
based on her personal beliefs regarding mastectomy and BCT. 
Third, there are limitations to our study due to the nature of the SEER-Medicare 
dataset. For example, because the SEER-Medicare data only include complete claims for 
fee-for-service  and not for managed care patients, the results of the study may not be 
generalizable to all elderly women. Also, our measures of socioeconomic status were 
limited. Our measure of education was assessed at the census tract of residence, and we 
were unable to disaggregate whether the construct’s effect was related to a person’s 
personal wealth or education level, or if it was related to the resources of the community 
where the person lives. To attempt to mitigate this problem, we included one person-level 
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measure, state-buy in status, which indicated whether the patient ever applied for and was 
enrolled in the Medicare state buy-in program.102 
Fourth, as in most observational studies, we were unable to control for unmeasured 
confounding. Using propensity score methods, we successfully balanced women with and 
without breast MRI on observed clinical, sociodemographic, and surgical facility variables; 
however, we were unable to balance the women on unobserved characteristics that may be 
associated with breast MRI and our outcomes, and thus we are concerned that our models 
are underspecified due to variables not available in our dataset. For example, unmeasured 
confounders could include access to care, care-seeking behavior, healthcare coordination, 
and patient and surgeon preferences regarding the initial type of surgery. These factors may 
be associated with breast MRI receipt and my also influence the likelihood of a mastectomy 
or the time to complete surgical treatment. Future research should apply novel statistical 
methods such as instrumental variable analysis that may more adequately control for 
unmeasured confounding and help strengthen our confidence in these findings that are 
based on the examination of observational data. 
 Fifth, we were unable to control for confounding by indication and differentiate 
between the women who received breast MRI as a part of routine work-up compared to 
those women who were inadequately imaged using conventional assessment (i.e., 
suspected of multifocal or multicentric cancers, had heterogeneously dense breast tissue, or 
experienced a situation where the radiologist read the mammogram or ultrasound and 
recommended that the patient get a breast MRI). Women who are inadequately imaged 
using conventional assessment, such as those women with invasive lobular carcinoma, may 
have a higher baseline risk for mastectomy;17 thus, Future research, should explore 
confounding by indication in sub-analyses of women who are more likely to be inadequately 
imaged by conventional assessment. 
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As new and advanced imaging modalities, such as breast MRI, are introduced into 
clinical practice, it is important to generate evidence about their appropriateness and to 
inform their dissemination into practice. Given that preoperative breast MRI is associated 
with a slight surgical delay of surgery and increased odds of mastectomy for older women 
with breast cancer, healthcare providers and patients should consider breast MRI’s impact 
on the patient’s psychosocial outcomes, such as emotional distress, quality of life, 
satisfaction with the decision-making process, and preferences when deciding to use breast 
MRI preoperatively. Further research should examine the effectiveness of preoperative MRI 
in terms of outcomes, such as reoperation rates, recurrence, and survival in a population-
based sample.  
 ! 108!
!
 
   
SEER, Surveillance, Epidemiology and End Results 
* Meeting SEER-Medicare inclusion requirements of aged 66 or older at diagnosis, reporting source 
not autopsy or death certificate, laterality not bilateral or unknown, original reason for Medicare 
entitlement not disability or end stage renal disease, valid month of diagnosis, no health 
maintenance organization enrollment during study period, continuous enrollment in Part A & B 
during the study period, comorbidity score and was able to be matched to claims during the study 
period. Study period is defined here as the 12 months prior to diagnosis month till the end of data 
or death (For more details see Appendix Table A.1) 
† Breast surgical procedure includes breast excision, partial/subtotal mastectomy and mastectomy 
 
  
Figure 4.1. Inclusion/exclusion schematic for the time to surgery and initial type 
of surgery analyses 
 
Women diagnosed with their first primary breast cancer in SEER in 2004-2007* 
n= 39,652  
INCLUDED EXCLUDED 
Medicare claims identified conflicting surgical  
procedures on the same day;  
receipt of cancer treatments prior to surgery 
n=1,082 
Known Stage I-IIIA disease, tumor size <5cm, 
histology codes indicating malignant breast cancer 
N=26,751   
Stage 0 or IV disease, stage unknown; tumor size 
greater than 5cm; histology codes indicating in situ/
non-malignant disease or non-breast primary tumors 
n=12,901 
Able to determine the first definitive surgical treatment 
and have no prior cancer treatments before surgery 
n= 25,669   
Had a first biopsy or breast surgical procedure†  
Within 4 months of SEER diagnosis month 
n= 24,439  
First breast breast biopsy or surgical procedure† claim  
more than 4 months from SEER diagnosis month   
n= 599  
Patients with a breast surgical procedure 
Linkable to their surgical provider  
n= 25,038  
Unable to link patient to her surgical provider  
n= 631  
Sample for the analysis examining time to surgery 
n= 25,038  
Additional inclusion/ exclusion criteria for the initial type of surgery analysis: 
Sample for the analysis examining the likelihood of a mastectomy as the initial surgery 
n= 24,439  
INCLUDED EXCLUDED 
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BCS, breast conserving therapy. 
* Who meet our inclusion criteria 
 
 
 
 
 
 
 
Figure 4. 2. First surgical procedure comparison group definitions for the main 
and sub-analyses 
 
Patients identified as having BCS 
Initial surgery a partial mastectomy  
Initial surgery a breast excision  
Initial surgery a partial mastectomy 
Patients with  
surgery* 
n= 24,439  
Initial surgery a partial mastectomy 
Initial surgery a mastectomy 
EXCLUDED because the procedure  
could have been for diagnostic rather  
than therapeutic purposes (n=6,497) 
Sub-analysis:  
Mastectomy vs. partial mastectomy 
Main analysis:  
Mastectomy vs. BCS   
Analytic sample 
 for the  
main analysis 
n= 24,439  
Analytic sample 
 for the  
sub-analysis 
n= 17,942  
Patients with  
surgery* 
n= 24,439  
Initial surgery a breast excision  
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Unadjusted data 
 
 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-
value 
No breast 
MRI 
Breast 
MRI p-value 
  
N= 
25,038 
N= 
22,027 
N= 
3,011 N=21,849  N=2,999  
Preoperative breast MRI  (%) 12.0 0.0 100.0 <0.001 0 100 <0.001 
Had surgery (PM/TM) 89.2 88.6 93.7 <0.001 89.0 91.6 0.01 
Time to complete surgery, 
days 
84.8 
(97.9) 
82.0 
(95.6) 
104.1 
(110.7) <0.001 
82.5 
(95.6) 
105.6 
(110.5) <0.001 
Tumor size  (%) 
   
0.004 
  
0.03 
< 2cm 72.5 72.2 74.7 
 
72.6 75.5 
 ≥ 2cm, < 5cm 27.5 27.8 25.3 
 
27.4 24.5 
 Tumor grade  (%) 
   
<0.001 
  
0.95 
       Well differentiated 26.2 26.0 27.8 
 
26.2 26.1 
 Moderately differentiated 43.7 43.4 46.5 
 
43.8 44.2 
 Poorly differentiated 24.5 25.0 20.5 
 
24.4 24.5 
 Grade unknown 5.6 5.6 5.2 
 
5.6 5.2 
 Hormone receptor status  (%) 
   
0.005 
  
0.67 
Positive 78.9 78.6 80.8 
 
78.9 78.3 
 Negative 12.9 13.0 12.4 
 
12.9 13.9 
 Unknown 8.2 8.4 6.8 
 
8.2 7.8 
 Node positivity  (%) 20.6 20.4 21.9 0.06 20.6 20.6 >0.99 
Histology    <0.001   0.58 
Ductal 73.8 74.9 66.3  73.8 74.0  
Lobular 9.8 8.9 16.1  9.8 9.0  
Mixed ductal/lobular 8.0 7.4 12.2  8.0 8.9  
Other 8.4 8.9 5.3  8.4 8.2  
NCI Comorbidity Index (%)  
   
<0.001 
  
0.80 
0 63.3 62.0 73.0 
 
63.5 62.4 
 Between 0 and 1 28.0 28.7 23.0 
 
28.0 28.9 
 Greater than 1 8.7 9.3 4.0 
 
8.5 8.6 
 Age at diagnosis  (%) 
   
<0.001 
  
0.69 
65 to 69 20.3 18.5 33.5 
 
20.4 20.8 
 70 to 74 24.5 23.8 29.6 
 
24.7 25.9 
 75 to 79 24.1 24.5 20.9 
 
24.2 24.5 
 80 to 84 18.8 19.8 11.7 
 
18.8 18.3 
 85 and older 12.3 13.4 4.4 
 
11.9 10.5 
 Married  (%) 45.4 44.2 54.6 <0.001 45.6 45.6 0.97 
State buy-in coverage  (%) 
   
<0.001 
  
0.43 
No 89.0 88.2 94.6 
 
89.2 90.1 
 Yes 11.0 11.8 5.4 
 
10.8 9.9 
 Race  (%) 
   
<0.001 
  
0.50 
White 86.7 86.5 88.6 
 
86.8 87.6 
 Non-white 13.3 13.5 11.4 
 
13.2 12.4 
 Cooperative group affiliation 
of surgical facility  (%)† 51.2 49.5 63.2 <0.001 51.4 50.8 0.69 
NCI affiliation of surgical 
facility  (%) 5.4 5.1 7.5 <0.001 5.4 5.7 0.68 
Surgical facility a teaching 
hospital (or affiliated one) 
 
 
 
52.6 52.1 56.8 <0.001 52.9 56.6 0.02 
Table 4.1. Baseline characteristics of patients for the time to surgery      
analysis (n=25,038) 
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Unadjusted data 
 
 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-
value 
No breast 
MRI 
Breast 
MRI p-value 
  
N= 
25,038 
N= 
22,027 
N= 
3,011 N=21,849  N=2,999  
Surgical volume of surgical 
facility (%) 
   
<0.001 
  
0.70 
Low  49.7 52.1 32.3 
 
49.4 50.0 
 High 50.3 47.9 67.7 
 
50.6 50.0 
 Zip code proportion with at 
least high school education  
    (% in each quartile) 
   
<0.001 
  
0.66 
Low education 24.7 23.0 37.4 
 
24.8 24.4  
Low-medium education 24.1 23.9 25.5 
 
24.3 25.2 
 Medium-high education 23.6 24.0 20.7 
 
23.6 22.2 
 High education 23.6 25.2 12.2 
 
23.3 23.4 
 Unknown education 4.0 4.0 4.3 
 
4.0 4.7 
 Year of diagnosis  (%) 
   
<0.001 
  
0.13 
2004 25.1 26.9 11.9 
 
24.8 22.3 
 2005 24.6 25.5 17.8 
 
24.6 24.6 
 2006 24.9 24.6 27.1 
 
25 24.8 
 2007 25.4 22.9 43.2 
 
25.6 28.4 
 SEER Region (%) 
   
<0.001 
  
0.33 
California registries 32.5 31.5 39.7 
 
32.7 32.2 
 Northeast registries 23.3 22.7 27.2 
 
23.5 26.5 
 Georgia 3.3 3.4 2.9 
 
3.3 2.6 
 Detroit 6.9 7.2 4.8 
 
6.9 6.9 
 Iowa 7.2 7.8 2.8 
 
7.2 5.9 
 New Mexico 2.1 1.8 4.4 
 
2.1 1.8 
 Seattle 6.3 5.6 11.1 
 
6.4 6.8 
 Utah 2.7 2.8 2.3 
 
2.7 2.1 
 Kentucky 7.6 8.3 2.4 
 
7.3 8.3 
 Louisiana 6.9 7.5 2.2 
 
6.8 5.7 
 Hawaii 1.2 1.4 0.2 
 
1.1 1.4 
 p-values by t-test for continuous variables and chi2 test for binary / categorical variables, Mean (Standard 
Deviation) or % 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; PM, Partial 
mastectomy; TM, Total mastectomy; NCI, National Cancer Institute 
†  NCI Cooperative Groups having breast cancer research portfolios 
  
 
 
  
Table 4.1. Baseline characteristics of patients for the time to surgery      
analysis (cont.) 
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Unadjusted data 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= N= 
24,439 
N= 
21,522 
N= 
2,917 N=21,373  N=2,909  
Preoperative breast MRI  (%) 11.9 0 100 <0.001 0 100 <0.001 
Mastectomy as the first 
surgical procedure 
22.3 22.0 24.1 0.01 21.4 26.6 <0.001 
Tumor size  (%)    0.004   0.05 
< 2cm 72.9 72.6 75.1  73 75.6  
≥ 2cm, < 5cm 27.1 27.4 24.9  27.0 24.4  
Tumor grade  (%)    <0.001   0.99 
       Well differentiated 26.3 26.1 27.9  26.3 26.4  
Moderately differentiated 43.8 43.4 46.7  43.9 44.1  
Poorly differentiated 24.5 25 20.4  24.4 24.4  
Grade unknown 5.4 5.4 5.0  5.4 5.1  
Hormone receptor status  (%)    0.004   0.72 
Positive 78.9 78.6 81  79.0 78.4  
Negative 13 13.1 12.3  13.0 13.9  
Unknown 8.1 8.2 6.7  8.0 7.7  
Node positivity  (%) 20.6 20.4 21.8 0.08 20.6 20.4 0.89 
Histology    <0.001   0.57 
Ductal 73.9 74.9 66.7  73.9 74.1  
Lobular 9.7 8.9 16  9.8 8.8  
Mixed ductal/lobular 8 7.4 12.2  8.0 8.8  
Other 8.3 8.8 5.1  8.3 8.2  
NCI Comorbidity Index (%)     <0.001   0.66 
0 63.6 62.3 73.3  63.8 62.2  
Between 0 and 1 27.9 28.6 22.9  27.9 29.2  
Greater than 1 8.5 9.1 3.8  8.3 8.6  
Age at diagnosis  (%)    <0.001   0.74 
65 to 69 20.5 18.7 33.8  20.6 20.8  
70 to 74 24.7 24 29.6  24.8 26.0  
75 to 79 24.1 24.6 20.6  24.3 24.5  
80 to 84 18.8 19.7 11.7  18.8 18.2  
85 and older 12 13 4.3  11.6 10.4  
Married  (%) 45.8 44.6 54.8 <0.001 45.9 45.8 0.96 
State buy-in coverage  (%)    <0.001   0.53 
No 89.3 88.5 94.9  89.5 90.2  
Yes 10.7 11.5 5.1  10.5 9.8  
Race  (%)    <0.001   0.56 
White 87 86.7 88.9  87.1 87.8  
Non-white 13 13.3 11.1  12.9 12.2  
Cooperative group affiliation of 
surgical facility  (%)† 51 49.3 63.1 <0.001 51.2 50.7 0.75 
NCI affiliation of surgical 
facility  (%) 5.2 4.9 7.1 <0.001 5.2 5.4 0.78 
Surgical facility a teaching 
hospital or affiliated one, (%) 52.4 51.8 56.5 <0.001 52.6 56.6 0.01 
Surgical volume of surgical 
facility (%)    <0.001   0.64 
Low  49.8 52.2 32.0  49.6 50.3  
High  
 
50.2 47.8 68.0 
 
50.4 
 
49.7 
  
Table 4.2. Baseline characteristics of patients in the analysis examining the 
first surgical procedure (main analysis, n= 24,439) 
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Unadjusted data 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= N= 
24,439 
N= 
21,522 
N= 
2,917 N=21,373  N=2,909  
Zip code proportion with at 
least high school education 
(% in each quartile)    <0.001   0.6 
Low education 24.6 22.9 37.4  24.7 24.5  
Low-medium education 24.0 23.9 25.3  24.2 25.3  
Medium-high education 23.6 24.0 20.6  23.6 21.9  
High education 23.7 25.3 12.3  23.5 23.7  
Unknown education 4.0 3.9 4.3  4.0 4.6  
Year of diagnosis  (%)    <0.001   0.12 
2004 25.2 27.0 11.8  24.9 22.3  
2005 24.6 25.5 17.8  24.6 24.5  
2006 24.9 24.6 27.1  25.0 24.9  
2007 25.3 22.8 43.4  25.5 28.3  
SEER Region (%)    <0.001   0.28 
California registries 32.3 31.4 39.5  32.5 31.7  
Northeast registries 23.3 22.7 27.4  23.5 26.9  
Georgia 3.3 3.3 2.8  3.3 2.5  
Detroit 6.9 7.1 5.0  6.9 6.8  
Iowa 7.4 8.0 2.8  7.3 5.9  
New Mexico 2.1 1.8 4.3  2.0 1.7  
Seattle 6.3 5.7 11.2  6.4 6.8  
Utah 2.7 2.8 2.3  2.8 2.1  
Kentucky 7.6 8.3 2.5  7.4 8.4  
Louisiana 6.9 7.5 2.2  6.8 5.8  
Hawaii 1.2 1.4 0.2  1.1 1.3  
* p<0.05, ** p<0.01,  *** p<0.001"          
Exponentiated coefficients 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; NCI, 
National Cancer Institute; AIC, Akaike information criterion 
†  NCI Cooperative Groups having breast cancer research portfolios  
   
Table 4.2. Baseline characteristics of patients in the analysis examining the 
first surgical procedure (cont.) 
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Time to surgery 
analysis 
  
 
 
 
Type of first surgical procedure sample 
 
Main analysis: 
Patients with a 
mastectomy or BCS 
(n=24,439) 
Sub-analysis: 
Patients with a 
mastectomy or partial 
mastectomy 
(n=17,1942) 
 
 
 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Tumor size 
      < 2cm (ref.) 
 
(ref.) 
 
(ref.) 
 ≥ 2cm, < 5cm 0.97 [0.87, 1.07] 0.99 [0.89, 1.10] 0.92 [0.82, 1.03] 
Tumor grade 
      Well differentiated (ref.) 
 
(ref.) 
 
(ref.) 
 Moderately 
differentiated 1.02 [0.92, 1.13] 1.04 [0.94, 1.15] 0.99 [0.89, 1.12] 
Poorly differentiated 0.81** [0.71, 0.93] 0.85* [0.74, 0.97] 0.84* [0.72, 0.98] 
Grade unknown 0.90 [0.74, 1.11] 0.90 [0.73, 1.11] 0.86 [0.67, 1.09] 
Hormone receptor status  
      Positive (ref.) 
 
(ref.) 
 
(ref.) 
 Negative 1.16* [1.01, 1.34] 1.22** [1.06, 1.40] 1.20* [1.03, 1.40] 
Unknown 1.03 [0.87, 1.21] 1.02 [0.86, 1.20] 0.96 [0.80, 1.16] 
Node positivity   1.03 [0.92, 1.15] 1.11 [1.00, 1.24] 1.10 [0.98, 1.24] 
Histology       
Ductal (ref.)  (ref.)  (ref.)  
Lobular 2.18*** [1.92, 2.47] 2.13*** [1.88, 2.42] 2.16*** [1.87, 2.49] 
Mixed ductal/lobular 1.69*** [1.48, 1.94] 1.69*** [1.47, 1.94] 1.66*** [1.42, 1.93] 
Other 0.81* [0.68, 0.97] 0.79* [0.65, 0.95] 0.78* [0.64, 0.96] 
NCI Comorbidity Index   
      0 (ref.) 
 
(ref.) 
 
(ref.) 
 Between 0 and 1 0.79*** [0.72, 0.88] 0.79*** [0.71, 0.87] 0.78*** [0.70, 0.88] 
Greater than 1 0.55*** [0.45, 0.67] 0.53*** [0.43, 0.66] 0.50*** [0.39, 0.64] 
Age at diagnosis  
      65 to 69 (ref.) 
 
(ref.) 
 
(ref.) 
 70 to 74 0.69*** [0.62, 0.77] 0.68*** [0.61, 0.75] 0.67*** [0.60, 0.76] 
75 to 79 0.49*** [0.43, 0.55] 0.46*** [0.41, 0.52] 0.45*** [0.40, 0.52] 
80 to 84 0.34*** [0.30, 0.39] 0.32*** [0.28, 0.37] 0.33*** [0.28, 0.38] 
85 and older 0.19*** [0.15, 0.23] 0.17*** [0.14, 0.21] 0.16*** [0.12, 0.20] 
Married  1.10* [1.01, 1.20] 1.10* [1.01, 1.20] 1.15** [1.05, 1.27] 
State buy-in coverage  
      No (ref.) 
 
(ref.) 
 
(ref.) 
 Yes 0.59*** [0.49, 0.71] 0.57*** [0.47, 0.69] 0.62*** [0.51, 0.76] 
Race  
      White (ref.) 
 
(ref.) 
 
(ref.) 
 Non-white 0.91 [0.79, 1.04] 0.91 [0.79, 1.04] 0.91 [0.78, 1.06] 
Cooperative group affiliation 
of surgical facility† 1.36*** [1.24, 1.50] 1.35*** [1.23, 1.49] 1.34*** [1.20, 1.49] 
NCI affiliation of surgical 
facility 1.26** [1.06, 1.50] 1.19 [0.99, 1.42] 1.08 [0.88, 1.33] 
Surgical facility a teaching 
hospital (or affiliated one) 0.94 [0.85, 1.04] 0.93 [0.84, 1.03] 0.84** [0.75, 0.94] 
Surgical volume of surgical 
facility  
      Low  (ref.) 
 
(ref.) 
 
(ref.) 
 High  1.98*** [1.79, 2.19] 2.00*** [1.81, 2.22] 2.01*** [1.79, 2.25] 
Table 4.3. Multivariate logistic regression to generate preoperative breast MRI 
propensity scores 
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Time to surgery 
analysis 
  
 
 
 
Type of first surgical procedure sample 
 
Main analysis: 
Patients with a 
mastectomy or BCS 
(n=24,439) 
Sub-analysis: 
Patients with a 
mastectomy or partial 
mastectomy 
(n=17,1942) 
 
 
 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Zip code proportion with at  
   least a high school education  
   (quartiles) 
    Low education (ref.) 
 
(ref.) 
 
(ref.) 
 Low-medium education 0.70*** [0.63, 0.79] 0.70*** [0.63, 0.78] 0.70*** [0.62, 0.79] 
Medium-high 
education 0.66*** [0.59, 0.75] 0.66*** [0.58, 0.74] 0.67*** [0.59, 0.77] 
High education 0.48*** [0.41, 0.56] 0.48*** [0.41, 0.56] 0.49*** [0.41, 0.58] 
Unknown education 0.70** [0.57, 0.87] 0.71** [0.57, 0.89] 0.71** [0.56, 0.91] 
Year of diagnosis  
      2004 (ref.) 
 
(ref.) 
 
(ref.) 
 2005 1.61*** [1.39, 1.85] 1.62*** [1.40, 1.87] 1.61*** [1.37, 1.90] 
2006 2.67*** [2.33, 3.06] 2.69*** [2.35, 3.09] 2.74*** [2.35, 3.19] 
2007 5.02*** [4.42, 5.72] 5.06*** [4.44, 5.77] 4.85*** [4.19, 5.63] 
SEER Region  
      California registries (ref.) 
 
(ref.) 
 
(ref.) 
 Northeast registries 1.04 [0.92, 1.18] 1.06 [0.93, 1.20] 1.18* [1.02, 1.36] 
Georgia 0.53*** [0.42, 0.68] 0.53*** [0.41, 0.67] 0.58*** [0.45, 0.74] 
Detroit 0.55*** [0.45, 0.68] 0.58*** [0.47, 0.71] 0.63*** [0.49, 0.81] 
Iowa 0.42*** [0.33, 0.54] 0.42*** [0.32, 0.54] 0.45*** [0.34, 0.60] 
New Mexico 3.16*** [2.52, 3.96] 3.16*** [2.51, 3.97] 4.43*** [3.43, 5.72] 
Seattle 1.68*** [1.43, 1.97] 1.67*** [1.42, 1.96] 1.92*** [1.61, 2.28] 
Utah 0.62*** [0.47, 0.81] 0.63*** [0.48, 0.83] 0.77 [0.57, 1.03] 
Kentucky 0.28*** [0.21, 0.36] 0.28*** [0.21, 0.37] 0.31*** [0.24, 0.42] 
Louisiana 0.37*** [0.28, 0.49] 0.37*** [0.28, 0.49] 0.46*** [0.33, 0.62] 
Hawaii 0.11*** [0.04, 0.28] 0.12*** [0.05, 0.30] 0.091*** [0.03, 0.30] 
Observations 25,038 24,439 17,942 
AIC 15330.4 14905.2 11891.3 
* p<0.05, ** p<0.01,  *** p<0.001"          
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; NCI, National Cancer 
Institute; AIC, Akaike information criterion 
† NCI Cooperative Groups having breast cancer research portfolios
Table 4.3. Multivariate logistic regression to generate preoperative breast MRI 
propensity scores (cont.) 
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Figure 4.3a. Breast MRI propensity score distribution for the analysis 
examining time to surgery (n=25,038) 
 
Figure 4.3b. Breast MRI propensity score distribution for the analysis 
examining the type of initial surgery (n=24,439) 
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Table 4.4. Impact of preoperative breast MRI on the time until complete surgery  
  
Hazard 
ratio 
95% Conf. 
Interval n 
Unadjusted proportional hazard model 0.96 [0.93, 1.00] 25,038 
Proportional hazard model adjusted for covariates† 0.93*** [0.89, 0.97] 25,038 
Proportional hazard model with IPW¶ 0.90*** [0.85, 0.95] 25,038 
* p<0.05, ** p<0.01,  *** p<0.001" 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting 
† See Appendix Table A.4 for the coefficients for the additional covariates 
¶ Robust standard errors 
 
 
 
Table 4.5. Impact of preoperative breast MRI on the likelihood of a mastectomy 
compared to BCS as the first surgical procedure (main analysis, n= 24,439) 
  
Odds 
ratio 
95% Conf. 
Interval n 
Unadjusted logistic regression 1.12* [1.03, 1.23] 24,439 
Logistic regression adjusted for covariates† 1.55*** [1.40, 1.72] 24,439 
Logistic regression with IPW‡ 1.30*** [1.12, 1.50] 24,439 
* p<0.05, ** p<0.01,  *** p<0.001 
MRI, Magnetic Resonance Imaging; BCS; breast conserving surgery; IPW, Inverse probability weighting 
Note: BCS is defined as a breast excision or a partial mastectomy 
† See Appendix Table A.5 for the coefficients of the additional included variables 
‡ Robust standard errors 
 
 
Table 4.6. Impact of preoperative breast MRI on the likelihood of a mastectomy 
compared to partial mastectomy as the first surgical procedure (sub-analysis, 
n=17,942) 
  
Odds 
ratio 
95% Conf. 
Interval n 
Unadjusted logistic regression 0.93 [0.84, 1.02] 17,942 
Logistic regression adjusted for covariates† 1.48*** [1.33, 1.65] 17,942 
Logistic regression with IPW‡ 1.20* [1.02, 1.40] 17,942 
* p<0.05, ** p<0.01, *** p<0.001 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting 
† See Appendix Table A.7 for the coefficients for the additional covariates 
‡ Robust standard errors 
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CHAPTER 5: THE ASSOCIATION BETWEEN PREOPERATIVE BREAST MRI AND THE LIKELIHOOD OF 
A RE-EXCISION AND SECOND BREAST CANCER EVENT IN ELDERLY BREAST CANCER PATIENTS
Overview 
Breast magnetic resonance imaging (MRI) increasingly has been used in addition to 
conventional assessment in the preoperative evaluation of women with newly diagnosed 
breast cancer. Despite its rapid adoption, there is limited evidence to suggest that using MRI 
leads to improved short-term outcomes. The purpose of this study was to evaluate the 
relationship between preoperative breast MRI and the likelihood of a re-excision and a 
second breast cancer event in a large, population-based cohort of elderly women with early-
stage breast cancer.  
In this observational, retrospective analysis, we identified women diagnosed with 
early-stage (I-IIB) breast cancer from 2004-2007 in the Surveillance, Epidemiology, and End 
Results (SEER) registry data linked to Medicare claims. Cancer treatment and breast MRI 
receipt were identified from the Medicare claims.  Women were considered eligible for a re-
excision if their first surgical procedure was breast conserving surgery. A re-excision was 
defined as a claim submitted during the initial treatment phase for a breast surgical 
procedure, which was specified as a breast excision, partial mastectomy, or mastectomy, 
after the initial surgery. Second breast cancer events were identified through an algorithm 
validated in breast cancer patients using information regarding secondary cancers and 
surgical procedures from claims data and SEER registries. We used propensity score 
methods to control for measured confounders.  
Twelve percent of women in our samples received a breast MRI. Of the 17,199 
women who were considered eligible for re-excision, one-third of the patients in our sample 
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had an additional breast cancer surgical procedure after their initial surgical procedure 
(34.2% in the no MRI group vs. 29.2% of the MRI group [p<0.001]). Using inverse probability 
weighting, having a preoperative breast MRI was not significantly associated with the odds 
of having an additional surgical procedure (OR 1.11; 95% confidence interval (CI): [0.92, 
1.35]).  Of the 24,438 women who met our inclusion criteria and were included in our sample 
examining a second breast cancer event, 9.4% had a second breast cancer event (9.2% of 
the no MRI group; 11.0% of the MRI group, p<0.001). Using propensity score weighting, 
patients with a preoperative breast MRI were associated with an increased hazard of a 
second breast cancer event (HR: 1.37; 95% CI: [1.11, 1.68]) and were more likely to have a 
second breast cancer event one, three, and five years after their first suspected breast 
disorder when compared to women without preoperative breast MRI (OR: 2.13; 95% CI: 
[1.54, 2.94]; OR: 1.43; 95% CI: [1.12, 1.82];  OR: 1.57; 95% CI: [1.20, 2.07], respectively). 
We did not find evidence that preoperative breast MRI was associated with improved 
short-term outcomes. Preoperative breast MRI receipt was not associated with a difference 
in the likelihood of re-excision, but was associated with an increased hazard of a second 
breast cancer event.  
Introduction 
Breast magnetic resonance imaging (MRI) is increasingly being used as a part of 
preoperative planning for patients with early-stage invasive breast cancer.1-10!Breast MRI is 
able to identify lesions that are not detectable by conventional assessment, which includes 
clinical examination of the breasts, mammography, and ultrasonography.11 However, there 
is limited evidence that the use of preoperative breast MRI improves short-term surgical 
outcomes for early-stage invasive breast cancer patients. Despite the paucity of definitive 
evidence for the use of preoperative breast MRI as a part of surgical planning, the 
 ! 129 
percentage of elderly breast cancer patients with preoperative breast MRI increased from 
1.2% in 2002 to 18.8% in 2007.12 
The effect of preoperative breast MRI on short-term surgical outcomes, such as re-
excision rates and recurrence, has been examined in two randomized clinical trials 
(RCT)13,14 and multiple retrospective, single institution studies.11,15-22!Authors of one RCT 
from United Kingdom13 (n=1,623) reported no significant difference in the re-excision rates 
between the MRI and non-MRI groups (10% vs. 11%; p=0.77) and no difference in the one-
year, local recurrence-free interval rates. The other RCT from the Netherlands14 (n=149) 
found a significantly higher re-excision rate for the MRI group (34%) compared to the no 
MRI group (12%; p=0.008) and was not powered to detect recurrence rate differences.  
These results are consistent with previous retrospective, single institution studies showing 
that preoperative breast MRI was not associated with reduced re-excision rates8,21-23 or 
lower ipsilateral local recurrence rates.8,16  
There is a dearth of evidence examining the association between preoperative 
breast MRI used as a part of preoperative surgical planning to measure the extent of 
disease and short-term surgical outcomes, which have not been examined in a population 
comparable to the US elderly population. The patients and medical groups in the RCTs and 
single institution studies conducted to date were highly selective and not generalizable to 
US elderly population. For example, the median and mean ages for the RCTs were 5713 and 
55.5 years,14 almost two decades younger than the average age of breast cancer patients 
enrolled in Medicare24 and the average patient in our study (76.1 years).  Additionally, breast 
cancer treatment patterns, decision-making factors, health service/insurance structure, and 
fiscal considerations are different in the US compared to the European countries where the 
RCTs were conducted.25-28   
Research has shown that baseline characteristics of elderly women in the US who 
receive breast MRI, such as age, race, and health service area resources, differ from 
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women who do not undergo breast imaging.2 Although RCTs are the best method to control 
for treatment selection biases, conducting an RCT in the US elderly population would be 
expensive and would take years to generate results.  Thus, an observational analysis using 
a large, population-based dataset applying appropriate statistical methods would generate 
breast MRI treatment effects that may reflect real world practice in the US elderly 
population. 
In this retrospective study, we used the population-based Surveillance, 
Epidemiology, and End Results (SEER)-Medicare linked dataset and propensity score 
methods to examine the effectiveness of preoperative breast MRI in reducing the likelihood 
of re-excision and the hazard of a second breast cancer event for elderly breast cancer 
patients with early-stage breast cancer. 
Methods 
Data 
This retrospective study used the SEER-Medicare dataset, which links a consortium 
of population-based cancer registries across the United States to Medicare administrative 
data and healthcare claims.29 The SEER data encompass 17 registries nationwide and 
cover approximately 25% of the incident US cancer population. The data contain 
demographic and incident cancer characteristics including histology, grade, and stage as 
well as treatment information and vital statistics. The SEER data also contain ecological 
measures of income, education, and other characteristics at each patient’s census tract and 
zip code of residence.30 The sample covered by the program is comparable to the overall 
US population with regard to measures of poverty and education.29 
Medicare is the primary insurer for more than 97% of Americans aged 65 and 
older.31 Medicare covers hospital services, physician services, some drug therapy, and other 
medical services. The Medicare claims provide information about the use and cost of health 
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care services and co-morbid health conditions. The National Cancer Institute (NCI) hospital 
file contains hospital-level information, including staffing, structure, research network 
affiliation, and information on accreditation. 
Study Population 
 This study included women aged 66 or older with a primary diagnosis of unilateral, 
pathologically confirmed, stage I-IIB operable breast cancer (American Joint Committee on 
Cancer [AJCC] sixth edition, International Statistical Classification of Diseases and Related 
Health Problems, 9th revision, clinical modification [ICD-9-CM] code 174). Our sample 
included women diagnosed between January 1, 2004 and December 31, 2007. As we were 
only interested in elderly breast cancer patients, we focused our analysis on age-eligible 
women. Thus, we excluded women under the age of 65 who were eligible and enrolled in 
Medicare due to end-stage renal disease or disability only. We also excluded women with 
previous cancers, women who were not continuously enrolled in Medicare Part A and Part 
B, and women who were enrolled in a health maintenance organization (HMO) during the 
study period. We were concerned that these beneficiaries would have incomplete claims in 
the SEER-Medicare dataset and, therefore, we would be unable to examine their healthcare 
utilization in its entirety. A comorbidity index was calculated based on 12 months of claims 
prior to diagnosis; thus, women not enrolled 12 months prior to diagnosis were excluded 
(SEER-Medicare inclusion/exclusion table can be found in Appendix Table B.1).    
We limited this analysis to women whose first definitive treatment was surgery, thus 
excluding women who received neoadjuvant chemotherapy prior to surgery (n=435). These 
women were excluded because breast MRI can also be used to measure tumor response to 
neoadjuvant chemotherapy,32-36 and our research focuses on the use of breast MRI to 
measure extent of disease in the ipsilateral breast as a part of preoperative surgical 
planning. We also excluded patients who had conflicting claims for mastectomy and partial 
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mastectomy on the same day in the Medicare outpatient setting, inpatient setting, and 
physician files (n=647). We excluded these women because we were unable to determine 
the type of initial surgery. We also excluded women who had their first biopsy or breast 
surgical procedure more than four months before or after the SEER diagnosis month 
(n=599) because we were concerned that those surgical claims did not correspond to the 
first primary breast cancer identified from the SEER registry. Our study inclusion/exclusion 
criteria are presented in Figure 5.1. 
Re-excision analysis (main analysis and sub-samples). For both the main and sub-
analysis, we excluded those women who had a mastectomy as their first surgical procedure 
(n=4,631) because re-excisions after mastectomies are rare and unlikely.37 In our sample of 
women who had a mastectomy as their first surgery, only 2.0% had a re-excision. Given that 
the rate of contralateral breast cancer has been estimated at about 1% these surgeries may 
have been on the contralateral breast after a single mastectomy and thus, may be validly 
excluded.  
When examining re-excisions, we conducted both a main and sub-analysis using two 
different definitions of breast conserving surgery (BCS) to identify patients eligible for re-
excisions (Figure 5.2). In our main analysis, we liberally defined BCS as a breast excision or 
partial mastectomy (for procedure codes see Appendix Table B.2), and included women 
whose first surgical procedure was either a breast excision or partial mastectomy. In our 
sub-analysis, we conservatively defined BCS as a partial mastectomy alone and excluded 
women whose first surgery was a breast excision (n=5,837).  
We conducted both analyses because our study focuses on the use of preoperative 
breast MRI for therapeutic surgical planning; however, previous research has classified 
claims for breast excisions as both a diagnostic procedure38,39 and breast conserving 
surgical treatment.40-42 Based on claims data, it is not possible to differentiate between 
breast excisions that were intended to be curative (i.e., BCS) rather than diagnostic (i.e., 
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open biopsy). Thus, the main analysis estimates the likelihood of re-excision after any 
surgical procedure (whether or not the first surgical intent was curative), and the sub-
analysis limits our sample to women with definitive therapeutic surgeries (i.e., partial 
mastectomy). Furthermore, because re-excision after an initial breast excision could be 
intended as either the first definitive treatment (e.g., an open biopsy followed by a 
mastectomy) or as a second surgery to obtain clear margins (e.g., a lumpectomy followed 
by a mastectomy), we used the sub-analysis to limit our sample to examine re-excisions 
after surgical treatments with definitive curative intent (i.e., partial mastectomy).   
Variables and Measures 
We examined all claims in Medicare outpatient, inpatient, and physician claims files 
during each patient’s initial treatment phase from 2004 through 2009. The initial treatment 
phase was defined to capture the diagnostic, preoperative, and initial treatment stages. The 
start of the initial treatment phase began on the date of the first claim for a suspected breast 
disorder43 (e.g., lump or mass in breast, or abnormal mammogram; see Appendix Table B.2 
for codes) 12 or fewer months prior to the SEER diagnosis month. We defined the end of 
the initial treatment phase as the last day of breast cancer treatment (i.e., partial 
mastectomy, mastectomy, radiation, or chemotherapy; for codes, see Appendix 4.II) before 
a treatment gap of more than 90 days,44-46 the patient’s death, or the end of the study period, 
which was December 31, 2009. Breast cancer treatments, including surgery, were identified 
in Medicare outpatient, inpatient, and physician claims files using the American Medical 
Association Current Procedural Terminology (CPT) and the Healthcare Common Procedure 
Classification System (HCPCS) codes (See Appendix Table B.2).  
Our independent variable of interest was a binary indicator for whether or not the 
patient received a preoperative breast MRI. Patients were classified as having a 
preoperative breast MRI if they had a claim for a breast MRI (CPT: 76093-94, 77058-59, 
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HCPCS: C8903-C8908) on or after the first day of suspected breast disorder but before the 
date of their first surgical procedure. Though this approach may capture breast MRIs that 
were ordered for screening purposes, we are not concerned about including these breast 
MRIs as “preoperative” because breast images taken during the initial treatment phase, 
even for screening purposes, would most likely be used as a part of the surgical planning 
process (Dr. Keith Amos. Personal communication. May 23, 2012). 
Re-excisions. A re-excision was defined as a claim for a breast surgical procedure 
(i.e., breast excision, partial mastectomy, or mastectomy [Appendix Table B.2]) after the 
initial surgery but during the initial treatment phase. Therefore, a re-excision could either 
have been an additional BCS after the initial surgery or conversion to mastectomy after the 
initial BCS.  
Second breast cancer events. Since SEER registries do not capture cancer 
recurrence, we used a validated algorithm to identify second breast cancer events (Figure 
5.3).47 Our definition of a second breast cancer event was intended to include recurrence 
and second breast cancers because both may be associated with breast MRI receipt and 
affect cancer morbidity and mortality.48-51 Further, no validated algorithm currently exists to 
identify each outcome separately. The algorithm was validated against medical record 
review in patients with early-stage invasive breast cancer.47 We selected the algorithm with 
the highest specificity (99%) and positive predictive value (90%), which had a sensitivity of 
89%. We selected this algorithm over other algorithms with higher sensitivity because it 
provided the highest likelihood of identifying only women who had a second breast cancer 
event.  
To identify second breast cancer events, the study population (n=24,438) was first 
split by whether or not the patient had two visits with a code for a secondary malignant 
neoplasm within a 60-day period occurring more than 365 days after the primary breast 
cancer (for codes see Appendix Table B.2). For women who met this first criterion, they 
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were considered to have had a second breast event if they either did not have second 
cancer record in SEER or their second SEER cancer record was for breast cancer. Women 
who did not meet the first criterion were considered to have a second breast cancer event if: 
(a) they had a second breast cancer record in the SEER registry; or (b) they had a 
mastectomy 180 days after their SEER diagnosis, and the surgical procedure for the primary 
breast cancer reported in SEER was breast conserving surgery. Otherwise, it was assumed 
that women did not have a second breast cancer event. 
For each patient, we created a continuous variable representing the time (in days) 
until a second breast cancer event. The time interval began on the date of the first 
suspected breast cancer and ended on the date of the second breast cancer event. The 
date of the second breast cancer was defined as the date of the procedure or diagnosis 
(Figure 5.3) that identified the patient as having a second breast cancer event. For example, 
if the patient was considered to have a second breast cancer based on having a second 
primary cancer in the SEER registries (n=759), we used first day of the SEER diagnosis 
month for the second primary cancer. Since SEER registries do not capture the date of 
surgery, the date of a patient’s first mastectomy occurring more than 180 days after the 
primary breast cancer was used for women who were identified as having a second breast 
cancer based on the surgical procedure in SEER (n=161). For women who were identified 
as having a second breast cancer based on two visits with a code for a secondary malignant 
neoplasm within a 60-day period occurring more than 365 days after the primary breast 
cancer, the date of her second visit was used as the date of the second breast cancer event. 
Additional covariates. We examined numerous variables that could potentially be 
associated with breast MRI receipt and confound the relationship between breast MRI and 
surgical outcomes. We included a variable for tumor histology (ductal, lobular, mixed ductal 
lobular, and other) because research has shown that lobular tumors are more likely to be 
mammographically occult and, thus, patients may be more likely to receive and/or benefit 
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more from breast MRI.52 Tumor characteristics examined included grade (well, moderately, 
poorly/undifferentiated, and undetermined), tumor size (≤ 2cm vs. > 2cm & ≤ 5cm), any node 
positivity (yes vs. no), and hormone receptor status identified from SEER data (positive 
[ER+/PR+, ER+/PR-, ER+/no PR data, ER-/PR+, or no ER data/PR+], negative, unknown). 
We used the NCI Combined Comorbidity Index method to address competing health 
demands and risks of complications that may have affected treatment selection (0, 0-1, 
>1).53 Demographic characteristics examined included age group at diagnosis (in five-year 
intervals), marital status (married vs. unmarried), race (white vs. nonwhite), and SEER 
region.  We evaluated two measures to represent socio-economic status, quartiles of 
median household income in county of residence, and a person-level indicator for Medicare 
state buy-in coverage (yes vs. no), and retained the stronger predictor in the final model.  
We examined surgical facility characteristics that could be associated with breast 
MRI receipt and affect surgical outcomes. We identified the facility where the first surgical 
procedure took place and linked it to the NCI hospital file, which included measures for 
whether or not the organization was a teaching hospital  (yes vs. no), was a designated NCI 
Cancer Center  (yes vs. no), and had on-site radiation facilities  (yes vs. no).  We 
constructed a variable for whether or not the facility was affiliated (yes vs. no) with NCI 
Cooperative Groups having breast cancer research portfolios, including the American 
College of Surgeons Oncology Group (ACOSOG), Eastern Cooperative Oncology Group 
(ECOG), Cancer and Leukemia Group B (CALGB), Southwest Oncology Group (SWOG), 
and National Surgical Adjuvant Breast and Bowel Project (NSABP).54 We also controlled for 
facility ownership type (for-profit vs. not-for-profit) and breast cancer surgical volume (low 
volume vs. high volume).   
For the re-excision analysis, because having a biopsy prior to surgery may indicate 
improved surgical planning and may be associated a lower likelihood of a re-excision,38,55-57 
we considered including an indicator for whether or not the patient had a biopsy before her 
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first surgical procedure. However, because guidelines recommend that all suspicious MRI 
findings be biopsied,58 there is some concern that biopsy may be a mediating rather than a 
confounding variable. Thus, we explored whether to include a biopsy indicator in the model 
generating propensity scores (MRI OR 1.04, 95% CI [0.85,1.26]), in the second model 
examining the likelihood of a re-excision (MRI OR 01.08, 95% CI [0.89,1.31]) or omit the 
indicator from both models (MRI OR 0.93, 95% CI [0.78,1.11]). Since all models were 
qualitatively similar, we chose to consider biopsy a confounding variable and included it in 
the model to generate propensity scores. 
 For the second breast cancer event analysis, we included treatment variables that 
have been found to reduce the likelihood of a second breast cancer event. The indicators 
included whether or not the patient received chemotherapy and radiation as indicated in the 
Medicare claims (Appendix Table B.2). We also considered including whether the patient’s 
most extensive surgery was a breast excision, partial mastectomy, or mastectomy. Based 
on the results in Chapter 4: Aim I, the type of initial surgery is a mediator and was not 
included in the model to generate propensity scores but instead, was included in the second 
model examining the second breast cancer event even though the effect on breast MRI was 
quantitatively similar regardless of when it was included in the propensity score model (HR: 
1.32, 95% CI: [1.07,1.62]). It is worth noting that we were unable to control for oral hormone 
therapy receipt because it was not included in the Medicare database over the entire time 
period. However, as mentioned above, we included each patient’s hormone receptor status 
as a proxy.  
Statistical Analyses 
We compared unadjusted baseline characteristics between the group of patients with 
and without a preoperative breast MRI using the Pearson chi-squared test for categorical 
variables and Student’s t-test for continuous variables. We used multivariate logistic 
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regression to estimate the association of each covariate on the likelihood of receiving a 
breast MRI. We calculated odds ratios, 95% confidence intervals (CI), and two-sided p-
values for each predictor.  
Propensity score methods. Because elderly women who receive a preoperative 
breast MRI may differ systematically from women who do not, we used propensity score 
methods59 to balance the groups of women with and without breast MRI on measured 
covariates and to control for potential confounders. Numerous studies have previously used 
propensity score methods to examine SEER-Medicare data.60-64  
We used multivariate logistic regression to determine each patient’s propensity for 
receipt of preoperative breast MRI on the basis of observed patient and hospital 
characteristics.59 This process generated each patient’s likelihood of breast MRI receipt 
based on the included covariates or, in other words, each patient’s propensity score.  
Variables were selected based on their hypothesized relationship with breast MRI receipt 
and the outcome (either a re-excision or second breast cancer event).65  
Inverse probability weighting (IPW) was used to account for measured baseline 
differences between the group that received a breast MRI and the group that did not.66,67 
Each patient with a breast MRI was weighted by the inverse of the probability that she would 
be selected for a breast MRI based on her covariates, and each patient without a breast 
MRI was weighted by the inverse of the probability that she would not have a breast MRI. 
We then stabilized these weights by multiplying the inverse probability weights by the 
marginal prevalence of the breast MRI receipt.68,69  
We assessed the performance of the propensity model by examining the distribution 
of covariates and propensity scores between the two groups (MRI vs. no MRI), examining 
balance by decile of propensity score.70 Additionally, we calculated the change in 
standardized difference for each variable before and after inverse probability weighting.71 
We examined excluding patients with non-overlapping propensity score distributions (i.e., 
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women without a preoperative breast MRI who had a propensity score higher than the 
maximum or lower than the minimum propensity score of women with preoperative breast 
MRI).70,66 To reduce bias due to unmeasured confounders, we also assessed 
asymmetrically trimming patients who were treated most contrary to prediction.68 We 
examined trimming patients at three different cut points corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles at the tails of the 
propensity score distribution in the treated (i.e., breast MRI) and untreated (i.e., no breast 
MRI) patients, respectively.   
Analytic Approach. In our first analysis estimating the likelihood of a re-excision, we 
used multivariate logistic regression weighted with the inverse probability weights and robust 
standard errors.66,72 Wald tests and 95% confidence intervals were used to examine the 
difference in the likelihood of a re-excision between those women with and without a breast 
MRI.  
In the second analysis examining a second breast cancer event, we calculated the 
likelihood of a second breast cancer event within one, three, and five years after diagnosis. 
In these analyses, we used logistic regression using inverse probability weighting and robust 
standard errors. 66,72  Patients who had incomplete follow-up for each time period were 
excluded from each time period’s respective analysis. We used a liberal definition to define 
women eligible for a second breast cancer event and included women who died before they 
experienced a second breast cancer event. We included these women because it is unlikely 
that many of them would have actually experienced a second breast cancer event had they 
lived (between 3-7%).73 Results were quantitatively similar, however, when we explored 
using a more conservative definition of a second breast cancer event and excluded those 
women who died before one (MRI OR: 2.10, 95% CI:[1.52, 2.89]; n=23,907), three (MRI OR: 
1.35, 95% CI:[1.06, 1.72]; n=17,696), and five years (MRI OR: 1.27, 95% CI:[0.95, 1.69]; 
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n=7,115). This definition was more conservative because we included only women for which 
we could observe a second breast cancer event. 
We estimated hazard ratios using the Cox proportional-hazards model,74 generating 
unadjusted estimates and estimates: (a) adjusted for covariates; and (b) adjusted using 
inverse-probability weighting.74-76 Women without a second breast cancer event who were 
alive at the end of follow-up or who died were censored at the end of follow-up (December 
31, 2009) or their date of death. We evaluated the proportional hazards assumption by 
graphical methods using Schoenfeld residuals77 and did not find any clear violations of the 
proportional hazard assumption. We estimated unadjusted survival curves using the Kaplan-
Meier method56 and adjusted survival curves using the inverse-probability weighting 
approach from Cole and Hernan.75  
Diagnostic and procedure codes were identified and verified using medical literature, 
coding experts, EpiCoder (Yost Engineering Inc., Ohio), and the Integrated Cancer 
Information and Surveillance System coding references.78 Analyses were performed using 
Stata version 12.0 (Stata Corporation, College Station, Texas). All tests were conducted 
using a minimum significance level of 0.05. 
Results 
 Characteristics of the study population. Of the 39,652 women diagnosed with 
their first primary breast cancer in the SEER-Medicare dataset between 2004 and 2007, 
24,438 women were included in our analysis examining second breast cancer events 
(Figure 5.1) and 17,199 women were identified as eligible for re-excision. Baseline 
characteristics for both samples were similar (Tables 5.1 and 5.2) with 11.6% of women 
receiving a preoperative breast MRI in the re-excision analysis and 11.9% in the second 
breast cancer event analysis. In the unadjusted bivariate analysis, women who received a 
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breast MRI differed significantly from women who did not on all baseline characteristics 
(except lymph node involvement and race in the second breast cancer event analysis).  
In the multivariate logistic regression predicting MRI receipt to generate propensity 
scores (Appendix Table B.3), younger age, more recent diagnosis, fewer comorbidities, and 
SEER region were significant predictors of MRI receipt.  Women with lobular carcinomas 
were more likely to have received a breast MRI when compared to women diagnosed with 
ductal carcinomas. Women living in areas with fewer high school graduates and not covered 
by Medicare state-buy-in supplemental insurance were significantly more likely to have a 
breast MRI.  Women having their surgeries at facilities that were affiliated with cooperative 
groups and a high surgical volume had significantly increased odds of receiving a breast 
MRI. In the re-excision analysis, women with a biopsy before their first surgical procedure 
and a breast excision instead of a partial mastectomy as their first surgical procedure were 
more likely to have had a breast MRI. In the analysis examining second breast cancer 
events, women who received chemotherapy were more likely to have had a breast MRI.  
After adjustment using inverse probability weighting, the observed clinical, socio-
demographic, and surgical facility variables were well balanced (Tables 5.1 and 5.2). In all 
analyses, adjusting for the propensity scores demonstrated substantial improvement in 
covariate balance across the groups with and without breast MRI. In both samples in our 
final analysis, adjusting for the propensity scores reduced standardized differences 
(Appendix Figures B.1 and B.2) for all observed covariates below the threshold of 10% in 
absolute value, demonstrating substantial improvement in covariate balance across the 
groups with and without breast MRI.79 In all analyses, excluding patients with non-
overlapping propensity scores or trimming patients at the three different cut points did not 
change the significance of our estimates, and only attenuated the effect of breast MRI 
slightly (See Appendix Table D.3 and D.4). Thus, we report the results without trimming. 
Figure 5.4 shows the propensity score distribution of the samples in our analyses. 
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Re-excisions. Overall, 33.6% of women had a re-excision after their first surgical 
procedure, which included 34.2% of women without a breast MRI and 29.2% of women with 
a breast MRI (p<0.001).  For all models adjusted for covariates or using propensity score 
methods in our main analysis (Table 5.3), the likelihood of a re-excision after BCS was 
comparable for those women with and without preoperative breast MRI (IPW model: OR: 
1.11; 95% CI: 0.92, 1.35). In our sub-analysis examining the likelihood of a re-excision after 
partial mastectomy (Table 5.4), the association between breast MRI and the likelihood of a 
re-excision was also found to be non-significant (IPW model: OR: 0.67; 95% CI: 0.78, 1.27). 
Second breast cancer events. Our median follow-up time from first suspected 
breast disorder to study end or death was 3.9 years (interquartile range [IQR]: 2.86-4.99) for 
the group without breast MRI and 3.32 years (IQR: 2.63-4.35) for the group with breast MRI. 
We identified a second breast cancer event in 11.9% of women in our sample. Of the 
women in the group without a breast MRI, 9.4% had a second breast cancer event 
compared to 11.0% in the group with an MRI (p<0.001).  Across all models adjusting for 
covariates or using propensity score methods (Table 5.5), breast MRI receipt was 
significantly associated with a second breast cancer event. The unadjusted and adjusted 
time to event curves are presented in Figure 5.5. In the hazard model using IPW, women 
with a breast MRI were associated with an increased hazard of a second breast cancer 
event compared to those without a breast MRI (Hazard ratio [HR]: 1.37 95% CI: 1.11, 1.68). 
In the logistic regressions using IPW to examine the likelihood of a second breast cancer 
event (Table 5.5), women with breast MRI were more likely to experience a second breast 
cancer event within one year (OR: 2.13; 95% CI: [1.54, 2.94]), three years (OR: 1.43; 95% 
CI: [1.12, 1.82]) and five years (OR: 1.57; 95% CI: [1.20, 2.07]) than women without a breast 
MRI.  
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Discussion 
 In this large, population-based observational study of elderly women with breast 
cancer, we found that preoperative breast MRI was not significantly associated with a 
reduction in the likelihood of a re-excision after breast conserving surgery and was 
associated with an increased hazard of a second breast cancer.  Because baseline 
characteristics for the group of patients who received a breast MRI differed from those who 
did not receive a breast MRI, we used multiple multivariable regression modeling techniques 
and propensity score adjustments to balance the two groups on these observed 
characteristics.  Across all multivariable models and differing propensity score method 
adjustments, the association between breast MRI and re-excision remained statistically non-
significant and, for all models, women who received a preoperative breast MRI were 
consistently more likely to have a second breast cancer event than those women who did 
not.   
 Our findings are largely consistent with previous RCTs and multiple single institution 
studies reporting that breast MRI did not significantly improve short-term surgical outcomes, 
such as re-excisions8,21-23 and recurrence.8,16 Our findings were discordant with only two 
small, retrospective studies examining re-excisions15 and recurrence.18 However, one of 
these studies did not adjust for measured confounders18 and the other was conducted in two 
institutions in the Netherlands, a population more homogenous and perhaps not 
generalizable to the US elderly breast cancer population.15  
 Re-excisions after breast conserving surgery are an important surgical outcome. Re-
excisions have been found to occur in 17-60%37,80-84 of women who have already undergone 
breast conserving surgery, and in our study, we found that 34.4% of patients had a re-
excision. Re-excisions have multiple negative consequences, including a worsened 
cosmetic outcome, delay in adjuvant therapy, increased anxiety, possible increased rates of 
recurrence, and higher costs associated with the additional treatment.81,82,85-87 Reoperation 
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rates are also an important clinical issue in the elderly population. Operations and 
reoperations are more problematic for elderly women who more likely have co-morbidities 
and for whom it is riskier to undergo anesthesia. Furthermore, recovery from surgery is 
much more difficult for elderly women.  
 Studies of younger populations of early-stage breast cancer patients have shown 
that recurrence rates after the completion of adjuvant therapy are between 6–13%,88-90 and 
the likelihood of recurrence has been reported to peak within the first five years after primary 
treatment.45,46,91 We found that 9.4% of our sample had a second breast cancer event 
identified from Medicare claims, which is consistent with previous findings. A second breast 
cancer event is an important, short-term breast cancer outcome because of its effect on 
overall survival48 and the physiological and physical distress of additional cancer treatments. 
Additionally, anxiety from fear of recurrence or a second breast cancer is one of the most 
prevalent, long-term psychological consequences of breast cancer.92-94 
 The results of this study have two potentially differing interpretations. The first is that 
women receiving breast MRI were inadequately imaged using conventional assessment 
(i.e., mammogram and ultrasound) and have higher baseline risk for re-excisions and/or 
recurrence. In this scenario, the addition of breast MRI improved surgical planning and 
produced similar re-excision outcomes compared to women who may have been adequately 
imaged using conventional imaging and had a lower risk of re-excision. The use of MRI did 
not, however, result in a similar risk of a second breast cancer event since the MRI group 
had a higher likelihood of such an occurrence. Based on evidence from our study, this 
scenario may be plausible because women with invasive lobular carcinoma, a histology type 
that is more prone to multifocal and muticentric disease,95 mammographically occult 
tumors,52,96,97 and higher re-excision rates,80,98-101 were more likely to receive an MRI 
compared to women with ductal carcinoma (OR 2.22; 95% CI: [1.89, 2.57]). 
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The second interpretation of our results is that breast MRI is being overutilized in 
women who may not benefit from it and, thus, we do not see benefit from its routine use at a 
population level. Evidence from our study suggests that this scenario may also be plausible 
because breast MRI is being rapidly adopted (20.5% of the women diagnosed in 2007 from 
our study sample had received a preoperative breast MRI) and the variability we see by 
provider and SEER region suggests that it is unlikely that breast MRI’s utilization is based 
solely on whether or not the woman was adequately imaged using conventional 
assessment. Furthermore, our study focuses on breast cancer in elderly women, a 
population that is most likely to be adequately imaged by conventional assessment.102  
We are unable to say definitively which scenario is true based on claims data and, in 
fact, both scenarios may be happening simultaneously. However, our results provide 
evidence against the use of breast MRI as a part of routine work-up in the elderly population 
for either scenario because only certain sub-populations may benefit (first scenario) and 
there is no evidence of benefit at a population level (second scenario).  Future research 
should endeavor to identify sub-populations that are most likely to benefit and provide 
guidelines about the appropriate use of breast MRI in elderly breast cancer patients.  
 In the absence of evidence assessing clinical benefit, it is important to examine 
potential side effects associated with the use of preoperative breast MRI. Preoperative 
breast MRIs may contribute to greater use of unnecessary tests and morbidity from 
diagnostic procedures and initial treatments. Studies have found that breast MRI may be 
associated with more downstream imaging, such as follow-up ultrasounds, more biopsies, 
more extensive surgeries, and treatment delay.1,23,103 Furthermore, it is concerning that 
women may be electing or surgeons may be recommending more extensive surgery 
(Chapter 4: Aim I) based on additional lesions detected by MRI that may be adequately 
managed by radiation and systemic therapy.10 The increased morbidity that is possibly 
associated with breast MRI in absence of clinical benefit is troubling as more breast cancer 
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patients are having comparatively favorable prognoses, and many clinicians are focusing on 
reducing treatment burden and morbidity.104  
Limitations 
Our study has several limitations. As SEER registries do not capture recurrence, 
identification of second breast cancer events was limited to our algorithm. The validation 
study for the algorithm was conducted using a single non-profit, health-care system in a 
slightly younger population (mean age was 62.8 years compared to 76.1 years in our study). 
Thus, it is possible that coding practices, care-seeking behaviors, and access to care may 
differ in our study population when compared to a validated study population and the 
algorithm might be less sensitive and/ or specific. To analyze this limitation, we also 
examined models using additional algorithms with a high sensitivity for identifying second 
breast cancer events (Appendix Figure B.3) to examine whether the association between 
breast MRI and the likelihood of a second breast cancer event changed, which it did not 
(results not reported). It is also worth noting that the algorithm we used was not verified to 
identify the date of the second breast cancer event. However, since women who had a 
breast MRI were more likely to be diagnosed in recent years, we had a differential follow-up 
time for the groups with and without breast MRI and were required to establish a date of a 
second breast cancer recurrence. Despite this limitation, we believe our estimated date of a 
second breast cancer event is acceptable because when we stratified by year of diagnosis 
(results not shown), the association between breast MRI and the likelihood of a second 
breast cancer event was consistent with our reported results. Despite these limitations, we 
believe the algorithm, validated against medical record review in patients with early-stage 
invasive breast cancer, is an improvement over previous research examining recurrence 
with claims data that used a gap in treatment to identify recurrence.44-46  
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 Additionally, we were unable to differentiate breast cancer surgeries that were on the 
ipsilateral versus the contralateral breast due to missing laterality (i.e., side) information.  We 
believe this effect to be small because of the small rate of contralateral breast cancer, 
estimated to be less than 1% per year,105 but worth noting because MRI increases the 
likelihood of contralateral breast cancer detection.10 We found that the claims data 
inconsistently reported the laterality of the breast cancer surgical procedure with more than 
40% of the surgical claims missing breast laterality. We were uncertain of the direction of the 
bias that would be introduced if we included only observations with the non-missing laterality 
information. Not having laterality information affects our estimates of re-excisions because 
we were unable to discern whether the additional surgery was on the ipsilateral or 
contralateral breast.  
Propensity score methods are only able to balance the groups with and without 
breast MRI on observed characteristics, and any remaining unmeasured confounders 
associated with our outcomes and/or breast MRI receipt could have influenced our findings. 
For example, we were unable to adjust the two groups for several re-excision and 
recurrence risk factors such as multifocal disease, mammographic density and micro-
calcifications, and the difference in tumor size between MRI and ultrasonography.106-108 We 
were, nevertheless, able to control for tumor grade and histology, age, advanced stage, 
hormone receptor negative status, and radiation and chemotherapy receipt, which have also 
been reported as re-excision and/or second breast cancer event risk factors.46,106 However, 
our estimates showing that women with a breast MRI have an increased risk of a second 
breast cancer event indicate that we did not control for all variables confounding the 
relationship between breast MRI receipt and our outcome of interest because we did not 
hypothesize that breast MRI may cause an a second breast cancer event. Future research 
should apply novel statistical methods such as instrumental variable analysis that may more 
adequately control for unmeasured confounding. 
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Our study involves the usual limitations of SEER-Medicare data, including concern 
about the generalizability to all elderly breast cancer patients due to exclusion of patients 
who are not continuously enrolled in fee-for-service Medicare.  Additionally, as in most 
observational studies, we were unable to directly control for patient preferences, functional 
status, socioeconomic status, and social support, all of which may be correlated with breast 
MRI receipt and outcomes. However, we used variables such as the NCI Comorbidity Index, 
state buy-in coverage, and marriage to mitigate these biases.  
Conclusion 
Given the persistent finding that breast MRI was not significantly associated with 
improved short-term outcomes across models and statistical techniques, we believe our 
study findings contribute to the growing literature about the efficacy and effectiveness of 
breast MRI. To our knowledge, our study is one of the first to use nationally representative 
data to investigate the effect of preoperative breast MRI on short-term surgical outcomes in 
elderly women in the US. Our findings are supported by results from other studies, including 
two randomized control trials. Proponents for the use of preoperative breast MRI believe 
that it can improve surgical planning, however, this analysis, along with other studies, show 
that this assumption may not be the case in the general population. Based on our results, 
we are unable to suggest the optimum proportion of elderly breast cancer patients that 
should receive breast MRI. Thus, more research should be conducted to identify sub-
populations of breast cancer patients that may have improved short- and long-term benefits 
from preoperative assessment with MRI. In the absence of evidence suggesting that breast 
MRI may improve short-term surgical outcomes, the decision whether or not to use the 
imaging procedure should be based on conversations with informed patients discussing 
patient preferences and the potential harms and realistic benefits of breast MRI.  
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SEER, Surveillance, Epidemiology and End Results 
* Meeting SEER-Medicare inclusion requirements of aged 66 or older at diagnosis, reporting source 
not autopsy or death certificate, laterality not bilateral or unknown, original reason for Medicare 
entitlement not disability or end stage renal disease, valid month of diagnosis, no health 
maintenance organization enrollment during study period, continuous enrollment in Parts A & B 
during the study period, comorbidity score and was able to be matched to claims during the study 
period. Study period is defined here as the 12 months prior to diagnosis month till the end of data 
or death (For more details see Appendix 5.I). 
† Note: This was the sample size for the hazard of a second breast cancer event analysis; women 
were censored (1) at the day of the end of follow-up if they were alive and had yet to experience a 
second breast cancer event or (2) at their date of death if they died before they experienced a 
second breast cancer event. In the logistic regressions examining a second breast cancer event at 
1, 3, and 5 years, we excluded women who did not have complete follow-up at 3 or 5 years 
(n=4,617 and 14,161, respectively). 
‡ Breast conserving surgery is defined as breast excision or partial/ subtotal mastectomy 
  
Figure 5.1. Inclusion/exclusion schematic 
 Women diagnosed with their first primary breast cancer in SEER in 2004-2007* 
n= 39,652  
INCLUDED EXCLUDED 
Medicare claims identified conflicting surgical  
procedures on the same day;  
receipt of cancer treatments prior to surgery 
n=1,082 
Known Stage I-IIIA disease, tumor size <5cm, 
histology codes indicating malignant breast cancer 
N=26,751   
Stage 0 or IV disease, stage unknown; tumor size 
greater than 5cm; histology codes indicating in situ/
non-malignant disease or non-breast primary tumors 
n=12,901 
Able to determine the first definitive surgical treatment 
and have no prior cancer treatments before surgery 
n= 25,669   
Had a first biopsy or breast surgical procedure  
within 4 months of SEER diagnosis month 
n= 24,439  
First breast breast biopsy or surgical procedure claim  
more than 4 months from SEER diagnosis month   
n= 599  
Patients with a breast surgical procedure 
Linkable to their surgical provider  
n= 25,038  
Unable to link patient to her surgical provider  
n= 631  
INCLUDED EXCLUDED 
Did not have a second primary cancer identified  
in SEER  
n= 22,348  
Had a second primary cancer identified in SEER  
within 12 months of diagnosis 
n= 2,091  
Sample for the analysis examining the hazard of a second breast cancer event† 
n= 24,439  
Additional inclusion/ exclusion criteria for the re-excision analysis: 
Alive 12 months after diagnosis  
n= 21,830  
Died within 12 months of diagnosis 
n= 518  
Had breast conserving surgery‡  as the 
first surgical procedure 
n= 17,199  
Had mastectomy as the first surgical procedure  
n= 4,631  
Sample for the analysis examining the likelihood of a re-excision 
n= 17,199  
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BCS, breast conserving therapy. 
* Who meet our inclusion criteria 
 ! !
Figure 5.2. Patient sample eligible for a re-excision in the main and sub-analyses  
 
INCLUDED: Patients identified as 
 having BCS and considered eligible  
for re-excision 
Initial surgery a  
partial mastectomy  
Initial surgery a  
breast excision 
Patients with  
surgery*  
n= 21,830  
 
Initial surgery a  
mastectomy 
EXCLUDED: this procedure  
could have been for either diagnostic  
OR therapeutic purposes (n=5,837) 
EXCLUDED: Considered ineligible for 
re-excision (n=4,631) 
Main analysis:  
Patients eligible for re-excision after BCS 
!
Analytic sample 
 for the  
main analysis 
n= 17,199  
Sub-analysis:  
Patients eligible for re-excision after partial mastectomy 
INCLUDED: considered eligible  
for re-excision 
Initial surgery a  
partial mastectomy  
Initial surgery a  
breast excision 
Patients with  
surgery*  
n= 21,830  
 
Initial surgery a  
mastectomy 
EXCLUDED: considered ineligible  
for re-excision (n=4,631) 
Analytic sample  
for the  
sub-analysis 
n= 11,362  
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Figure created with permission from Chubak J, Yu O, Pocobelli G, et al: Administrative Data Algorithms to 
Identify Second Breast Cancer Events Following Early-Stage Invasive Breast Cancer. J Natl Cancer Inst  
104:931-940, 2012. 
Note: This algorithm was selected due to its estimated high specificity (99%) and positive predictive value (90%). 
Sensitivity (89%) based on a validation study using a different study population (Chubak et al. 2012). See 
Appendix 5.VIII for additional algorithms examined.  
BCS, breast conserving surgery (i.e. breast excision or partial mastectomy); SEER, Surveillance, Epidemiology 
and End Results 
* One woman did not have a surgery that was either a mastectomy or BCS and was excluded from the analysis, 
thus, our sample size went from 24,439 to 24,438 based on our definition of recurrence. ! !
Figure 5.3. Algorithm for identifying a second breast cancer event 
 
 Two visits with a code for a secondary malignant neoplasm within a 60 day period occurring >365 days after the primary 
breast cancer 
(n = 24,439) 
A non-breast cancer record in the 
SEER registry after the primary 
breast cancer 
(n = 1706) 
A second breast cancer 
record in the SEER registry 
(n=22,733) 
A mastectomy >180 days 
after the primary breast 
cancer 
(n= 21,974) 
Second breast 
cancer event 
(n=759) 
No second breast 
cancer event 
(n=128) 
Surgical procedure for the 
primary breast cancer 
(SEER registry) 
(n=290)* 
No second breast 
cancer event 
(n=21,684) 
Second breast 
cancer event 
(n=161) 
Second breast 
cancer event 
(n=1,377) 
No second breast 
cancer event 
(n=329) 
Yes No 
BCS 
Yes 
Yes 
Mastectomy 
Yes 
No 
No 
No 
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Unadjusted data 
 
 
Data adjusted using inverse 
probability weighting 
 
Overall No breast MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= 
17,199 N= 15,198 
N= 
2,001 N=15,045 
N= 
1,992 
Preoperative breast MRI  (%) 11.6 0 100 <0.001    
Re-excision after first surgical 
procedure 33.6 34.2 29.2 <0.001 33.6 35.7 0.34 
Biopsy before first surgical 
procedure 60.8 58.2 80.3 <0.001 61.2 59.5 0.45 
Initial BCS procedure    <0.001   0.16 
Partial Mastectomy 66.1 64.4 78.3  66.3 63.3  
Breast Excision 33.9 35.6 21.7  33.7 36.7  
Tumor size  (%)    0.04   0.34 
≤ 2cm 79.4 79.2 81.1  79.6 81.1  
> 2cm, ≤ 5cm 20.6 20.8 18.9  20.4 18.9  
Tumor grade  (%)    <0.001   0.98 
       Well differentiated 28.2 28 29.7  28.1 27.5  
Moderately differentiated 44.1 43.7 46.7  44.0 44.7  
Poorly differentiated 22.4 22.9 18.7  22.5 22.3  
Grade unknown 5.4 5.5 4.9  5.4 5.5  
Hormone receptor status  (%)    0.02   0.19 
Positive 81.0 80.7 83.3  81.0 77.5  
Negative 11.8 12 10.5  11.9 14.7  
Unknown 7.2 7.3 6.2  7.1 7.9  
Node positivity  (%) 16.5 16.3 17.5 0.17 16.5 17.5 0.50 
Histology    <0.001   0.43 
Ductal 74.1 74.9 67.9  74.5 73.7  
Lobular 9.4 8.5 15.8  9.1 7.8  
Mixed ductal/lobular 7.8 7.4 10.8  7.8 8.7  
Other 8.7 9.2 5.5  8.6 9.9  
NCI Comorbidity Index (%)     <0.001   0.75 
0 65.6 64.5 73.3  65.8 64.7  
Between 0 and 1 27.2 27.8 22.9  27.1 27.4  
Greater than 1 7.3 7.7 3.8  7.1 7.9  
Age at diagnosis  (%)    <0.001   0.81 
65 to 69 22.2 20.5 35.1  22.0 21.4  
70 to 74 25.6 25.1 29.2  25.9 28.0  
75 to 79 24.1 24.7 19.5  24.3 24.2  
80 to 84 17.6 18.3 11.6  17.6 16.9  
85 and older 10.6 11.4 4.5  10.3 9.6  
Married  (%) 47.7 46.7 54.8 <0.001 47.9 46.1 0.38 
State buy-in coverage  (%)    <0.001   0.61 
No 90.6 90 95.1  90.9 91.5  
Yes 9.4 10 4.9  9.1 8.5  
Race  (%)    0.13   0.68 
White 87.2 87.1 88.3  87.5 88.0  
Non-white 12.8 12.9 11.7  12.5 12.0  
Cooperative group affiliation of 
surgical facility  (%)† 51.5 50 63.1 <0.001 51.8 50.3 0.46 
NCI affiliation of surgical       
facility  (%) 
 
5.6 5.4 7.5 <0.001 5.6 6.3 0.38 
Table 5.1. Baseline characteristics of patients for the re-excision analysis (main 
analysis) 
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Unadjusted data 
 
 
Data adjusted using inverse 
probability weighting 
 
Overall No breast MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= 
17,199 N= 15,198 
N= 
2,001 N=15,045 
N= 
1,992 
Surgical facility a teaching 
hospital (or affiliated one) 53.3 52.9 56.5 0.002 53.9  
 
56.6                    0.19 
Surgical volume of surgical   
facility (%)    <0.001   0.2 
Low 48.6 50.9 30.8  48.4 51.0  
High 51.4 49.1 69.2  51.6 49.0  
Zip code proportion with at least 
high school education (% in 
each quartile)    <0.001   0.49 
Low education 25.5 24.0 37.1  25.5 24.2  
Low-medium education 24.4 24.1 26.4  24.7 26.4  
Medium-high education 23.6 23.9 20.9  23.5 21.2  
High education 22.6 24.0 11.8  22.3 23.4  
Unknown education 3.9 3.9 3.8  4.0 4.8  
Year of diagnosis  (%)    <0.001   0.78 
2004 24.6 26.3 11.5  24.3 22.8  
2005 24.2 25.1 16.9  24.4 25.0  
2006 25.6 25.4 26.9  26.0 25.5  
2007 25.6 23.1 44.6  25.4 26.6  
SEER Region (%)    <0.001   0.57 
California registries 32.9 31.9 40.6  33.3 32.0  
Northeast registries 25 24.5 28.6  25.5 28.4  
Georgia 3.2 3.3 2.4  3.3 2.6  
Detroit 7.3 7.6 5.1  7.5 7.2  
Iowa 6.4 6.9 2.5  6.4 6.0  
New Mexico 2.1 1.8 4.5  2.0 1.3  
Seattle 6.1 5.6 10.2  6.0 6.2  
Utah 2.6 2.7 2.1  2.7 2.1  
Kentucky 6.8 7.4 1.6  6.3 7.5  
Louisiana 6.2 6.7 2  6.1 5.0  
Hawaii 1.4 1.5 0.1  1.1 1.7  
p-values by t-test for continuous variables and chi2 test for binary / categorical variables, Mean (Standard 
Deviation) or % 
BCS, breast conserving surgery; MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and 
End Results; NCI, National Cancer Institute 
†  NCI Cooperative Groups having breast cancer research portfolios !!
Table 5.1. Baseline characteristics (cont.) 
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Unadjusted data 
 
 
Data adjusted using inverse 
probability weighting† 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-  
value 
 
No breast 
MRI 
Breast 
MRI p-
value 
   
N=  
24,438 
N= 
21,521 
N= 
2,917 
N= 
21,3521 
N=  
2,917 
Preoperative breast MRI  (%) 11.9 0.0 100.0 <0.001    
Second breast cancer event  9.4 9.2 11.0 0.001 9.1 12.3 0.002 
Time to second breast event 
(years) 1.8 (1.4) 1.9 (1.4) 1.3 (1.3) <0.001 1.8 (1.4) 1.8 (1.6) 0.82 
Most extensive surgery*    <0.001   0.005 
Breast excision 10.0 10.6 5.5  10.3 7.3  
Partial mastectomy 56.2 55.4 62.3  56.7 56.3  
Mastectomy 33.8 34.0 32.2  33.0 36.4  
Received radiation 51.9 50.5 62.4 <0.001 52.2 54.3 0.24 
Received chemotherapy 20.6 19.9 26.1 <0.001 20.7 20.6 0.92 
Tumor size  (%)    0.004   0.02 
≤ 2cm 72.9 72.6 75.1  73.0 76.1  
> 2cm, ≤ 5cm 27.1 27.4 24.9  27.0 23.9  
Tumor grade  (%)    <0.001   0.68 
       Well differentiated 26.3 26.1 27.9  26.3 25.8  
Moderately differentiated 43.8 43.4 46.7  43.9 43.5  
Poorly differentiated 24.5 25.0 20.4  24.4 24.2  
Grade unknown 5.4 5.4 5.0  5.4 6.5  
Hormone receptor status  (%)    0.004   0.52 
Positive 78.9 78.6 81.0  79.0 77.1  
Negative 13.0 13.1 12.3  13.0 13.7  
Unknown 8.1 8.2 6.7  8.0 9.2  
Node positivity  (%) 20.6 20.4 21.8 0.08 20.5 20.3 0.84 
Histology    <0.001   0.41 
Ductal 73.9 74.9 66.7  73.9 72.9  
Lobular 9.7 8.9 16.0  9.8 8.7  
Mixed ductal/lobular 8.0 7.4 12.2  8.0 8.7  
Other 8.3 8.8 5.1  8.3 9.6  
NCI Comorbidity Index (%)     <0.001   0.42 
0 63.6 62.3 73.3  63.9 61.4  
Between 0 and 1 27.9 28.6 22.9  27.9 30.2  
Greater than 1 8.5 9.1 3.8  8.3 8.4  
Age at diagnosis  (%)    <0.001   0.93 
65 to 69 20.5 18.7 33.8  20.6 20.4  
70 to 74 24.7 24.0 29.6  24.8 25.8  
75 to 79 24.1 24.6 20.6  24.3 24.1  
80 to 84 18.8 19.7 11.7  18.8 17.9  
85 and older 12.0 13.0 4.3  11.6 11.7  
Married  (%) 45.8 44.6 54.8 <0.001 45.9 45.3 0.70 
State buy-in coverage  (%)    <0.001   0.49 
No 89.3 88.5 94.9  89.5 90.3  
Yes 10.7 11.5 5.1  10.5 9.7  
Race  (%)    <0.001   0.47 
White 87.0 86.7 88.9  87.1 87.9  
Non-white 
 
13.0 13.3 11.1  12.9 12.1 
 
Table 5.2. Baseline characteristics of patients for the second breast cancer 
event analysis 
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Unadjusted data 
 
 
Data adjusted using inverse 
probability weighting† 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-  
value 
 
No breast 
MRI 
Breast 
MRI p-
value 
   
N=  
24,438 
N= 
21,521 
N= 
2,917 
N= 
21,3521 
N=  
2,917 
Cooperative group affiliation 
of surgical facility  (%)† 51.0 49.3 63.1 <0.001 51.2 49.8 0.42 
NCI affiliation of surgical 
facility  (%) 5.2 4.9 7.1 <0.001 5.3 5.4 0.85 
Surgical facility a teaching 
hospital (or affiliated one, 
%) 52.4 51.8 56.5 <0.001 52.8 54.7 0.28 
Surgical volume of surgical 
facility (%)    <0.001   0.44 
Low  49.8 52.2 32.0  49.5 50.9  
High  50.2 47.8 68.0  50.5 49.1  
Zip code proportion with at 
least high school education 
(% in each quartile)    <0.001   0.48 
Low education 24.6 22.9 37.4  24.7 24.0  
Low-medium education 24.0 23.9 25.3  24.2 24.9  
Medium-high education 23.6 24.0 20.6  23.6 21.7  
High education 23.7 25.3 12.3  23.5 24.9  
Unknown education 4.0 3.9 4.3  4.0 4.6  
Year of diagnosis  (%)    <0.001   0.17 
2004 25.2 27.0 11.8  24.9 22.0  
2005 24.6 25.5 17.8  24.6 25.6  
2006 24.9 24.6 27.1  25.0 24.5  
2007 25.3 22.8 43.4  25.5 27.9  
SEER Region (%)    <0.001   0.59 
California registries 32.3 31.4 39.5  32.5 31.1  
Northeast registries 23.3 22.7 27.4  23.5 26.4  
Georgia 3.3 3.3 2.8  3.3 2.5  
Detroit 6.9 7.1 5.0  6.9 6.8  
Iowa 7.4 8.0 2.8  7.3 7.4  
New Mexico 2.1 1.8 4.3  2.0 1.7  
Seattle 6.3 5.7 11.2  6.4 6.7  
Utah 2.7 2.8 2.3  2.8 2.0  
Kentucky 7.6 8.3 2.5  7.4 8.2  
Louisiana 6.9 7.5 2.2  6.8 5.8  
Hawaii 1.2 1.4 0.2  1.1 1.4  
P-values by t-test for continuous variables and chi2 test for binary / categorical variables, Mean 
(Standard Deviation) or % 
BCS, breast conserving surgery; MRI, Magnetic Resonance Imaging; SEER, Surveillance, 
Epidemiology and End Results; NCI, National Cancer Institute 
*  Variable not included in model generating inverse probability weights 
† NCI Cooperative Groups having breast cancer research portfolios 
  
  
Table 5.2. Baseline characteristics of patients for the second breast cancer 
event analysis (cont.) 
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Figure 5.4a. Breast MRI propensity score distribution for the analysis 
examining re-excisions (n=17,199) 
 
Figure 5.4b. Breast MRI propensity score distribution for the analysis 
examining second breast cancer events  (n=24,438) 
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Table 5.3. Impact of preoperative breast MRI on the likelihood of a re-excision after 
BCS (main analysis, n=17,199) 
  Odds ratio 
95% Conf. 
Interval n 
Unadjusted logistic regression  0.80*** [0.72, 0.88] 17,199 
Logistic regression adjusted for covariates†  1.04 [0.93, 1.17] 17,199 
Logistic regression using IPW‡  1.11 [0.92, 1.35] 17,199 
* p<0.05, ** p<0.01, *** p<0.001 
BCS, breast conserving surgery (i.e., breast excision or partial mastectomy) MRI, Magnetic Resonance Imaging; 
IPW, Inverse probability weighting 
† See Appendix Table B.4 for the coefficients of the additional included variables 
‡ Robust standard errors 
 
 
 
Table 5.4. Impact of preoperative breast MRI on the likelihood of a re-excision after 
partial mastectomy (sub-analysis, n=11,362) 
  Odds ratio 
95% Conf. 
Interval n 
Unadjusted logistic regression 1.01 [0.88, 1.16] 11,362 
Logistic regression adjusted for covariates† 0.92 [0.79, 1.07] 11,362 
Logistic regression using IPW‡ 0.67 [0.78, 1.47] 11,362 
* p<0.05, ** p<0.01,  *** p<0.001 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting 
† See Appendix Table B.7 for the coefficients for the additional covariates 
‡ Robust standard errors  
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Table 5.5. Association between breast MRI and a second breast cancer event 
  
Hazard/
odds 
ratio 
95% Conf. 
Interval n 
Hazard of a second breast cancer event 
   Unadjusted proportional hazard model 1.31*** [1.17, 1.48] 24,438 
Proportional hazard model adjusted for covariates†  1.29*** [1.14, 1.46] 24,438 
Proportional hazard model with IPW  1.37*** [1.11, 1.68] 24,438 
Proportional hazard model with IPW, adjusted for the 
first surgical treatment after estimating the IPW† 
 1.32** [1.07, 1.63] 24,438 
   
Likelihood of a second breast cancer event within 1 year§ 
  Unadjusted logistic regression 2.39*** [1.99, 2.86] 24,438 
Logistic regression adjusted for covariates‡ 2.16*** [1.76, 2.64] 24,438 
Logistic regression using IPW 2.13*** [1.54, 2.94] 24,438 
Logistic regression using IPW, adjusted for the first 
surgical treatment after estimating the IPW  
2.07*** [1.51, 2.84] 
 
24,438 
Likelihood of a second breast cancer event within 3 years§ 
  Unadjusted logistic regression  1.74*** [1.50, 2.01] 19,821 
Logistic regression adjusted for covariates‡  1.66*** [1.42, 1.95] 19,821 
Logistic regression using IPW  1.43** [1.12, 1.82] 19,821 
Logistic regression using IPW, adjusted for the 
complete treatment after estimating the IPW  
 1.39** 
 
[1.10, 1.76] 
 
19,821 
Likelihood of a second breast cancer event within 5 years§ 
  Unadjusted logistic regression  2.86*** [2.44, 3.36] 10,278 
Logistic regression adjusted for covariates‡  2.11*** [1.77, 2.52] 10,278 
Logistic regression using IPW  1.57** [1.20, 2.07] 10,278 
Logistic regression using IPW, adjusted for the 
complete treatment after estimating the IPW 
 1.57** 
 
[1.20, 2.05] 
 
10,278 
Note: IPW analyses use robust standard errors  
* p<0.05, ** p<0.01,  *** p<0.001" 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting 
† See Appendix Table B.5 for the coefficients for the additional covariates 
‡ See Appendix Table B.5 for covariates included in the models (coefficients not reported).  
§ Sample size reflects excluding due to limited follow-up. We excluded women who did not have complete follow-
up at 3 (n=4,617) or 5 years (n=14,160). 
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CHAPTER 6: ESTIMATING THE COSTS OF INITIAL CANCER TREATMENT RELATED TO 
PREOPERATIVE BREAST MRI IN ELDERLY BREAST CANCER PATIENTS
Overview 
Background: The cost of breast cancer care is escalating. Evidence suggests that growing 
breast cancer prevalence, changing treatment patterns, and use of advanced imaging are all 
contributing to the increasing cost burden. Research has shown that preoperative breast 
magnetic resonance imaging (MRI), an advanced imaging procedure being adopted rapidly, 
may change treatment patterns through additional diagnostic work-up and an increased 
likelihood of more extensive surgery. However, to date, there is a dearth of literature 
examining the cost associated with breast preoperative MRI in the United States. The goal 
of this analysis was to estimate the costs associated with breast MRI for elderly breast 
cancer patients in the United States from the perspective of Medicare. 
In this large, population-based, observational study, we identified women diagnosed 
between 2004-2007 with early-stage (I-IIB), operable breast cancer from the Surveillance, 
Epidemiology, and End Results-Medicare dataset. Using claims from 2004 through 2009, 
we identified Medicare payments during the initial treatment phase, which included the 
diagnostic, preoperative, surgical, and adjuvant therapy stages of care. For women with and 
without a preoperative breast MRI, we examined unadjusted total all-cause and breast 
cancer-attributable Medicare payments per-patient during the initial treatment phase. 
Further, we used generalized linear models to estimate the adjusted multiplicative and 
marginal effects of preoperative breast MRI on all-cause or breast cancer-attributable 
Medicare payments. 
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Of the 22,974 women included in our sample, twelve percent (n=2,751) had a 
preoperative breast MRI. Women with breast MRI, on average, had higher unadjusted, per-
person Medicare payments than those without MRI during the initial treatment phase, which 
lasted an average of 4.9 months. The average all-cause Medicare payment was $23,683—
$22,987 for the non-MRI group and $28,795 for the MRI group (p-value <0.001). The 
average per-patient, breast cancer-attributable payment was $19,749, $19,025 for the non-
MRI group and $25,075 for the MRI group (p-value <0.001). In our multivariate models, we 
found that preoperative breast MRI was associated with 10%-higher all-cause payments 
[95% CI: (1.08, 1.13)] and 14%-greater breast cancer-attributable payments [95% CI: (1.12, 
1.16)] during the initial treatment phase. The average marginal effect of breast MRI was 
$2,348 for all-cause payments and $2,619 for breast cancer-attributable payments [95% CI: 
($1,771, $2,924), ($2,208, $3,030)]. Payments not attributable to breast cancer during the 
initial treatment phase did not significantly differ by MRI receipt 
The additional cost to Medicare associated with breast MRI should be evaluated in 
concert with preoperative breast MRI effectiveness data to inform policy makers about the 
value of breast MRI in the elderly breast cancer population. 
Introduction 
Breast cancer is the most common cancer among women, with an estimated 3.5 
million breast cancer survivors in the US as of 2020. Its prevalence is expected to grow to 
4.5 million by 2010.1 With an estimated $16.5 billion spent nationally on breast cancer, it is 
the most expensive cancer site with costs comprising 13.3% of total healthcare spending on 
cancer. Based on US population changes alone, it has been estimated that national 
expenditures for breast cancer will increase by 24.2% and reach $20.5 billion by 2020.1  
Spending on breast cancer is not only growing due to increased prevalence, but also due to 
escalating treatment costs per-patient. 2-4  It has been estimated that the inflation-adjusted 
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cost of the initial phase of care for each breast cancer patient increased by 25% from 
$16,775 in 1991 to $20,964 in 2002.5 
Given the increasing cost burden of breast cancer, it is important to examine what 
factors drive the cost of breast cancer care.  The rising cost of breast cancer treatment has 
been attributed to changes in treatment patterns and to the increased use of targeted 
therapies and supportive medicine.2-4 Additionally, it has been estimated that the growing 
use of advanced imaging contributes to the accelerating cost, which are increasing at a 
greater rate than the total costs among Medicare beneficiaries with cancer.6,7 
Breast magnetic resonance imaging (MRI) is an example of an advanced imaging 
modality that is being rapidly adopted.6,8-20 The percentage of elderly breast cancer patients 
with preoperative breast MRI increased from 1.2% in 2002 to 18.8% in 2007.17  However, 
evidence suggests that breast MRI may not be associated with improved outcomes, such as 
fewer reoperations21-26!or lower recurrence rates10,20,24-27 (see results from Chapter 5).  
Preoperative breast MRI is used in addition to conventional assessment (i.e., mammogram 
and ultrasound, as needed)27 to measure the extent of disease as a part of surgical planning 
in women with newly diagnosed breast cancer. It is worth noting that, breast MRI is used for 
other, non-preoperative indications such as to screen high risk women 16,27-34 or to monitor 
responses to neoadjuvant therapy;35-41 however, these uses are not the focus of the present 
study. 
Research has shown that preoperative breast MRI may change treatment patterns in 
ways that can affect the cost of the initial treatment phase. First, breast MRI has been 
associated with additional diagnostic procedures, such as second-look ultrasounds and MR- 
or ultrasound-guided biopsies,25,42,43 which is consistent with guidelines recommending that 
suspicious lesions identified on breast MRI should be pathologically confirmed with a 
biopsy.27,36,44,45 As well, evidence suggests that breast MRI is associated with an increased 
likelihood of a mastectomy as the first surgical procedure21-25!(Chapter 4), a more extensive 
 ! 171 
and expensive surgery compared to breast conserving surgery (BCS). Additionally, one of 
the purported benefits of breast MRI is that it improves surgical planning and reduces the 
likelihood of re-excision; however, research has shown that women with and without a 
preoperative breast MRI have a similar likelihood of re-excision21-26 (Chapter 5), suggesting 
that there will be no difference in costs for re-excision for women with and without 
preoperative breast MRI. 
To our knowledge, no study has examined the association between breast MRI and 
the cost of initial treatment in the United States. The only study to examine the cost of breast 
MRI is a randomized controlled trial conducted in the United Kingdom,46 which found a small 
difference in cost between women who received breast MRI and those women who did not 
(£5,508 compared with £5,214). After controlling for other covariates, however, this 
difference was not statistically significant. However, because breast cancer treatment 
patterns, payment structures, and decision-making factors are different in the United States 
compared to the United Kingdom,47-51 it is important that the cost of breast MRI be examined 
in the United States.  
 The purpose of this analysis was to estimate the costs associated with preoperative 
breast MRI during the initial treatment phase for elderly breast cancer patients. Using 
Medicare claims from 2004 through 2009, we identified all-cause and breast cancer-
attributable Medicare payments during the initial treatment phase (mean 4.9 months), which 
we defined to include the diagnostic, preoperative, surgical, and adjuvant therapy stages of 
care (See Table 6.1). We compared unadjusted all-cause and breast cancer-attributable 
payments during the initial treatment phase for women with and without preoperative breast 
MRI.  Further, we used multivariate generalized linear models to generate the adjusted 
multiplicative and marginal effects of preoperative breast MRI on all-cause and breast 
cancer-attributable Medicare payments. We hypothesized that breast MRI would be 
associated with increased costs to Medicare in the initial treatment phase due to the 
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additional cost of the procedure itself, along with its association with supplementary 
diagnostic work-up and more extensive surgeries. 
Methods 
Data 
 We used the SEER-Medicare dataset to conduct this retrospective study. The SEER-
Medicare dataset links 17 population-based cancer registries across the United States to 
Medicare administrative data and healthcare claims.52 The SEER registries cover 
approximately 25% of the incident US cancer population. The SEER-Medicare dataset is 
comparable to the overall US population with regard to measures of poverty and 
education.52 SEER registry data capture demographic and incident cancer characteristics, 
including stage, grade, and histology as well as treatment information and vital statistics.53 
The SEER data also contain ecological measures of income, education, and other 
characteristics at each patient’s census tract and zip code of residence. The Medicare data 
cover claims for hospital services, physician services, some drug therapy, and other medical 
services. Medicare data include information about the use and cost of health care services 
and co-morbid health conditions. The National Cancer Institute (NCI) hospital file contains 
hospital-level information, including staffing, structure, research network affiliation, and 
information on accreditation. 
Study Population 
 The present study included women with a primary diagnosis of unilateral, 
pathologically confirmed, stage I-IIB operable breast cancer identified from SEER-Medicare 
data (with staging determined by the American Joint Committee on Cancer [AJCC] sixth 
edition, International Statistical Classification of Diseases and Related Health Problems, 9th 
revision, clinical modification [ICD-9-CM] code 147). Women were included if they were 
diagnosed with their first primary breast cancer between January 1, 2004 and December 31, 
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2007, and had no previous cancers. Focusing on elderly breast cancer patients, we 
excluded women who were younger than 66 at diagnosis or enrolled in Medicare for renal 
disease or disability. We also excluded women who were not continuously enrolled in 
Medicare Part A and Part B, and who were enrolled in a health maintenance organization 
(HMO) during the study period because these beneficiaries would have incomplete claims in 
the SEER-Medicare dataset, and we would be unable to examine their healthcare utilization 
in its entirety. The National Cancer Institute (NCI) comorbidity index54  was calculated based 
on 12 months of claims. Thus, women not enrolled 12 months prior to diagnosis were 
excluded (SEER-Medicare inclusion/exclusion table can be found in Appendix Table C.1).    
We limited this analysis to women whose first definitive treatment was surgery, thus 
excluding women who received neoadjuvant chemotherapy prior to surgery. These women 
were excluded because breast MRI can also be used to measure tumor response to 
neoadjuvant chemotherapy,37-41 which is not the focus of this study. We also excluded 
patients who had conflicting claims for mastectomy and partial mastectomy on the same day 
in the Medicare outpatient, inpatient, and physician files. We excluded these women 
because we were unable to determine the type of initial surgery. We also excluded women 
who had their first biopsy or breast surgical procedure more than four months before or after 
the SEER diagnosis month because we were concerned that these surgical claims did not 
correspond to the first primary breast cancer identified from the SEER registry. We 
eliminated women who died within 12 months of diagnosis or women who died during 
treatment because research has shown that healthcare utilization and cost is significantly 
different in the terminal phase of care than in the initial phase of care,55-61 which is the focus 
of the present study. Study inclusion/exclusion criteria are presented in Figure 6.1. 
Variables and Measures 
We examined all claims during the initial treatment phase (Table 6.1) from 2004 
through 2009. The initial treatment phase was defined to capture the diagnostic, 
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preoperative, and initial treatment stages and to include all costs from when the patient was 
first suspected of having breast cancer up through the end of the patient’s initial treatment 
and lasted an average of 4.9 months. Specifically, the start of the initial treatment phase 
began on the date of the first claim for a suspected breast disorder (e.g., lump or mass in 
breast, or abnormal mammogram; see Appendix Table C.2 for codes) 12 or fewer months 
prior to the SEER diagnosis month. We defined the end of the initial treatment phase as the 
last day of breast cancer treatment (i.e., partial mastectomy, mastectomy, radiation, or 
chemotherapy; for codes, see Appendix Table C.2) before a treatment gap of more than 90 
days,62-64 the patient’s death, or the end of the study period, which was December 31, 2009. 
We identified healthcare utilization, breast cancer events, and Medicare payments using the 
Medicare outpatient, carrier, and Medicare Provider Analysis And Review (MEDPAR) files 
using American Medical Association Current Procedural Terminology (CPT), Healthcare 
Common Procedure Classification System (HCPCS) and International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) for codes (See Appendix Table 
C.2). 
Our independent variable of interest was a binary indicator for whether or not the 
patient received a preoperative breast MRI. Patients were classified as having a 
preoperative breast MRI if they had a claim for a breast MRI (CPT: 76093-94, 77058-59, 
HCPCS: C8903-C8908) on or after the first day of suspected breast disorder but before the 
date of their first surgical procedure. Though this approach may capture breast MRIs that 
were ordered for screening purposes, we are not concerned about including these breast 
MRIs as “preoperative” because breast images taken during the initial treatment phase, 
even for screening purposes, would most likely be used as a part of the surgical planning 
process (Dr. Keith Amos. Personal communication. May 23, 2012). 
Healthcare utilization during the initial treatment phase. To examine whether 
differential breast cancer-attributable healthcare utilization exists for women with and without 
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breast MRI, we identified breast cancer diagnostic and therapeutic services (See Table C.2 
for HCPCS and ICD-9-CM codes). We included diagnostic procedures such as 
mammograms, ultrasounds, and biopsies, and surgical procedures, such as the receipt of a 
mastectomy, as the initial surgery and adjuvant, post-surgical treatments, such as radiation 
and chemotherapy.  
Initial treatment phase costs.  Our main dependent variable of interest was cost from 
a Medicare perspective. Thus, we defined cost as the amount paid by Medicare. This 
approach is consistent with previous SEER–Medicare cost of care studies.5,55,65 Medicare 
payments, unlike Medicare charges, are an appropriate proxy for medical care costs 
because they are payments derived from reimbursement formulas intended to reflect the 
average resource utilization for that health service.5  However, Medicare payments do not 
include healthcare payments from private insurance or supplemental insurers, such as 
Medigap or Medicaid, and do not include the beneficiary’s co-insurance amount or 
deductible. Costs not included in our estimates include costs for oral prescription 
medications such as oral chemotherapy, patient prescription drugs, and chemotherapy not 
administered by a physician. All costs were adjusted to 2012 dollars using the Consumer 
Price Index for medical care to account for medical inflation.66  
We examined several different estimates of cost per-patient during the initial 
treatment phase (Table 6.1), including total all-cause and total breast cancer-attributable 
Medicare payments. For each patient, the total all-cause Medicare payment was defined as 
the sum of Medicare payments during the initial treatment phase for all claims found in the 
outpatient, carrier, and MEDPAR files. The total breast cancer-attributable Medicare 
payment was the sum of each patient’s Medicare payments during the initial treatment 
phase from claims for breast biopsy, breast surgery, chemotherapy, radiation, mammogram, 
ultrasound, breast MRI, or from a claim with a breast diagnosis code within the claim’s first 
four diagnosis codes from the outpatient and carrier files. To examine if non-cancer related 
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care costs differ by MRI receipt, we defined payments not attributable to breast cancer as 
the difference between all-cause and breast cancer-attributable payments.  
Additional covariates. We examined numerous variables that could potentially be 
associated with breast MRI receipt and confound the relationship between breast MRI and 
cost. We included a variable for tumor histology (ductal, lobular, mixed ductal lobular, and 
other) because research has shown that lobular tumors are more likely to be 
mammographically occult and, thus, patients may be more likely to receive and/or benefit 
more from breast MRI.67 Tumor characteristics examined included grade (well, moderately, 
poorly/undifferentiated, and undetermined), tumor size (≤ 2cm vs. > 2cm & ≤ 5cm), any node 
positivity (yes vs. no), and hormone receptor status identified from SEER data (positive 
[ER+/PR+, ER+/PR-, ER+/no PR data, ER-/PR+, or no ER data/PR+], negative, unknown). 
We used the NCI Combined Comorbidity Index method to address competing health 
demands and risks of complications that may affect treatment selection (0, 0-1, >1).54 
Demographic characteristics examined included age group at diagnosis (in 5-year 
increments), marital status (married vs. unmarried), race (white vs. nonwhite), Medicare 
state buy-in coverage (yes vs. no), residence in a metropolitan zip code (yes vs. no), and 
SEER region. We also included surgical facility characteristics, such as whether it was a 
designated NCI Cancer Center  (yes vs. no) or whether or not the facility was affiliated (yes 
vs. no) with NCI Cooperative Groups having breast cancer research portfolios (i.e., 
American College of Surgeons Oncology Group, Eastern Cooperative Oncology Group, 
Cancer and Leukemia Group B, Southwest Oncology Group, and the National Surgical 
Adjuvant Breast and Bowel Project).68  
 Additionally, we included indicators for other diagnostic procedures and treatments in 
our models that may confound the relationship between breast MRI and cost. Previous 
research has shown that breast MRI is associated with the receipt of additional advanced 
imaging tests41 that may increase the cost of the initial treatment phase. Thus, we included 
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an indicator for whether or not the patient had a claim for an “advanced imaging” test 
defined by previous research7,69 (i.e., computed tomography [CT], positron emission 
tomography, bone scan, brain magnetic resonance imaging, or nuclear medicine). Because 
chemotherapy and radiation therapy represent a large proportion of the initial treatment 
episode’s cost,70,71 we also included indicators for whether the patient had chemotherapy or 
radiation. Although these diagnostic procedures and treatments are correlated with breast 
MRI and cost, we assumed breast MRI receipt did not cause the receipt of advanced 
imaging, chemotherapy, and radiation.  
Because a mastectomy is an extensive inpatient procedure, women with 
mastectomies may have higher surgical costs than women with BCS. Additionally, women 
receiving a breast MRI may be converted to mastectomy from BCS based on additional MRI 
findings,21 and research has shown that women with a breast MRI are more likely to 
undergo a mastectomy as their initial surgery (Chapter 4).21-25 Thus, we considered including 
an indicator for whether or not the patient had a mastectomy as her initial treatment. We 
also examined whether stratifying by mastectomy receipt was appropriate. The effect of 
breast MRI was quantitatively similar, regardless of the model used (no mastectomy 
indicator 1.14, 95% CI: [1.12 1.16], mastectomy indicator included in the model, 1.13, 95% 
CI:  [1.10 1.15], patients with mastectomies only 1.14, 95% CI: [1.10 1.19], patients with 
BCS only 1.13, 95% CI: [1.09 1.15])), but slightly lower when we controlled for mastectomy 
receipt. Based on the hypothesized relationship between breast MRI and mastectomy, we 
assumed that mastectomy was a mediator and on the causal pathway from MRI to cost, and 
thus, we omitted mastectomy from our final model.  
Statistical Analyses 
Descriptive statistics were calculated for patients with and without a preoperative 
breast MRI.  We tested for differences in the clinical, demographic, and treatment 
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characteristics across patients with and without breast MRI using the Pearson chi-squared 
test for categorical variables and the Student’s t-test for continuous variables. We also used 
t-tests and chi-squared tests in our bivariate analyses of breast MRI receipt and different 
measures of healthcare utilization and cost.  
In our multivariate analyses examining the association between breast MRI and cost, 
we fitted a generalized linear model (GLM) with a log-link and gamma distribution variance 
function with robust standard errors.72,73  We used a log transformation to normalize the cost 
distribution, which is typically highly skewed.44 Because all of the women in our sample had 
surgery within our study’s timeframe, almost all women had Medicare payments during the 
initial treatment phase and two-part models were not required.74,75  (Note: Ten women did 
not have any Medicare payments, which may be due to the fact that some private insurers 
may pay before Medicare.76) 
Diagnostic and procedure codes were identified and verified using the medical 
literature, coding experts, EpiCoder (Yost Engineering Inc., Ohio) and the Integrated Cancer 
Information and Surveillance System coding references.77 Analyses were performed using 
Stata version 12.0 (Stata Corporation, College Station, Texas). All tests were conducted 
using a minimum significance level of 0.05.  
Sensitivity Analysis 
Much of the previous literature examining the cost of the initial breast cancer 
treatment phase with SEER-Medicare data uses a 12-month window beginning with 
diagnosis.60,78 Since our definition of initial treatment phase comprised an average of 4.9 
months, in order to make our results comparable, we replicated all of the analyses described 
above using a 12-month time frame. Rather than included all claims from the first claim for a 
suspected breast disorder to the end of treatment as was done in the main analysis, in the 
sensitivity analysis, we included all claims from the 12 months after the first claim for a 
suspected breast disorder. Other than capturing a different time frame, the cost definitions 
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remained the same (i.e., for all-cause and breast cancer-attributable payments) and 
identical covariates were included in the multivariate models. 
Results 
 Of the 26,751 women diagnosed with stage I-IIB breast cancer between 2004-2007 
from SEER-Medicare data, 22,974 women were included in our sample (Figure 6.1). Twelve 
percent (12.0%) of women in our sample received a preoperative breast MRI (Table 6.2). 
The initial treatment phase lasted an average of 4.9 months, 4.8 months for women who 
received an MRI and 5.9 months for women who did not. On average, when compared to 
patients that did not receive a breast MRI, patients with breast MRI were more likely to 
experience longer treatment duration, have invasive lobular carcinoma, have a hormone 
receptor-positive tumor, be healthier, younger, white, married, and not in a Medicare state 
buy-in program. Patients with a breast MRI also were more likely to be diagnosed more 
recently, live in a metropolitan zip code, and had surgery at a breast cancer Cooperative 
Group and NCI-affiliated facility. MRI receipt also significantly differed by SEER region.  
Patients with breast MRI had different healthcare utilization patterns compared with 
women who had not undergone preoperative breast MRI with respect to services received 
during diagnosis and initial treatment (Table 6.3). Women with breast MRI were more likely 
to have a claim for a mammogram, ultrasound, biopsy, and advanced imaging, such as 
nuclear medicine tests, CT and PET scans. Women with breast MRI, on average, were 
more likely to have a mastectomy as their first surgical procedure and to receive radiation 
and chemotherapy.  
 In analyses examining unadjusted costs during the initial treatment phase (Table 
6.4), women with preoperative breast MRI were significantly more likely to have higher costs 
than those women who had not undergone preoperative breast MRI with the exception of 
payments not attributable to breast cancer.  Overall, the mean per-patient, all-cause 
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payment during the initial treatment phase was, on average, $23,683, which amounted to 
$22,987 for women without a preoperative breast MRI and $28,795 for women with a breast 
MRI (p <0.001). The mean per-patient, breast cancer-attributable payment was $19,749 for 
all patients, which amounted to $19,025 for women without a preoperative breast MRI and 
$25,075 for women with a breast MRI (p <0.001).  The difference in costs for other causes 
was not statistically significant (p=0.31) and accounted for roughly $3,900 for all patients.  
 Multivariate analyses. In our multivariate models, breast MRI was significantly 
associated with an increase in Medicare payments for all-cause and breast cancer-
attributable payments (Table 6.5) in the initial treatment phase. On average, women with a 
breast MRI had 10%-higher total all-cause payments (95% confidence interval [CI]: 1.08, 
1.13) and 14%-higher breast cancer-attributable payments (95% CI: 1.12, 1.16), The 
average marginal effect of breast MRI on all-cause Medicare payments was $2,348 (95% 
CI: $1,771, $2,924) and $2,619 for breast cancer-attributable payments (95% CI: $2,208, 
$3,030). Medicare payments in the initial treatment phase not attributable to breast cancer 
were not significantly different according to preoperative breast MRI receipt.  
 Sensitivity analysis. In our sensitivity analysis we repeated analyses using a 12-
month time frame rather than what we defined as the initial treatment phase earlier, which 
lasted on average of 4.9 months. All payments in all categories (i.e., all-cause, breast 
cancer-attributable, non-breast cancer-attributable) were higher than those in our main 
sample (See Table 6.4), most likely due to the extended time frame. In the multivariate 
analyses (Table 6.5), the effect of breast MRI on breast cancer-attributable payments was 
similar to results from our main analysis (1.11, 95% CI: 1.08, 1.12). However, breast MRI 
was not significantly associated with increased all-cause Medicare payments (1.03, 95% CI: 
1.00, 1.06). Thus, the increases in breast cancer-attributable payments may have been 
offset by reductions in costs for other causes since breast MRI receipts was significantly 
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associated with a reduction in payments not attributable to breast cancer (0.86, 95% CI: 
0.79, 0.94). 
Discussion 
In this large, population-based, observational study of elderly women with breast 
cancer, we found that breast MRI was significantly associated with increased total all-cause 
and breast cancer-attributable Medicare payments during the initial treatment phase, which 
lasted on average 4.9 months. Breast MRI was associated with 10%-higher all-cause 
payments and 14%-higher breast cancer-attributable payments during the initial treatment 
phase. On average, breast MRI reciept was associated with an increase of $2,348 for all-
cause payments and $2,619 for breast cancer-attributable payments. Payments not 
attributable to breast cancer during the initial treatment phase did not significantly differ 
according to MRI receipt. 
We believe that Medicare costs during the initial treatment phase are higher among 
women receiving breast MRI than in women who did not receive breast MRI for several 
reasons. First, since breast MRI augments rather than replaces some or all of conventional 
assessment, there is the additional upfront cost of the procedure, an average of $617. 
Second, breast MRI may influence treatment patterns in ways that increases costs. 
Consistent with previous literature,25,42,43 our analyses demonstrated that breast MRI is 
associated with additional diagnostic procedures, such as ultrasounds and biopsies, which 
is consistent with guidelines recommending that suspicious lesions identified by breast MRI 
should be followed up with second-look ultrasound and pathologically confirmed with a 
biopsy before implementing changes in clinical management.27,36,44,45 Additionally, breast 
MRI may have affected surgical treatment by causing conversion from BCS to mastectomy 
based on the additional findings of the MRI,21 which would result in higher surgical treatment 
costs. We observed this effect when we controlled for mastectomy receipt in the models, 
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and the effect of breast MRI was attenuated (OR 1.14, 95% CI: [1.12,1.16] main model, 
breast cancer-attributable payments; OR 1.13, 95% CI: [1.10,1.15] model controlling for 
mastectomy receipt). Furthermore, although one of the purported benefits of breast MRI is 
that it improves surgical planning, women with and without a preoperative breast MRI may 
have a similar likelihood of re-excision (Chapter 5 and other studies21-26), suggesting that 
women who received a preoperative breast MRI may not have fewer re-excision costs than 
those who did not receive a preoperative breast MRI. 
Our estimates of breast cancer treatment costs are comparable to other sources 
using SEER-Medicare data with breast-cancer attributable costs amounting to $23,683 
during the initial treatment phase.1,5,79 When examining breast MRI compared to other 
drivers of high-cost cancer care, the effect of breast MRI on costs was not as strong as other 
breast cancer services, such as chemotherapy and radiation therapy. Women receiving 
radiation therapy had a 61% increase in breast cancer-attributable payments (95% CI: 1.59, 
1.64), and women receiving chemotherapy had a 138% increase in breast cancer-
attributable payments (95% CI: 2.32, 2.44). The results are shown in Appendix Table C.3.  
Although breast MRI might not be a primary driver of breast cancer costs, the used 
of this procedure is costly to Medicare. Breast MRI is being rapidly adopted with the 
percentage of older women receiving breast MRI increasing from 2.5% in 2004 to 20.5% in 
2007. If MRI utilization remains constant at the 2007 level (roughly 20%), Medicare would 
spend an average of $11.4 million on breast MRI procedures and experience an additional 
$48.1 million for breast cancer care annually. With the projected increase in breast cancer 
prevalence,1 we would expect these figures to rise to $14.8 million and $62.9 million, 
respectively by 2020.  
The increased cost to Medicare associated with preoperative breast MRI is 
concerning given the mounting evidence suggesting that breast MRI does not improve 
patient outcomes. Two randomized controlled trials, numerous retrospective single 
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institution studies, several meta-analyses, and one observational study using the elderly 
SEER-Medicare breast cancer population (Chapter 5) have shown that breast MRI does not 
significantly improve short-term surgical outcomes, such as fewer reoperations21-26 or lower 
recurrence rates10,20,24-27 (see results from Chapter 5).  In the absence of survival or 
recurrence differences, quality of life would have to significantly improved to justify its 
routine use. However, recent evidence suggests that quality of life may not be improved,80-83 
as breast MRI has been shown to be associated with an increased likelihood of mastectomy 
compared to BCS (Chapter 4).21-25 Additionally, two studies have shown that preoperative 
breast MRI does not improve quality-adjusted life expectancy.46,84 Furthermore, the one 
randomized controlled trial that examined the cost-effectiveness of breast MRI in the United 
Kingdom determined that “the addition of MRI to triple assessment did not result in a 
reduction in operation rates, and the use of MRI would thus consume extra resources with 
few or no benefits in terms of cost-effectiveness or health-related quality of life (p. iv).”46  
 Though it is unlikely that breast MRI is cost-effective based on our findings in 
Chapter 5 as well as mounting efficacy and effectiveness data, future research could use 
our cost data in combination with efficacy and effectiveness data to examine the cost-
effectiveness of breast MRI. Future research could utilize our estimates of the per-person 
cost to assess the upfront cost of the procedure and the downstream effects of breast MRI 
on cancer costs in combination with outcome data, such as disease-free survival, overall 
survival, and health related quality of life. By quantifying the costs and benefits of breast 
MRI using a common measure, such as quality adjusted life years or years of life saved, we 
could then compare the cost-effectiveness of breast MRI to the cost-effectiveness of other 
breast cancer diagnostic procedures and treatments.   
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Limitations 
Our study has several limitations. First, as in all observational studies, we are 
concerned with omitted variable bias. Women who received breast MRI may differ from 
women who did not receive breast MRI based on unobserved characteristics such as 
unmeasured tumor biology, health seeking-behavior, access to healthcare, and patient and 
provider preferences for certain diagnostic procedures and treatments. These unmeasured, 
omitted variables may be associated with healthcare utilization and initial treatment costs 
and, thus, have the potential to bias our estimates. For example, who received breast MRI 
may have higher initial treatment phase costs because they have more invasive or 
complicated cancers17 than those women who do not undergo breast MRI. These women 
may have undergone a breast MRI because their tumor was inadequately imaged with 
conventional assessment.26,35,43,44 Thus, these women may have needed additional 
diagnostic mammograms, ultrasounds, or nuclear medicine tests in addition to the breast 
MRI that assisted in determining the extent of disease.85,86 We attempted to control for 
cancer tumor biology by including tumor size, grade, histology, nodal status, and adjuvant 
therapy receipt in our models. When compared to women who did not receive a breast MRI, 
women who undergo breast MRI may be more likely to have access to more expensive 
cancer care technologies in addition to MRI,69,87 which may increase the likelihood of 
receiving these procedures68,81 and increase initial treatment phase costs, regardless of a 
perceived indication of clinical benefit. We attempted to control access to and use of 
expensive cancer technologies/therapies by including indicators in our models for whether 
or not the patient received advanced imaging, chemotherapy and/or radiation therapy. By 
examining payments not attributable to breast cancer care, we assessed whether women 
with breast MRI had a higher baseline propensity for overall healthcare utilization, 
independent of their cancer treatment, which would bias our all-cause initial treatment phase 
costs. However, we do not believe that is the case since the association between breast 
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MRI and non-cancer related payments in the initial treatment phase was statistically non 
significant (Table 6.4), and breast MRI was associated with a reduction in non-cancer 
payments during the first 12 months after the first suspicion of breast cancer in the 
sensitivity analysis.  Despite our best efforts to mitigate omitted variable bias, we were 
unable to control for all factors that potentially confound the relationship between breast MRI 
and cost and, thus, we are unable to conclude that the observed effect is due to the impact 
of preoperative breast MRI on treatment patterns alone. 
Second, for our estimate of cancer care cost, we included only those costs directly 
related to cancer management, rather than using a comparison group without cancer. 
Though we were concerned that this may somewhat underestimate the costs by possibly 
not capturing the side effects associated with cancer treatment, we employed several 
measures to ensure this was not the case. First, for our main analysis we included only 
costs during the first treatment phase (~4.9 months) rather than the entire first year of 
diagnosis to provide a more accurate estimate of costs incurred when the patient was 
actually in the preoperative phase or in active treatment. Second, when identifying “breast 
cancer-attributable” claims, we conducted a sensitivity analysis (not reported) to determine 
the appropriate diagnosis code position (i.e. first through tenth) that would most likely 
capture services for breast cancer.  We conducted this sensitivity analysis because we were 
concerned that women may have a breast cancer diagnosis code in later diagnosis code 
positions even if the claim was for something non-cancer related because they were in the 
initial breast cancer treatment phase. In our sensitivity analysis, we compared the costs in 
claims with breast cancer diagnosis code in the first position compared to the cost in claims 
with a breast cancer code in the sixth diagnosis code position or lower. We determined that 
claims with a breast cancer diagnosis code in the first through fourth positions were 
appropriate to capture cancer costs. 
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Third, because we used SEER-Medicare data, we were limited in that we were only 
able to focus on costs reimbursed by Medicare. We were unable to capture breast cancer 
services not paid for by Medicare, such as care provided by private health insurance 
through an employer or services for which Medicare does not reimburse.  We also were 
unable to include any insurance payments secondary to Medicare or co-insurance or 
deductibles paid by the beneficiary. We did not capture other indirect costs, such as 
productivity loss. Additionally, our study has the usual SEER-Medicare dataset limitations, 
including concern about the generalizability to all elderly breast cancer patients due to the 
exclusion of patients who are not continuously enrolled in fee-for-service Medicare.  
Conclusion 
Recent concerns about the increasing use of advanced imaging, changing treatment 
patterns, and escalating cancer costs prompted us to undertake this study estimating the 
effect of breast MRI on costs of cancer care among elderly women enrolled in 
Medicare.4,6,7,69 Proponents of healthcare cost containment strategies have stressed the 
importance of using evidence-based medicine to address the increasing costs of cancer 
care.2,51 The adoption of preoperative breast MRI is an example of just the opposite, an 
additive advanced imaging modality with limited evidence that it improves patient outcomes 
that changes treatment patterns. In this study, we found that breast MRI was significantly 
associated with increased all-cause and breast cancer-attributable Medicare payments. The 
additional costs of breast MRI should be evaluated in concert with breast MRI effectiveness 
data to inform policy makers about the value of breast MRI in the elderly breast cancer 
population. 
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Table 6.1: Initial phase of care and cost definitions 
Term Definition 
Initial treatment phase 
All claims from the date of the first claim for a suspected breast 
disorder (i.e. lump or mass in breast, abnormal mammogram, see 
Appendix Table C.2) 12 or fewer months prior to the SEER 
diagnosis month to the last day of a treatment claim before a gap 
in treatment claims of at least 90 days. The average initial 
treatment phase lasted 4.9 months. 
 
All-cause payments 
 
The sum of Medicare payments from all claims during the initial 
treatment phase from the outpatient, carrier, and MEDPAR files 
(including claims for ED, long and short-term inpatient, and skilled 
nursing facility stays).   
Breast cancer-attributable 
payments 
The sum of Medicare payments from claims with breast biopsy, 
breast surgery, chemotherapy, radiation, mammogram, 
ultrasound, breast MRI or from a claim with a breast diagnosis 
code within the claim’s first four diagnosis codes during the initial 
treatment phase. Claims from the outpatient, carrier, and 
MEDPAR files were included. 
Payments not attributable 
to breast cancer care 
Difference between all-cause and breast cancer-attributable 
payments 
SEER, Surveillance, Epidemiology, and End Results; ED, emergency department; MEDPAR, 
Medicare Provider Analysis And Review. 
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SEER, Surveillance, Epidemiology and End Results 
* Meeting SEER-Medicare inclusion requirements of aged 66 or older at diagnosis, reporting source 
not autopsy or death certificate, laterality not bilateral or unknown, original reason for Medicare 
entitlement not disability or end stage renal disease, valid month of diagnosis, no health 
maintenance organization enrollment during study period, continuous enrollment in Part A&B during 
the study period, comorbidity score, and was able to be matched to claims during the study period. 
Study period is defined here as the 12 months prior to diagnosis month till the end of data or death 
(For more details see Appendix Table C.1). 
† Breast surgical procedure includes breast excision, partial/subtotal mastectomy, and mastectomy 
 
  
Figure 6.1. Inclusion/exclusion schematic 
 
Women diagnosed with their first primary breast cancer in SEER in 2004-2007* 
n= 39,652  
INCLUDED EXCLUDED 
Medicare claims identified conflicting surgical  
procedures on the same day;  
receipt of cancer treatments prior to surgery 
n=1,082 
Known Stage I-IIIA disease, tumor size <5cm, 
histology codes indicating malignant breast cancer 
N=26,751   
Stage 0 or IV disease, stage unknown; tumor size 
greater than 5cm; histology codes indicating in situ/
non-malignant disease or non-breast primary tumors 
n=12,901 
Able to determine the first definitive surgical treatment 
and have no prior cancer treatments before surgery 
n= 25,669   
Had a breast surgical procedure† 
within 4 months of SEER diagnosis month 
n= 24,439  
Did not have a breast surgical procedure† or had  
one > 4 months before/after SEER diagnosis month   
n= 599  
Patients with linkable to her surgical provider 
n= 25,038  
Unable to link patient to her surgical provider  
n= 631  
Had a breast surgical procedure† within within a year  
of the first claim for a suspected breast disorder 
n= 23,593 
Did not have a breast surgical procedure† within  
a year of the first claim for a suspected breast disorder 
n= 846 
Alive for a year after diagnosis and  
did not die while in active treatment 
n= 22,974 
Died within a year of diagnosis or  
while in active treatment 
n= 629  
Analytical Sample 
n= 22,974 
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Overall 
(N=22,974) 
No breast 
MRI  
(N= 20,223) 
Breast MRI 
(N=2,751) p-value 
Preoperative breast MRI receipt 12.0 0 100.0 <0.001 
Treatment length (months) 4.9 (4.3) 4.8 (4.2) 5.9 (4.6) <0.001 
Tumor size between 2 and 5 cm 26.6 26.8 25.2 0.07 
Tumor grade  (%) 
  
<0.001 
Well differentiated 26.4 26.2 27.8 
 Moderately differentiated 44 43.6 46.9 
 Poorly differentiated 24.2 24.8 20.3 
 Grade unknown 5.4 5.5 5.0 
 Hormone receptor status  (%) 
 
0.006 
Positive 79.2 78.9 81.2 
 Negative 12.8 12.9 12.2 
 Unknown 8.0 8.2 6.6 
 Node positivity  (%) 20.3 20.1 21.8 0.04 
Histology 
    Ductal 73.9 74.9 67.0 <0.001 
Lobular 9.8 8.9 16.0 
 Mixed ductal/lobular 7.9 7.4 11.9 
 Other 8.4 8.8 5.1 
 NCI comorbidity index  (%) 
  
<0.001 
0 64.2 63 73.2 
 Between 0 and 1 27.8 28.5 22.9 
 Greater than 1 8.0 8.5 3.8 
 Age at diagnosis  (%) 
  
<0.001 
65 to 69 20.7 18.9 34.0 
 70 to 74 24.7 24.2 29.0 
 75 to 79 24.3 24.8 20.8 
 80 to 84 18.6 19.6 11.8 
 85 and older 11.6 12.6 4.4 
 State buy-in coverage  (%) 
  
<0.001 
No 89.5 88.7 95.0 
 Yes 10.5 11.3 5.0 
 Race  (%) 
   
<0.001 
White 86.9 86.6 89.2 
 Non-white 13.1 13.4 10.8 
 Married  (%) 46.2 45.0 54.6 <0.001 
Zip code of residence  (%) 
   
<0.001 
Metropolitan 84.7 83.7 92.7 
 Non-metropolitan 15.3 16.3 7.3 
      
Table 6.2. Baseline characteristics!
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Overall 
(N=22,974) 
No breast 
MRI  
(N= 20,223) 
Breast MRI 
(N=2,751) p-value 
Cooperative group affiliation of 
surgical facility  (%)† 
51.2 49.5 63.2 <0.001 
NCI affiliation of surgical facility  (%) 5.1 4.9 6.9 <0.001 
Year of diagnosis (%) 
  
<0.001 
2004 25.2 27.1 11.7 
 2005 24.6 25.5 18.1 
 2006 24.8 24.5 27.0 
 2007 25.4 22.9 43.2 
 SEER Region (%) 
  
<0.001 
California registries 32.4 31.4 39.5 
 Northeast registries 23.2 22.7 27.3 
 Georgia 3.3 3.3 2.7 
 Detroit 6.9 7.1 5.0 
 Iowa 7.3 8.0 2.8 
 New Mexico 2.1 1.8 4.4 
 Seattle 6.4 5.7 11.3 
 Utah 2.7 2.8 2.3 
 Kentucky 7.6 8.3 2.5 
 Louisiana 6.8 7.5 2.2 
 Hawaii 1.2 1.4 0.1 
 Mean (Standard Deviation) or %, P-values by t-test for continuous variables and chi-squared test 
for binary / categorical variables 
† NCI Cooperative Groups having breast cancer research portfolios 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; NCI, 
National Cancer Institute.  
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Table 6.3. Healthcare utilization and Medicare payments during the initial 
treatment phase, by patients with and without preoperative breast MRI 
 
Percent with utilization (%) 
  
Overall  
(N=22,974) 
No MRI 
(N=20,223) 
MRI  
(N= 2,751) p-value 
Diagnostic/ preoperative 
procedures     
Mammogram 93.2 92.8 96.3 <0.001 
Ultrasound 78.8 77.3 89.9 <0.001 
Biopsy 73.1 70.9 89.7 <0.001 
     
Advanced Imaging 64.3 62.3 78.6 <0.001 
Bone scan 19.0 18.3 24.3 <0.001 
Brain MRI 2.7 2.6 3.3 0.03 
CT scan 24.7 23.7 31.6 <0.001 
PET scan 9.2 8.2 16.0 <0.001 
Nuclear medicine 49.4 47.5 63.2 <0.001 
     
Treatments     
Mastectomy as first surgery 21.8 21.6 23.7 0.01 
Radiation 55.2 54.0 63.9 <0.001 
Chemotherapy 15.9 15.2 21.2 <0.001 
P-values from chi-squared test  
CT, Computed tomography; MRI, Magnetic resonance imaging; PET, Positron emission 
tomography. 
Note: If a claim for a biopsy occurred on the same day as a breast excision it was considered a 
breast excision. If a claim for a breast excision occurred on the same day as a partial 
mastectomy or a mastectomy, it was considered a partial mastectomy or a mastectomy, 
respectively. If there were conflicting claims for a partial mastectomy and a mastectomy on 
the same day, the patient was excluded 
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Table 6.4. Unadjusted Medicare payments, by breast MRI receipt  
 Overall  
(N=27,935) 
No breast MRI 
(N=25,065) 
Breast MRI 
(N=2,870) p-value 
Payments during the initial treatment phase    
All Payments $23,683 ($22,525) $22,987 ($22,208) 
$28,795 
($24,131) <0.001 
Breast cancer-
attributable 
payments* 
$19,749 ($16,827) $19,025 ($16,383) 
$25,075 
($18,956) <0.001 
Payments not 
attributable to breast 
cancer** 
$3,933 ($11,792) $3,962 ($11,971) $3,720 ($10,377) 0.31 
Payments during first 12 months of diagnosis 
and treatment (sensitivity analysis)*** 
   
All Payments $31,297 ($30,339) 
$31,062 
($31,050) 
$33,024 
($24,420) 0.001 
Breast cancer-
attributable 
payments* $20,557 ($15,330) 
$19,936 
($15,104) 
$25,124 
($16,185) <0.001 
Payments not 
attributable to breast 
cancer** $10,740 ($25,181) 
$11,127 
($26,104) 
$7,900 
($16,638) <0.001 
Note: Mean (Standard Deviation), P-values by t-test 
MRI, Magnetic resonance imaging. 
* Breast cancer-attributable payments include total Medicare payments from claims associated with 
breast cancer diagnosis or treatment or from claims with a breast diagnosis code within the 
claim’s first four diagnosis codes.  
** Payments not attributable to breast cancer are the difference between all payments and breast 
cancer-attributable payments 
*** First 12 months of diagnosis and treatment defined as all claims for 12 months after the first 
claim with a breast diagnosis code !!!! !
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Table 6.5. Multivariate models examining the effect of preoperative breast MRI on Medicare 
payments and average marginal effect estimates  
  
All Medicare 
payments  
Breast cancer-
attributable 
payments† 
Payments not 
attributable to 
breast cancer‡ 
Payments during the initial treatment phase    
Multiplicative effect of 
preoperative breast MRI 
1.10*** 1.14***  0.98 
[1.08, 1.13] [1.12, 1.16]    [0.88, 1.10] 
   Average marginal effect of 
preoperative breast MRI $2,344*** $2,617*** 
$-65 
 [$1,767, $2,921] [$2,206, $3,027] [$-491, $360] 
Payments during first 12 months of diagnosis and 
treatment (sensitivity analysis) 
  
Multiplicative effect of 
preoperative breast MRI 
1.03 1.11*** 0.86*** 
[1.00, 1.06] 
 
[1.09, 1.14] 
 
[0.79, 0.94] 
 
Average marginal effect of 
preoperative breast MRI 
$804 $2,241*** -$1592*** 
[-$79, $1,687] [$1,824, $2,657] [-$2,494, -$690] 
N 
AIC, main analysis 
AIC, sensitivity analysis 
22,974 22,974 22,974 
5.0e+05 
5.2e+05 
5.0e+05 
4.9e+05 
4.2e+05 
4.7e+05 
* p<0.05  ** p<0.01  *** p<0.001 
95% confidence intervals in brackets, generalized linear models use log-link and gamma 
distribution with robust standard errors.  
MRI, Magnetic resonance imaging; AIC, Akaike information criterion 
Models control for treatment variables (whether or not the patient had radiation, chemotherapy, 
advanced Imaging), patient characteristics (tumor stage, nodal status, hormone receptor status, 
histology, NCI Comorbidity, age, state buy-in coverage, race), metropolitan zip code of 
residence, SEER region, year, and whether or not the women had her surgery at a facility having 
NCI Cooperative Groups breast cancer research portfolios or that is NCI affiliated. For full results 
see Appendix Table C.3 and C.4. 
† Total Medicare payments from claims associated with breast cancer diagnosis or treatment or 
from a claim with a breast diagnosis code within the claim’s first four diagnosis codes  
‡ Controlling for non-cancer related characteristics (see Appendix Table C.3 and C.4) 
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CHAPTER 7: DISCUSSION
Summary of findings 
 Breast magnetic resonance imaging (MRI) has been increasingly used in the 
preoperative evaluation of women with newly diagnosed breast cancer, with almost one-fifth 
of elderly breast cancer patients receiving a preoperative breast MRI by 2007. Despite its 
rapid adoption, limited evidence exists to support the routine use of breast MRI, creating 
controversy in breast cancer management.1-20 Numerous single institution studies, several 
meta-analyses, and two randomized controlled trials suggest that breast MRI changes 
treatment patterns, leading to surgical treatment delay and more extensive surgeries.  
However, breast MRI may not produce improved outcomes in terms of fewer re-
excisions4,11,21-23 or lower recurrence rates.12,21,24-27 There is a dearth of evidence examining 
the effect of breast MRI on surgical planning and outcomes in elderly women with breast 
cancer, and few studies assess breast MRI at a population level. This study is one of the 
first to examine the association between preoperative breast MRI and surgical planning, 
short-term outcomes, and cost in the elderly breast cancer population using SEER-Medicare 
data.  
In Chapter 4, we examined the association between preoperative breast MRI and 
surgical planning in elderly women with early-stage, invasive breast cancer and found that 
preoperative breast MRI was associated with treatment delay and more extensive initial 
surgeries.  Women who received preoperative breast MRI differed from women who did not 
in terms of baseline patient, tumor, and surgical facility characteristics. We used propensity 
score methods to reduce the risk of bias that could result from factors associated with initial 
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receipt of MRI, as differentiated from factors associated with subsequent treatment and 
timing of care. The median time from the first suspicion of breast cancer to complete surgery 
was 53 days for patients without a breast MRI and 63 days for patients with a breast MRI 
(p<0.001), and we found that preoperative breast MRI was associated with a median 15-day 
delay in the time to complete surgery using propensity score methods.  More than 20% of 
women in our sample had a mastectomy as their first surgical procedure and, after 
adjustment using propensity scores, receipt of a breast MRI was associated with 
significantly greater odds of having a mastectomy as the initial surgery (OR: 1.30, 95% CI 
[1.12, 1.50]). This finding is consistent with previous literature documenting breast MRI’s 
association with treatment delay28-30 and more extensive surgeries.4,11,21-23!  
In Chapter 5, we examined whether preoperative breast MRI was associated with 
improved short-term outcomes. We found that breast MRI was not associated significantly 
with re-excision rates, but was associated with an increased hazard of a second breast 
cancer event (i.e., recurrence or a second primary breast cancer).  We defined a re-excision 
as an additional breast surgical procedure after breast conserving surgery (BCS) during the 
initial treatment phase (i.e., before a gap in treatment of 90 days). One-third of patients in 
our sample had a re-excision and, after adjustment using propensity score methods, receipt 
of a preoperative breast MRI was not associated with the odds of having a re-excision. We 
identified second breast cancer events through a validated algorithm31 using information 
regarding secondary cancers and surgical procedures from claims data and SEER 
registries. We found that 9.4% of our sample had a second breast cancer event. Using 
propensity score methods, undergoing a preoperative breast MRI was associated with an 
increased hazard of a second breast cancer event. These women were significantly more 
likely to have experienced a second breast cancer event one, three, and five years after the 
first suspected breast cancer compared to women who did not receive preoperative breast 
 ! 203 
MRI. Our results add to the mounting evidence4,11,12,21-27!that breast MRI is not associated 
with improved outcomes vis-à-vis fewer re-excisions and lower recurrence rates. 
In Chapter 6, we examined the costs associated with preoperative breast MRI during 
the initial treatment phase from the perspective of Medicare. We found that women with 
breast MRI had higher total all-cause and breast cancer-attributable costs than those 
women without MRI. We defined costs during the initial treatment phase as Medicare 
payments for all claims from the date of the first suspected breast disorder to the last day of 
treatment before a gap in treatment of at least 90 days. We also examined breast cancer-
attributable costs using Medicare payments for breast cancer procedures and claims with 
breast cancer diagnosis codes. The average per-patient, all-cause cost during the initial 
treatment episode was $23,683, which equated to $22,987 for those who did not receive an 
MRI and $28,795 for those who did (p-value <0.001). The average per-patient, breast 
cancer-attributable payment was $19,749, which meant $19,025 for those who did not 
receive an MRI and $25,075 for those who did (p-value <0.001). In our multivariate models, 
we found that preoperative breast MRI was associated with 10% higher all-cause costs 
[95% CI: (1.08, 1.13)] and 14% higher breast cancer-attributable costs [95% CI: (1.12, 1.16)] 
during the initial treatment phase. The average marginal effect of breast MRI was $2,348 for 
all-cause costs and $2,619 for breast cancer-attributable costs [95% CI: ($1,771, $2,924), 
($2,208, $3,030)]. Costs not attributable to breast cancer during the initial treatment phase 
did not significantly differ by MRI receipt in either our unadjusted or adjusted models. We 
conclude that the increased cost to Medicare associated with preoperative breast MRI is 
cause for concern in light of the mounting evidence suggesting that breast MRI is associated 
with a treatment delay and more extensive initial surgeries (Chapter 4) in the absence of 
improved outcomes (Chapter 5). 
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Contributions to existing literature, and policy and practice implications 
This dissertation makes several important contributions to the existing literature 
examining preoperative breast MRI. First, few studies have examined the use of 
preoperative breast MRI in elderly women. Most of the existing research examined breast 
MRI in younger breast cancer populations.22 For example, the average participant in the two 
RCTs examining breast MRI was in their mid-50s,21,23!two decades younger than the 
average age of breast cancer patients enrolled in Medicare32 and the average patient in our 
study (76.1 years). Given that older women are likely to be underrepresented in clinical 
trials,33 effectiveness research, like this dissertation, is warranted to inform patients and their 
providers about the risks and benefits of breast MRI specific to their age group. This 
information, in turn, can be used in the decision-making process by elderly women and their 
providers about whether or not to use breast MRI. Furthermore, older age may be 
associated with clinical heterogeneity40,41 and influence the magnitude of the effect of breast 
MRI. Specifically, older patients, in addition to having complex co-morbidities and cognitive 
or functional impairment, are more likely to have less dense breasts and, therefore, fewer 
occult tumors with conventional assessment.34-39 Thus, they may be least likely to 
experience any benefit from imaging technology, but more likely to experience harm from 
more extensive surgeries associated with breast MRI.  Evidence from our studies about the 
effectiveness of breast MRI specific to elderly breast cancer patients is intended to help 
clinicians and patients understand which patients will benefit most, who is least likely to 
benefit, and who is at greatest risk of experiencing adverse outcomes. 
Second, a dearth of evidence exists examining the impact of breast MRI on surgical 
planning or short-term outcomes at the US population level. As previously mentioned, much 
of the existing literature examining breast MRI is based on multiple studies from single 
institutions and two randomized controlled trials, and does not use population-level data. 
The RCTs and single institution studies were highly selective and restrictive in their inclusion 
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criteria; thus, the study populations were not comparable to the US elderly population. 
Furthermore, the two RCTs were conducted in Europe21,23!where physician practice patterns 
and patient treatment preferences differ significantly from the US.40-42  Our study is novel in 
that it uses the SEER-Medicare dataset, a large, population-based dataset to examine the 
association between breast MRI and surgical planning and outcomes at a population level 
using rich information about patient and tumor characteristics as well as healthcare 
utilization. Information from our study can be used as a part of the decision-making process 
to inform elderly women with breast cancer and their providers about the potential risks and 
benefits of using breast MRI.  
Third, no study, to our knowledge, has examined the association between breast 
MRI and the cost of initial breast cancer treatment in the United States. The only study to 
examine the cost of breast MRI was a randomized controlled trial conducted in the United 
Kingdom43 where treatment patterns, payment structures, and fiscal considerations are 
different.40-42,44,45 Our study findings are among the first cost estimates that could be used in 
concert with effectiveness data to generate information about the comparative cost-
effectiveness of breast MRI.  
This study has several policy and clinical practice implications. The results of this 
study have the potential to improve the quality of breast cancer care by generating 
additional evidence about the appropriate use of preoperative breast MRI. The Institute of 
Medicine (IOM) has defined overuse as a quality of care problem,46 and recent publications 
document unnecessary overtreatment for breast cancer.47-50 These studies have shown that 
more extensive treatment does not necessarily improve outcomes and, in fact, may increase 
the risk for complications and the cost to treat the incident breast cancer. Our study results 
suggest that breast MRI may be an example of an overuse of technology. Indeed, the 
addition of breast MRI to conventional assessment was not associated with improvement in 
short-term outcomes, but was associated with an increased likelihood of a mastectomy and 
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higher cancer treatment costs. The scientific evidence generated by our study may be used 
to inform new policies and strategies to help determine when breast MRI is appropriate. 
Additionally, the results of this study add to the growing evidence about the risks and 
benefits of breast MRI and, thus, may contribute to the likelihood of consistently delivering 
appropriate care. The more definitive the evidence for (or against) breast MRI, the more 
likely that it will be consistently used (or abandoned) in clinical practice.51 Our findings also 
have the potential to improve patient outcomes by reducing morbidity from unnecessary 
biopsies and more extensive surgeries.!
This dissertation responds to the IOM’s call for more comparative effectiveness 
research (CER) to improve quality of care.52 According to the IOM, “CER is the generation 
and synthesis of evidence that compares the potential benefits and harms of alternative 
methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the 
delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, and 
policy makers to make informed decisions that will improve health care at both the individual 
and population levels.”53 The evidence generated by our study can be used to inform new 
policies and strategies for delivering appropriate care to this cancer population. Based on a 
population-level, ‘real-world’ setting, this study will assist healthcare providers and patients 
in making informed decisions about whether or not to use breast MRI in older women with 
breast cancer and may encourage more appropriate, targeted imaging of patients. Thus, the 
indirect effect of this new information may benefit the many thousands of elderly women 
who are diagnosed with breast cancer each year. 
Examining the cost of care is increasingly important given the concern over the cost 
of Medicare and its contribution to our national deficit.54 One of the goals of the Affordable 
Care Act of 2010 was to cut overspending on healthcare and rein in costs to improve the US 
deficit and increase longevity of the Medicare program. This dissertation informs policy 
makers about the additional cost of using breast MRI in the preoperative evaluation of 
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elderly breast cancer patients and may allow for improved use of Centers for Medicare and 
Medicaid’s resources. Future research, as discussed later in this chapter, should combine 
our cost estimates with effectiveness data to generate information about the comparative 
cost effectiveness of breast MRI to inform policy makers who determine Medicare 
reimbursement policies. 
Limitations  
First, although the SEER-Medicare dataset is among the strengths of this 
dissertation, the dataset is not without limitations. In order to capture the complete claims 
experience for each patient, we excluded women who were not continuously enrolled in 
Medicare Part A and B, and not enrolled in a health maintenance organization during the 
study period. Despite the fact that the SEER-Medicare dataset covers approximately 25% of 
the incident US cancer population, it is not perfectly generalizable to the US elderly 
population. For example, women in SEER regions are slightly more likely to be affluent, well 
educated, and reside in urban areas than the general elderly population.55  
Second, our study sample may not reflect the most current breast cancer diagnosis 
and treatment approaches because data for women diagnosed after 2007 were not yet 
available. Thus, our findings may have limited generalizability to more recent years as 
breast MRI technology improves, and radiologists and surgeons become more experienced 
with imaging.  Additionally, our study sample does not capture possible changes in breast 
MRI utilization after publication of the two randomized trials in 2010 and 2011.  
Third, because the use of breast MRI is more prevalent in the later years of our 
study, we have limited follow-up for women who received a breast MRI and were unable to 
examine the likelihood of a second breast cancer event beyond five years. Due to the high 
survival rate of early-stage breast cancer patients, including those in our sample, we were 
unable to draw conclusions about the association between breast MRI and survival. More 
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studies are needed as the data accumulate with extended follow-up periods. However, we 
believe our study results are valuable because women are most likely to experience cancer 
recurrence during the first five years after a primary diagnosis.56-58  
Fourth, because we used claims data, we were unable to explicitly control for the 
reasons why the MRI was ordered and are concerned about confounding by indication. 
Results from our study suggest that some women in our sample may have received a breast 
MRI as a part of routine preoperative work-up and other women may have received an MRI 
because they were inadequately imaged using conventional assessment (See Discussion, 
Chapter 5).  Women who are inadequately imaged using conventional assessment, such as 
those women with invasive lobular carcinoma, may have a higher baseline risk for 
mastectomy, re-excisions, and/or recurrence59-66 than women who were adequately imaged. 
Future research, described in the next section, should explore confounding by indication in 
sub-analyses of women who are more likely to be inadequately imaged by conventional 
assessment. 
Fifth, because this was an observational study, we were unable to control for all 
patient and surgeon characteristics that may have influenced surgical planning, short-term 
outcomes, and cost. Using propensity score methods as described in Chapters 4 and 5, we 
were able to balance the observed characteristic of women who did and did not receive a 
breast MRI. However, we were unable to balance these groups based on unobserved 
characteristics.  Specifically, as explained in Chapter 4, we were unable to control for patient 
preferences regarding surgery and whether or not women preferred to have mastectomy 
compared to BCS. We also were unable to observe surgeon preferences for one procedure 
over another. Chapter 5 indicates that we were unable to adjust the two groups based on 
several re-excision and recurrence risk factors such as multifocal disease, mammographic 
density and microcalcifications, and the difference in tumor size between MRI and 
ultrasonography.67-69 Also, we were unable to control for surgeon experience and practice 
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style, which may be correlated with breast MRI and re-excisions.70,71 As noted in Chapter 6, 
we were unable to balance the women on patient factors, such as family history and care-
seeking behavior as well as on physician behaviors, such as their tendency to use more 
intensive cancer care. Future research, described in the next section, should explore the 
use of instrumental variables to diminish the effect of these potential unobserved 
confounders. 
Future research 
 This dissertation sets the foundation for important future work. We examined the 
effect of breast MRI as a part of routine diagnostic work-up for all women with early-stage 
invasive breast cancer, but future research should determine whether breast MRI is 
associated with improved surgical planning and outcomes in subsets of women that may 
benefit from breast MRI because they may be likely to be inadequately imaged using 
conventional assessment. For example, some evidence suggests that breast MRI may 
improve surgical outcomes in women with invasive lobular carcinoma (ILC),22,72 which 
comprised 9.5% of our sample. Thus, we could assess potential confounding by indication 
by restricting our analysis to elderly women with ILC.  Further examination of subsets of 
women most likely to benefit from breast MRI may be clarified through linkage to, or explicit 
examination of, additional datasets beyond SEER-Medicare such as the Breast Cancer 
Surveillance Consortium, which has more detailed clinical information and data on 
radiological results. With additional information, including breast density and radiologist’s 
recommendations, we would be able to examine the association between breast MRI and 
outcomes in women for which breast MRI may have been indicated73 (i.e., patients with 
conflicting mammogram and ultrasound results or for women with possible multifocal or 
multicentric disease). 
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  Future research should also focus on the effect of breast MRI in more recent years 
because, as with most technologies, its use may vary over time. First, RCT results from 
2010-2011 indicated that breast MRI did not improve outcomes.21,23 Second, due in part to 
the RCT findings and additional publications, breast MRI has become an increasingly 
controversial topic in breast cancer management.2-5,7-20 Third, it is important to continue to 
examine breast MRI as surgeons and radiologists gain experience with the technology.!This 
evolution in our understanding of the association between MRI and outcomes, and our 
appreciation of balancing harms, benefits, and costs, is likely to have had an effect on the 
utilization of this service in more recent years. Furthermore, as data accumulate, it is 
important to examine the likelihood of a second breast cancer event with longer follow-up 
periods. With additional years of data, we also may be able to examine the association 
between breast MRI and survival.  
Future research should apply novel statistical methods that may more adequately 
control for unmeasured confounding and help strengthen our confidence in these findings 
that are based on the examination of observational data. For example, instrumental variable 
analysis74,75 may be useful, however, a key challenge is in finding one or more suitable 
instruments that are substantially correlated with the endogenous explanatory variable (MRI 
use) and only correlated with our outcomes via their impact through MRI use. Two potential 
instruments we plan to examine in future research are the volume of breast MRI at the 
patient’s surgical facility and surgical facility affiliation with the American College of 
Radiology Imaging Network (ACRIN), the NCI Cooperative Group that conducts radiology 
trials. 
Future research should combine our cost estimates (Chapter 6) with our 
effectiveness results (Chapters 4 and 5) to model the cost-effectiveness of preoperative 
breast MRI for elderly women with breast cancer. Information about quality-adjusted life 
expectancy from previously published studies examining breast MRI43,76 should be 
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considered in this analysis. Additional data regarding baseline patient clinical, social, and 
demographic information as well as patient-reported outcomes, quality of life, and long-term 
outcomes associated with breast MRI in elderly women with breast cancer would also be 
useful in understanding MRI utilization, other treatment decisions, and outcomes. By 
quantifying the costs and benefits of breast MRI using a common measure, such as an 
incremental cost-effectiveness ratio in US dollars per quality adjusted life year, we then 
could compare the cost-effectiveness of breast MRI to other breast cancer diagnostic 
procedures and treatments. The results from this analysis could help decision-makers 
determine how to best use resources and inform policy makers that define Medicare 
reimbursement policies.  
Conclusion 
Findings from this dissertation indicate that breast MRI was associated with a slight 
surgical delay and increased likelihood of a mastectomy as the initial surgery in elderly 
breast cancer patients. We did not find that breast MRI was associated with improved short-
term outcomes, such as a decreased likelihood of a re-excision or second breast cancer 
event. Furthermore, we found that breast MRI was associated with increased all-cause and 
breast cancer-attributable costs during the initial treatment phase. Our findings are 
supported by results from numerous studies, including two randomized controlled 
trials.4,11,12,21-27 This study contributes to the existing literature by being one of the first to 
examine preoperative breast MRI and surgical planning, outcomes, or cost using a 
population-level dataset composed exclusively of elderly breast cancer patients. Given that 
preoperative breast MRI was associated with a slight delay in surgery and an increased 
likelihood of mastectomy in the absence of evidence for improved short-term outcomes, 
healthcare providers and their patients should consider these factors when making informed 
decisions about the use of breast MRI for elderly women with breast cancer. Furthermore, 
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results from this study are intended to inform Medicare policy decision-makers about the 
risks, benefits, and costs of routine preoperative breast MRI in the elderly breast cancer 
population. 
 
 
Note: References for this chapter appear after the appendices on page 256. 
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APPENDIX A: SUPPLEMENTAL TABLES AND FIGURES FOR CHAPTER 4 
Table A.1: SEER-Medicare inclusion/exclusion criteria 
Inclusion Criteria Included Excluded 
Breast cancer diagnosis in SEER 260,079  
Diagnosed between 2003 and 2007 (inclusive) 143,757 116,322 
First or initial cancer 131,974 11,783 
Age 66 or older at diagnosis 86,127 45,847 
Female 85,367 760 
Reporting source not autopsy or death certificate 84,466 901 
Laterality is not bilateral or unknown 83,659 807 
Original reason for Medicare entitlement not disability or ESRD 79,355 4,304 
Has valid month of diagnosis 79,114 241 
Has no HMO enrollment during study period* 56,652 22,462 
Has continuous enrollment in Part A&B during the study period* 52,038 4,614 
Has comorbidity score and was able to be matched to claims during the 
study period* 48,283 3,755 
Diagnosed between 2004 and 2007** 39,652 8,631 
ESRD, end stage renal disease; HMO, Health Maintenance Organization; SEER, Surveillance, 
Epidemiology and End Results 
*  Study period is 12 months prior to diagnosis month until the end of data or death **!We excluded patients diagnosed in 2003 because few patients (n=148) had a breast MRI, and 
were unable to be balanced using propensity scores. 
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Table A.2: Codes for identifying breast cancer events and surgical procedures 
Study time frame Definition 
Initial treatment 
phase 
The date of the first claim with a breast-related diagnosis code to the end of 
the initial treatment as defined as the last day of treatment before a gap in 
treatment of 90 days or more or the end of the study period (December 31, 
2009) or the patient’s death. 
First suspected 
breast disorder 
date 
Definition 
Suspected breast 
disorder 
diagnosis codes 
174.*     Malignant neoplasm of female breast 
217.       Benign neoplasm of breast 
233.0     Carcinoma in situ of breast 
238.3     Neoplasm of uncertain behavior of breast 
239.3     Neoplasms of unspecified nature breast 
610.0     Solitary cyst of breast 
610.1     Diffuse cystic mastopathy 
610.2     Fibroadenosis of breast 
610.3     Fibrosclerosis of breast 
610.9     Benign mammary dysplasia, unspecified 
611.0     Inflammatory disease of breast 
611.1     Hypertrophy of breast 
611.3     Fat necrosis of breast 
611.8     Other specified disorders of breast 
611.9     Unspecified breast disorder 
611.71   Signs and symptoms in breast 
611.72   Lump or mass in breast 
611.79   Signs and symptoms in breast 
793.80   Abnormal mammogram, unspecified 
793.81   Mammographic microcalcification 
793.89   Other (abnormal) findings on radiological examination of breast 
V711      Observation for suspected malignant neoplasm 
First suspected 
breast disorder 
date 
The day of the first breast-related diagnosis code listed above within one 
year prior to the SEER diagnosis month 
Surgical 
Procedure 
Code identified in claims 
Breast excision ICD-9-CM: 85.20-85.22; HCPCS: 19120, 19125, 19126, 19300 
Partial mastectomy ICD-9-CM:  85.23; HCPCS: 19160/2, 19301/2 
Mastectomy ICD-9-CM: 85.4X; HCPCS: 19180, 19182, 19200, 19220, 19240, 19303-7 
Histology Code identified in SEER 
 Ductal ICD-O-3: 8500, 8521, 8523, 8514, 8541 
 Lobular ICD-O-3: 8520, 8524 
 Mixed ductal/ 
lobular  ICD-O-3: 8522 
 Other* 
ICD-O-3: 8480, 8211, 8010, 8140, 8201, 8255, 8401, 8510, 8000, 8022, 
8031, 8032, 8033, 8035, 8050, 8141, 8260, 8310, 8323, 8513, 8540, 8560, 
8570, 8571, 8572, 8573, 8574, 8575, 8980, 8982, 9020,  
Excluded** 8501,  8502, 8503, 8504, 8507, 8508, 8230, 8525, 8543, 8012, 8013, 8041, 8070, 8074, 8200, 8251, 8490 
SEER, Surveillance, Epidemiology and End Results; HCPCS, Healthcare Common Procedure 
Classification System; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical 
Modification. 
*Note: Two-thirds of “other histology” were mucinous or tubular adenocarcinomas 
** Excluded do to pre-malignant (in situ) or non-malignant lesions histologies indicating non-breast 
initial tumors 
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Table A.4. Multivariate proportional hazard model examining the time to 
complete surgery 
 
 
 
 
 
Hazard 
Ratio 
95% Conf. 
Interval 
Preoperative breast MRI 0.93*** [0.89, 0.97] 
Tumor size 
  < 2cm (ref.) 
 ≥ 2cm, < 5cm 1.17*** [1.14, 1.21] 
Tumor grade 
  Well differentiated (ref.) 
 Moderately differentiated 1.05** [1.02, 1.09] 
Poorly differentiated 1.07** [1.02, 1.11] 
Grade unknown 0.84*** [0.79, 0.90] 
Hormone Receptor Status  
  Positive (ref.) 
 Negative 1.01 [0.97, 1.05] 
Unknown 0.97 [0.92, 1.01] 
Node positivity   1.06** [1.02, 1.10] 
Histology 
  Ductal (ref.) 
 Lobular 0.95* [0.91, 1.00] 
Mixed ductal/lobular 0.95* [0.90, 0.99] 
Other 0.97 [0.92, 1.02] 
NCI Comorbidity Index   
  0 (ref.) 
 Between 0 and 1 0.94*** [0.91, 0.97] 
Greater than 1 0.91*** [0.86, 0.95] 
Age at diagnosis  
  65 to 69 (ref.) 
 70 to 74 1.00 [0.96, 1.04] 
75 to 79 1.03 [0.99, 1.07] 
80 to 84 1.04 [0.99, 1.09] 
85 and older 1.05 [1.00, 1.11] 
Married  1.03* [1.01, 1.06] 
State buy-in coverage  
  No (ref.) 
 Yes 0.93** [0.89, 0.97] 
Race  
  White (ref.) 
 Non-white 0.91 [0.79, 1.04] 
Cooperative group affiliation of surgical facility† 0.97 [0.94, 1.00] 
NCI affiliation of surgical facility 0.76*** [0.72, 0.81] 
Surgical facility a teaching hospital (or affiliated one) 0.95** [0.93, 0.98] 
Surgical volume of surgical facility  
  Low  (ref.) 
 High  1.02 [0.99, 1.05] 
Zip code proportion with at least a high school 
education (quartiles) 
  Low education (ref.) 
 Low-medium education 0.98 [0.94, 1.01] 
Medium-high education 0.97 [0.93, 1.01] 
High education 1.01 [0.97, 1.06] 
Unknown education 0.96 [0.89, 1.03] 
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Hazard 
Ratio 
95% Conf. 
Interval 
Year of diagnosis  
2004 (ref.) 
 2005 1.00 [0.96, 1.04] 
2006 0.96* [0.92, 0.99] 
2007 0.97 [0.93, 1.01] 
SEER Region  
  California registries (ref.) 
 Northeast registries 0.98 [0.93, 1.02] 
Georgia 1.02 [0.94, 1.10] 
Detroit 0.99 [0.93, 1.05] 
Iowa 1.55*** [1.45, 1.65] 
New Mexico 1.09 [0.99, 1.20] 
Seattle 1.07* [1.01, 1.14] 
Utah 1.44*** [1.32, 1.57] 
Kentucky 1.23*** [1.16, 1.30] 
Louisiana 1.36*** [1.28, 1.44] 
Hawaii 1.13 [1.00, 1.29] 
Observations 25,038 
AIC 418911.7 
* p<0.05, ** p<0.01,  *** p<0.001       
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting; SEER, Surveillance, 
Epidemiology and End Results; NCI, National Cancer Institute; AIC, Akaike information 
criterion 
† Robust standard errors 
‡  NCI Cooperative Groups having breast cancer research portfolios 
 
 
  
Table A.4. Multivariate proportional hazard model examining the time to 
complete surgery (cont.) 
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Odds 
Ratio 
95% Conf. 
Interval 
Preoperative breast MRI 1.55*** [1.40, 1.72] 
Tumor size 
  < 2cm (ref.) 
 ≥ 2cm, < 5cm 2.84*** [2.65, 3.05] 
Tumor grade 
  Well differentiated (ref.) 
 Moderately differentiated 1.11* [1.02, 1.21] 
Poorly differentiated 1.23*** [1.11, 1.36] 
Grade unknown 1.18* [1.01, 1.39] 
Hormone receptor status  
  Positive (ref.) 
 Negative 1.32*** [1.19, 1.46] 
Unknown 1.57*** [1.40, 1.76] 
Node positivity   1.93*** [1.79, 2.08] 
Histology 
  Ductal (ref.) 
 Lobular 1.14* [1.02, 1.27] 
Mixed ductal/lobular 1.11 [0.98, 1.25] 
Other 0.83** [0.73, 0.95] 
NCI Comorbidity Index 
  0 (ref.) 
 Between 0 and 1 1.09* [1.01, 1.17] 
Greater than 1 1.25*** [1.12, 1.40] 
Age at diagnosis  
  65 to 69 (ref.) 
 70 to 74 1.19*** [1.08, 1.32] 
75 to 79 1.42*** [1.28, 1.58] 
80 to 84 1.79*** [1.61, 2.00] 
85 and older 1.80*** [1.59, 2.03] 
Married  1.10* [1.01, 1.20] 
State buy-in coverage  
  No (ref.) 
 Yes 1.28*** [1.15, 1.43] 
Race  
  White (ref.) 
 Non-white 1.13* [1.01, 1.25] 
Cooperative group affiliation of surgical facility† 1.14*** [1.06, 1.23] 
NCI affiliation of surgical facility 0.73*** [0.62, 0.87] 
Surgical facility a teaching hospital (or affiliated 
one) 0.97 [0.90, 1.05] 
Surgical volume of surgical facility  
  Low  (ref.) 
 High  0.91* [0.85, 0.98] 
Zip code proportion with at least a high school 
education (quartiles) 
  Low education (ref.) 
 Low-medium education 1.12* [1.01, 1.23] 
Medium-high education 1.16** [1.05, 1.29] 
High education 1.18** 
Unknown education 1.28** [1.07, 1.52] 
 
  
Table A.5. Multivariate logistic regression examining the 
likelihood of a mastectomy as the first surgical procedure 
(main analysis, n= 24,439) † 
 ! 221 
   
  
 
Odds 
Ratio 
95% Conf. 
Interval 
Year of diagnosis  
2004 (ref.) 
 2005 1.03 [0.94, 1.13] 
2006 0.98 [0.90, 1.08] 
2007 1.07 [0.97, 1.17] 
SEER Region  
  California registries (ref.) 
 Northeast registries 0.62*** [0.55, 0.69] 
Georgia 1.31** [1.09, 1.57] 
Detroit 0.73*** [0.62, 0.85] 
Iowa 2.02*** [1.75, 2.34] 
New Mexico 0.87 [0.68, 1.11] 
Seattle 1.13 [0.98, 1.29] 
Utah 1.13 [0.92, 1.38] 
Kentucky 1.75*** [1.53, 2.02] 
Louisiana 1.36*** [1.18, 1.56] 
Hawaii 0.91 [0.66, 1.25] 
Observations 24,439 
AIC 23223.7 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting; SEER, 
Surveillance, Epidemiology and End Results; AIC, Akaike information criterion; 
NCI, National Cancer Institute 
* p<0.05, ** p<0.01,  *** p<0.001  
† Robust standard errors 
#  NCI Cooperative Groups having breast cancer research portfolios 
 
 
  
Table A.5. Multivariate logistic regression examining the 
likelihood of a mastectomy (cont.)  
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 Unadjusted data 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-value 
  
N= 
17,942 
N= 
15,514 
N= 
2,428 
N= 
15,431  N= 2,416 
Preoperative breast MRI (%) 13.5 0.0 100.0 <0.001 0.0 100.0 <0.001 
Mastectomy as the first 
surgical procedure 
30.3 30.6 29.0 0.01 29.3 34.0 0.008 
Tumor size  (%)    <0.001   0.05 
< 2cm 69.2 68.6 73.5  69.4 72.4  
≥ 2cm, < 5cm 30.8 31.4 26.5  30.6 27.6  
Tumor grade  (%)    <0.001   0.98 
       Well differentiated 25.3 24.9 28.0  25.3 25.8  
Moderately differentiated 44.0 43.7 46.0  44.0 43.8  
Poorly differentiated 26.0 26.7 21.4  25.9 25.8  
Grade unknown 4.8 4.8 4.6  4.8 4.5  
Hormone receptor status  (%)    0.004   0.32 
Positive 78.1 77.7 80.4  78.1 78.8  
Negative 13.6 13.7 12.8  13.6 14.2  
Unknown 8.3 8.5 6.8  8.2 7.0  
Node positivity  (%) 22.5 22.4 23.0 0.47 22.4 22.2 0.86 
Histology    <0.001   0.5 
Ductal 74.3 75.4 67.2  74.3 74.7  
Lobular 9.8 8.9 15.7  9.8 9.3  
Mixed ductal/lobular 8.3 7.7 12.2  8.4 9.3  
Other 7.6 8.0 4.9  7.5 6.7  
NCI Comorbidity Index (%)     <0.001   0.78 
0 64.3 62.8 74.0  64.4 63.3  
Between 0 and 1 27.4 28.2 22.4  27.4 28.6  
Greater than 1 8.3 9.1 3.5  8.2 8.1  
Age at diagnosis  (%)    <0.001   0.61 
65 to 69 20.0 17.9 33.6  20.1 19.7  
70 to 74 24.3 23.5 29.6  24.5 26.6  
75 to 79 23.8 24.3 20.5  23.9 23.8  
80 to 84 19.1 20.2 12.2  19.1 18.8  
85 and older 12.7 14.1 4.1  12.4 11.1  
Married  (%) 45.3 43.8 55.2 <0.001 45.4 46.5 0.49 
State buy-in coverage  (%)    <0.001   0.1 
No 89.6 88.8 94.8  89.7 91.5  
Yes 10.4 11.2 5.2  10.3 8.5  
Race  (%)    0.002   0.24 
White 87.2 86.9 89.2  87.4 88.7  
Non-white 12.8 13.1 10.8  12.6 11.3  
Cooperative group affiliation 
of surgical facility  (%)‡ 53.6 52.0 63.7 <0.001 53.8 54.0 0.88 
NCI affiliation of surgical 
facility  (%) 5.2 5.0 6.0 0.05 5.2 5.0 0.72 
Surgical facility a teaching 
hospital or affiliated one 
 
 
53.0 52.7 54.7 0.07 53.2 56.8 0.03 
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 Unadjusted data 
Data adjusted using Inverse 
Probability Weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-value 
  
N= 
17,942 
N= 
15,514 
N= 
2,428 
N= 
15,431  N= 2,416 
Surgical volume of surgical 
facility (%) 
<0.001 0.84 
Low  46.0 48.6 29.9  45.9 46.2  
High  54.0 51.4 70.1  54.1 53.8  
Zip code proportion with at 
least high school education 
(% in each quartile)    <0.001   
 
0.48 
Low education 27.2 25.4 38.6  27.3 27.1  
Low-medium education 24.9 24.8 25.5  25.0 26.0  
Medium-high education 22.6 23.0 20.1  22.6 20.8  
High education 21.3 22.9 11.5  21.1 21.1  
Unknown education 3.9 3.9 4.3  4.0 5.0  
Year of diagnosis  (%)    <0.001   0.21 
2004 23.1 25.0 11.2  22.9 20.2  
2005 24.1 25.1 17.5  24.1 24.1  
2006 26.0 25.6 28.3  26.0 26.4  
2007 26.8 24.3 43.0  27.0 29.3  
SEER Region (%)    <0.001   0.45 
California registries 34.8 34.1 39.7  34.9 33.9  
Northeast registries 22.6 22.1 26.0  22.8 25.9  
Georgia 3.7 3.7 3.2  3.6 2.9  
Detroit 6.1 6.4 4.4  6.2 6.3  
Iowa 6.9 7.5 2.6  6.8 5.3  
New Mexico 1.9 1.5 4.8  1.9 1.7  
Seattle 6.7 5.9 12.0  6.8 6.8  
Utah 2.7 2.7 2.4  2.7 2.3  
Kentucky 7.5 8.3 2.7  7.4 8.8  
Louisiana 5.8 6.4 2.1  5.8 4.9  
Hawaii 1.2 1.4 0.1  1.1 1.2  
 
P-values by t-test for continuous variables and chi2 test for binary / categorical variables, Mean (Standard 
Deviation) or % 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; PM, Partial 
mastectomy; TM, Total mastectomy; NCI, National Cancer Institute 
‡  NCI Cooperative Groups having breast cancer research portfolios  
Table A.6. Baseline characteristics of patients in the analysis examining the first 
surgical procedure (sub-analysis, cont.) 
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Odds 
Ratio 
95% Conf. 
Interval 
Preoperative breast MRI 1.48*** [1.33, 1.65] 
Tumor size 
  < 2cm (ref.) 
 ≥ 2cm, < 5cm 2.54*** [2.36, 2.74] 
Tumor grade 
  Well differentiated (ref.) 
 Moderately differentiated 1.09 [0.99, 1.19] 
Poorly differentiated 1.18** [1.05, 1.31] 
Grade unknown 1.37*** [1.15, 1.63] 
Hormone receptor status  
  Positive (ref.) 
 Negative 1.31*** [1.18, 1.46] 
Unknown 1.49*** [1.32, 1.68] 
Node positivity   1.92*** [1.77, 2.08] 
Histology 
  Ductal (ref.) 
 Lobular 1.17* [1.04, 1.31] 
Mixed ductal/lobular 1.12 [0.98, 1.27] 
Other 0.90 [0.78, 1.03] 
NCI Comorbidity Index  
  0 (ref.) 
 Between 0 and 1 1.12** [1.04, 1.21] 
Greater than 1 1.35*** [1.19, 1.52] 
Age at diagnosis  
  65 to 69 (ref.) 
 70 to 74 1.19** [1.06, 1.33] 
75 to 79 1.45*** [1.30, 1.61] 
80 to 84 1.79*** [1.59, 2.01] 
85 and older 1.69*** [1.48, 1.93] 
Married  0.93* [0.86, 1.00] 
State buy-in coverage  
  No (ref.) 
 Yes 1.40*** [1.25, 1.57] 
Race  
  White (ref.) 
 Non-white 1.23*** [1.10, 1.38] 
Cooperative group affiliation of surgical facility† 1.04 [0.96, 1.12] 
NCI affiliation of surgical facility 0.74** [0.62, 0.89] 
Surgical facility a teaching hospital (or affiliated) 0.94 [0.86, 1.01] 
Surgical volume of surgical facility  
  Low  (ref.) 
 High  1.98*** [1.79, 2.19] 
Zip code proportion with at least a high school 
education (quartiles) 
  Low education (ref.) 
 Low-medium education 1.16** [1.05, 1.28] 
Medium-high education 1.31*** [1.17, 1.47] 
High education                         1.45***     [1.28, 1.64] 
Unknown education 1.46*** [1.22, 1.75] 
 
 
  
Table A.7. Multivariate logistic regression examining the 
likelihood of a mastectomy as the first surgical 
procedure (sub-analysis, n=17, 942) † 
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Odds 
Ratio 
95% Conf. 
Interval 
Year of diagnosis  
2004 (ref.) 
 2005 0.93 [0.84, 1.03] 
2006 0.80*** [0.73, 0.89] 
2007 0.87** [0.79, 0.96] 
SEER Region  
  California registries (ref.) 
 Northeast registries 0.67*** [0.60, 0.75] 
Georgia 1.33** [1.10, 1.61] 
Detroit 0.93 [0.79, 1.11] 
Iowa 2.53*** [2.15, 2.98] 
New Mexico 0.96 [0.74, 1.24] 
Seattle 1.15 [0.99, 1.34] 
Utah 1.29* [1.04, 1.60] 
Kentucky 1.98*** [1.70, 2.30] 
Louisiana 1.95*** [1.67, 2.28] 
Hawaii 0.83 [0.59, 1.17] 
Observations 17,942 
AIC 19507.9 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End 
Results; AIC, Akaike information criterion; NCI, National Cancer Institute 
* p<0.05, ** p<0.01,  *** p<0.001  
† Robust standard errors 
 
  
Table A.7. Multivariate logistic regression examining the 
likelihood of a mastectomy as the first surgical procedure 
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Figure A.3. Breast MRI propensity score distribution for the analysis 
examining the first surgical procedure (sub-analysis, n=17,942) 
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APPENDIX B: SUPPLEMENTAL TABLES AND FIGURES FOR CHAPTER 5 
Table B.1. SEER-Medicare inclusion/exclusion criteria 
Inclusion Criteria Included Excluded 
Breast cancer diagnosis in SEER 260,079  
Diagnosed between 2003 and 2007 (inclusive) 143,757 116,322 
First or primary cancer 131,974 11,783 
Age 66 or older at diagnosis 86,127 45,847 
Female 85,367 760 
Reporting source not autopsy or death certificate 84,466 901 
Laterality is not bilateral or unknown 83,659 807 
Original reason for Medicare entitlement not disability or ESRD 79,355 4,304 
Has valid month of diagnosis 79,114 241 
Has no HMO enrollment during study period* 56,652 22,462 
Has continuous enrollment in Part A&B during the study period* 52,038 4,614 
Has comorbidity score and was able to be matched to claims during the 
study period* 48,283 3,755 
Diagnosed between 2004 and 2007** 39,652 8,631 
*Study period is 12 months prior to diagnosis month until the end of data or death 
ESRD, end stage renal disease; HMO, Health Maintenance Organization; SEER, Surveillance, Epidemiology 
and End Results  **!We excluded patients diagnosed in 2003 because few patients (n=148) had a breast MRI, and were unable to 
be balanced using propensity scores. 
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Table B.2. Codes for identifying breast cancer events and treatments 
Study time frame Definition 
Initial treatment phase 
for the re-excision 
analysis 
The date of the first claim with a breast-related diagnosis code to the 
end of the initial treatment as defined as the last day of treatment before 
a gap in treatment of 90 days or more or the end of the study period 
(December 31, 2009) or the patient’s death. 
Date of second breast 
cancer event 
The date of the event (Figure 5.3) that identified the patient as having a 
second breast cancer event. For example, if the patient was considered 
to have a second breast cancer based on having a second primary in 
the SEER registries (n=759), the SEER date of the second primary was 
used. For women who were identified as having a second breast cancer 
based on the surgical procedure in SEER  (n=161), the date of her 
mastectomy >180 days after the primary breast cancer was used 
because SEER does not capture the date of surgery. For women who 
were identified as having a second breast cancer based on two visits 
with a code for a secondary malignant neoplasm within 60 days and 
>365 days after the primary breast cancer, the date of her second visit 
was used as the date of the second breast cancer event. 
First breast-related 
diagnosis code date 
Definition 
Breast-related 
diagnosis code 
174.*     Malignant neoplasm of female breast 
217.       Benign neoplasm of breast 
233.0     Carcinoma in situ of breast 
238.3     Neoplasm of uncertain behavior of breast 
239.3     Neoplasms of unspecified nature breast 
610.0     Solitary cyst of breast 
610.1     Diffuse cystic mastopathy 
610.2     Fibroadenosis of breast 
610.3     Fibrosclerosis of breast 
610.9     Benign mammary dysplasia, unspecified 
611.0     Inflammatory disease of breast 
611.1     Hypertrophy of breast 
611.3     Fat necrosis of breast 
611.8     Other specified disorders of breast 
611.9     Unspecified breast disorder 
611.71   Signs and symptoms in breast 
611.72   Lump or mass in breast 
611.79   Signs and symptoms in breast 
793.80   Abnormal mammogram, unspecified 
793.81   Mammographic microcalcification 
793.89   Other (abnormal) findings on radiological examination of breast 
V711      Observation for suspected malignant neoplasm 
First breast-related 
diagnosis code date 
The day of the first breast-related diagnosis code listed above within one 
year prior to the SEER diagnosis month 
Surgical Procedure Code identified in claims 
Breast Excision ICD-9-CM: 85.20-85.22; HCPCS: 19120, 19125, 19126, 19300 
Partial Mastectomy ICD-9-CM:  85.23; HCPCS: 19160/2, 19301/2 
Mastectomy ICD-9-CM: 85.4X; HCPCS: 19180, 19182, 19200, 19220, 19240, 19303-7 
SEER, Surveillance, Epidemiology and End Results; HCPCS, Healthcare Common Procedure 
Classification System; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical 
Modification; CPT, Current Procedural Terminology; DRG, Diagnosis-related group. 
• Algorithm and codes defined by Chubak et al. (2012). 
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Table B.2. Codes for identifying breast cancer events and treatments (cont.) 
Other treatment Code identified in claims 
Radiation 
ICD-9-CM: 92.2X. 93.3, 92.4 
HCPCS: 77401-77499, 77520, 77522, 77523, 77525, 77373, 77750-
77799; G0243; G0174, G0251, G0339, G0340 
Revenue Center Code: 0333 
DRG: 409 
Other:  V58.0, V66.1, V67.1 
Chemotherapy 
ICD-9-CM procedure: 99.25, 285.3, 999.81 
CPT/HCPCS: 51720, 96400–96549, 99555, Q008–3Q0085 (oral), 
C9127, C9415, C9420, C9421, C9431, C8953–C8955, S9329–S9331, 
G0355, G0357–G0363, G9021–G9032, J8510, J8520, J8521, J8530–
J8999 (oral), J9000–J9999 (IV) 
Revenue Center Code: 0331, 0332, 0335 
DRG: 410, 492 
Other: V58.1, V58.11, V66.2, V67.2, V87.41, NDC codes 
Second breast cancer 
event diagnosis 
codes* 
Code identified in claims 
Secondary malignant 
neoplasm ICD-9-CM: 196.x, 197.x, 198.x, 199.x 
Secondary non-breast 
malignant neoplasm ICD-9-CM: 197.x, 198.x excluding 198.2 & 198.81 
SEER, Surveillance, Epidemiology and End Results; HCPCS, Healthcare Common Procedure 
Classification System; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical 
Modification; CPT, Current Procedural Terminology; DRG, Diagnosis-related group. 
* Algorithm and codes defined by Chubak et al. (2012). 
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Analysis examining re-excisions 
 
 
Analysis examining 
second breast cancer 
events 
 
(n=24,438) 
 
Main analysis: 
Patients with initial BCS 
eligible for re-excision 
(n=17,199) 
Sub-analysis: 
Patients with an partial 
mastectomy eligible for 
re-excision 
(n=11,362) 
  
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Biopsy before first surgical 
procedure 2.00*** [1.77, 2.27] 3.63*** [2.73, 4.83]   
Received radiation 
therapy     1.04 [0.95, 1.14] 
Received chemotherapy     1.30*** [1.16, 1.46] 
Tumor size 
      ≤ 2cm (ref.) 
 
(ref.) 
 
(ref.) 
 > 2cm, ≤ 5cm 0.90 [0.79, 1.04] 0.85* [0.73, 0.99] 0.95 [0.86, 1.06] 
Tumor grade 
      Well differentiated (ref.) 
 
(ref.) 
 
(ref.) 
 Moderately 
differentiated 1.05 [0.93, 1.19] 1.03 [0.90, 1.19] 1.02 [0.92, 1.13] 
Poorly differentiated 0.86 [0.73, 1.01] 0.90 [0.75, 1.09] 0.80** [0.70, 0.92] 
Grade unknown 0.93 [0.71, 1.19] 0.85 [0.62, 1.16] 0.89 [0.72, 1.10] 
Hormone receptor status  
      Positive (ref.) 
 
(ref.) 
 
(ref.) 
 Negative 1.09 [0.91, 1.30] 1.03 [0.84, 1.27] 1.15 [1.00, 1.32] 
Unknown 1.03 [0.83, 1.27] 0.97 [0.76, 1.24] 1.02 [0.86, 1.21] 
Node positivity   1.07 [0.93, 1.23] 1.10 [0.94, 1.29] 1.03 [0.92, 1.15] 
Histology       
Ductal (ref.)  (ref.)  (ref.)  
Lobular 2.22*** [1.89, 2.57] 2.27*** [1.89, 2.72] 2.13*** [1.88, 2.42] 
Mixed ductal/lobular 1.50*** [1.25, 1.77] 1.43*** [1.17, 1.74] 1.68*** [1.46, 1.92] 
Other 0.82 [0.66, 1.02] 0.80 [0.62, 1.02] 0.79* [0.65, 0.94] 
NCI Comorbidity Index 
      0 (ref.) 
 
(ref.) 
 
(ref.) 
 Between 0 and 1 0.85** [0.75, 0.95] 0.85* [0.74, 0.98] 0.79*** [0.71, 0.87] 
Greater than 1 0.63*** [0.49, 0.82] 0.61** [0.45, 0.83] 0.54*** [0.44, 0.67] 
Age at diagnosis  
      65 to 69 (ref.) 
 
(ref.) 
 
(ref.) 
 70 to 74 0.68*** [0.60, 0.78] 0.68*** [0.58, 0.78] 0.69*** [0.62, 0.77] 
75 to 79 0.47*** [0.41, 0.55] 0.46*** [0.39, 0.54] 0.48*** [0.43, 0.54] 
80 to 84 0.36*** [0.31, 0.43] 0.38*** [0.31, 0.46] 0.35*** [0.30, 0.40] 
85 and older 0.23*** [0.18, 0.29] 0.21*** [0.16, 0.28] 0.19*** [0.15, 0.23] 
Married  1.07 [0.96, 1.18] 1.13 [1.00, 1.27] 1.10* [1.00, 1.19] 
State buy-in coverage  
      No (ref.) 
 
(ref.) 
 
(ref.) 
 Yes 0.61*** [0.49, 0.77] 0.71* [0.55, 0.92] 0.57*** [0.47, 0.69] 
Race  
      White (ref.) 
 
(ref.) 
 
(ref.) 
 Non-white 1.00 [0.85, 1.18] 1.00 [0.82, 1.21] 0.90 [0.78, 1.03] 
Cooperative group 
affiliation of surgical 
facility† 
 
1.32*** [1.18, 1.48] 1.35*** [1.18, 1.54] 1.34*** [1.22, 1.48] 
Table B.3. Multivariate logistic regression to generate preoperative breast MRI 
propensity scores 
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Analysis examining re-excisions 
 
 
Analysis examining 
second breast cancer 
events 
 
(n=24,438) 
 
Main analysis: 
Patients with initial BCS 
eligible for re-excision 
(n=17,199) 
Sub-analysis: 
Patients with an partial 
mastectomy eligible for 
re-excision 
(n=11,362) 
  
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
Odds 
Ratio 
95% Conf. 
Interval 
NCI affiliation of surgical 
facility 1.19 [0.96, 1.46] 0.98 [0.76, 1.26] 1.17 [0.98, 1.39] 
Surgical volume of 
surgical facility  
      Low  (ref.) 
 
(ref.) 
 
(ref.) 
 High  1.91*** [1.69, 2.14] 1.96*** [1.71, 2.25] 1.98*** [1.79, 2.18] 
Zip code proportion with at least  
   a high school education  
    (quartiles) 
    Low education (ref.) 
 
(ref.) 
 
(ref.) 
 Low-medium 
education 0.77*** [0.68, 0.88] 0.78*** [0.67, 0.90] 0.70*** [0.63, 0.78] 
Medium-high 
education 0.74*** [0.64, 0.86] 0.76** [0.64, 0.90] 0.66*** [0.58, 0.75] 
High education 0.54*** [0.45, 0.65] 0.55*** [0.44, 0.69] 0.48*** [0.41, 0.56] 
Unknown education 0.68** [0.51, 0.89] 0.65** [0.47, 0.89] 0.72** [0.58, 0.90] 
Year of diagnosis  
      2004 (ref.) 
 
(ref.) 
 
(ref.) 
 2005 1.53*** [1.27, 1.82] 1.50*** [1.21, 1.85] 1.62*** [1.40, 1.88] 
2006 2.42*** [2.05, 2.86] 2.55*** [2.10, 3.09] 2.70*** [2.35, 3.09] 
2007 4.70*** [4.01, 5.52] 4.61*** [3.83, 5.56] 5.09*** [4.46, 5.80] 
SEER Region  
      California registries (ref.) 
 
(ref.) 
 
(ref.) 
 Northeast registries 1.06 [0.91, 1.22] 1.12 [0.94, 1.32] 1.03 [0.91, 1.17] 
Georgia 0.45*** [0.33, 0.62] 0.51*** [0.36, 0.71] 0.52*** [0.41, 0.66] 
Detroit 0.54*** [0.42, 0.69] 0.51*** [0.38, 0.68] 0.55*** [0.45, 0.68] 
Iowa 0.44*** [0.32, 0.61] 0.45*** [0.31, 0.65] 0.41*** [0.32, 0.52] 
New Mexico 3.48*** [2.66, 4.55] 5.43*** [3.98, 7.41] 3.10*** [2.46, 3.90] 
Seattle 1.56*** [1.29, 1.90] 1.71*** [1.38, 2.12] 1.67*** [1.42, 1.96] 
Utah 0.62** [0.44, 0.87] 0.76 [0.51, 1.11] 0.62*** [0.47, 0.81] 
Kentucky 0.22*** [0.15, 0.32] 0.23*** [0.15, 0.35] 0.28*** [0.21, 0.36] 
Louisiana 0.39*** [0.27, 0.55] 0.49*** [0.33, 0.74] 0.37*** [0.28, 0.48] 
Hawaii 0.082*** [0.02, 0.27] 0.036** [0.00, 0.27] 0.11*** [0.05, 0.29] 
Observations 17,199 11,362 24,438 
AIC 10345.1 7682.5 14887.5 
* p<0.05, ** p<0.01,  *** p<0.001"          
BCS, Brest conserving surgery (i.e. partial mastectomy or breast excision); MRI, Magnetic Resonance 
Imaging; SEER, Surveillance, Epidemiology and End Results; NCI, National Cancer Institute; AIC, Akaike 
information criterion 
† NCI Cooperative Groups having breast cancer research portfolios !  
Table B.3. Multivariate logistic regression to generate preoperative breast MRI 
propensity scores (cont.) 
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  Odds Ratio 
 
 
 
95% Conf. 
Interval 
Preoperative breast MRI 0.97 [0.86, 1.09] 
Biopsy before first surgical procedure 1.56*** [1.38, 1.77] 
Initial BCS procedure was a breast excision 11.0*** [9.67, 12.45] 
Tumor size 
  ≤ 2cm (ref.) 
 > 2cm, ≤ 5cm 1.39*** [1.27, 1.53] 
Tumor grade 
  Well differentiated (ref.) 
 Moderately differentiated 1.14** [1.04, 1.24] 
Poorly differentiated 1.25*** [1.11, 1.40] 
Grade unknown 1.22* [1.03, 1.46] 
Hormone receptor status  
  Positive (ref.) 
 Negative 1.03 [0.92, 1.17] 
Unknown 1.13 [0.98, 1.29] 
Node positivity   1.55*** [1.40, 1.71] 
Histology   
Ductal (ref.)  
Lobular 1.52*** [1.34, 1.73] 
Mixed ductal/lobular 1.36*** [1.19, 1.57] 
Other 1.04 [0.91, 1.19] 
NCI Comorbidity Index  
  0 (ref.) 
 Between 0 and 1 1.04 [0.96, 1.13] 
Greater than 1 0.99 [0.85, 1.14] 
Age at diagnosis  
  65 to 69 (ref.) 
 70 to 74 0.93 [0.84, 1.03] 
75 to 79 0.87** [0.78, 0.96] 
80 to 84 0.80*** [0.71, 0.90] 
85 and older 0.54*** [0.47, 0.63] 
Married  1.07 [0.99, 1.15] 
State buy-in coverage  
  No (ref.) 
 Yes 1.00 [0.87, 1.14] 
Race  
  White (ref.) 
 Non-white 1.00 [0.85, 1.18] 
Cooperative group affiliation of surgical facility† 0.86*** [0.79, 0.93] 
NCI affiliation of surgical facility 0.97 [0.82, 1.15] 
Surgical volume of surgical facility  
  Low volume (ref.) 
 High volume 1.09* [1.01, 1.19] 
Zip code proportion with at least a high school education (quartiles) 
Low education (ref.) 
 Low-medium education 0.95 [0.85, 1.05] 
Medium-high education 0.98 [0.88, 1.10] 
High education 1.11 [0.98, 1.25] 
Unknown education 0.84 [0.69, 1.04] 
 
 
 
  
Table B.4. Multivariate logistic regression examining the 
likelihood of a re-excision after BCS (main analysis, 
n=17,199) 
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  Odds Ratio 
 
 
 
95% Conf. 
Interval 
Year of diagnosis  
2004 (ref.) 
 2005 1.04 [0.94, 1.15] 
2006 1.15** [1.04, 1.27] 
2007 1.00 [0.90, 1.10] 
SEER Region  
  California registries (ref.) 
 Northeast registries 1.32*** [1.18, 1.48] 
Georgia 1.31* [1.06, 1.63] 
Detroit 2.19*** [1.88, 2.56] 
Iowa 0.76** [0.64, 0.91] 
New Mexico 1.61*** [1.27, 2.05] 
Seattle 0.81* [0.68, 0.98] 
Utah 0.94 [0.74, 1.20] 
Kentucky 1.02 [0.87, 1.20] 
Louisiana 1.73*** [1.48, 2.03] 
Hawaii 0.94 [0.66, 1.33] 
Observations 17,199 
AIC 18022.7 
BCS, breast conserving surgery (i.e. breast excision or partial mastectomy); MRI, 
Magnetic Resonance Imaging; IPW, Inverse probability weighting; SEER, 
Surveillance, Epidemiology and End Results; NCI, National Cancer Institute; AIC, 
Akaike information criterion 
* p<0.05, ** p<0.01,  *** p<0.001 
Table B.4. Multivariate logistic regression examining the 
likelihood of a re-excision for patients with a BCS (cont.) 
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Model adjusted for 
covariates 
 
 
Model with IPW, 
adjusted for the first 
surgical treatment after 
estimating the IPW 
  
Hazard 
Ratio 
95% Conf. 
Interval 
Hazard 
Ratio 
95% Conf. 
Interval 
Preoperative breast MRI 1.29*** [1.14, 1.46] 1.32* [1.07, 1.63] 
Complete surgery     
Breast conserving surgery  (ref.)  (ref.)  
Mastectomy 1.41*** [1.14, 1.46] 1.92*** [1.73, 2.13] 
Received radiation therapy 1.40*** [1.23, 1.58]   
Received chemotherapy 2.16*** [1.94, 2.40]   
Tumor size 
  
  
≤ 2cm (ref.) 
 
  
> 2cm, ≤ 5cm 1.32*** [1.19, 1.45]   
Tumor grade 
  
  
Well differentiated (ref.) 
 
  
Moderately differentiated 1.11 [0.98, 1.25]   
Poorly differentiated 1.36*** [1.18, 1.56]   
Grade unknown 1.13 [0.90, 1.42]   
Hormone receptor status  
  
  
Positive (ref.) 
 
  
Negative 1.37*** [1.22, 1.54]   
Unknown 1.20* [1.02, 1.40]   
Node positivity   1.55*** [1.40, 1.72]   
Histology     
Ductal (ref.)    
Lobular 0.88 [0.75, 1.04]   
Mixed ductal/lobular 1.21* [1.05, 1.40]   
Other 0.81* [0.67, 0.98]   
NCI Comorbidity Index  
  
  
0 (ref.) 
 
  
Between 0 and 1 1.15** [1.06, 1.29]   
Greater than 1 1.35*** [1.19, 1.61]   
Age at diagnosis  
  
  
65 to 69 (ref.) 
 
  
70 to 74 1.04 [0.91, 1.18]   
75 to 79 1.28*** [1.11, 1.44]   
80 to 84 1.30*** [1.11, 1.49]   
85 and older 1.37*** [1.25, 1.78]   
Married  0.96 [0.85, 1.02]   
State buy-in coverage  
  
  
No (ref.) 
 
  
Yes 1.17* [1.02, 1.34]   
Race  
  
  
White (ref.) 
 
  
Non-white 0.90 [0.79, 1.03]   
Cooperative group affiliation of 
surgical facility† 1.04 [0.95, 1.15]   
NCI affiliation of surgical facility 1.19 [1.00, 1.43]   
Surgical volume of surgical 
facility  
  
  
Low  (ref.) 
 
  
High  1.01 [0.92, 1.12]   
   
Table B.5. Multivariate proportional hazard regression analysis of 
second breast cancer events 
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Model adjusted for 
covariates 
 
 
Model with IPW, 
adjusted for the first 
surgical treatment after 
estimating the IPW 
  
Hazard 
Ratio 
95% Conf. 
Interval 
Hazard 
Ratio 
95% Conf. 
Interval 
Zip code proportion with at least a  
  high school education (quartiles) 
Low education (ref.) 
 
  
Low-medium education 0.94 [0.87, 1.12]   
Medium-high education 0.93 [0.84, 1.11]   
High education 0.97 [0.84, 1.14]   
Unknown education 1.16 [0.94, 1.46]   
Year of diagnosis  
  
  
2004 (ref.) 
 
  
2005 0.90 [0.80, 1.01]   
2006 0.94 [0.83, 1.06]   
2007 0.95 [0.81, 1.06]   
SEER Region  
  
  
California registries (ref.) 
 
  
Northeast registries 1.18* [1.04, 1.34]   
Georgia 0.93 [0.72, 1.21]   
Detroit 1.07 [0.89, 1.28]   
Iowa 1.12 [0.91, 1.34]   
New Mexico 1.18 [0.89, 1.56]   
Seattle 1.11 [0.92, 1.33]   
Utah 0.95 [0.72, 1.25]   
Kentucky 1.21* [1.01, 1.45]   
Louisiana 1.03 [0.85, 1.24]   
Hawaii 0.71 [0.43, 1.18]   
Observations 24,438 24,438 
AIC 44,257.7 45,192.9 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting; SEER, 
Surveillance, Epidemiology and End Results; NCI, National Cancer Institute; AIC, 
Akaike information criterion 
†  NCI Cooperative Groups having breast cancer research portfolios
Table B.5. Multivariate proportional hazard regression 
analysis of second breast cancer events (cont.) 
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 Figure B.3. Additional algorithms for identifying a second breast cancer event 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure created with permission from Chubak J, Yu O, Pocobelli G, et al: Administrative Data Algorithms to 
Identify Second Breast Cancer Events Following Early-Stage Invasive Breast Cancer. J Natl Cancer Inst  
104:931-940, 2012. 
  
A.  Algorithm with estimated high sensitivity 
 
 
Sensitivity was estimated to be 96%, 
specificity 95%, and positive predictive 
value 74% based on validation study 
using a different study population 
(Chubak et al. 2012) 
 
 
Two visits with a code for a secondary malignant neoplasm 
within a 60 day period occurring >365 days after the primary 
breast cancer 
(n = 24,439) 
A second breast cancer 
record in the SEER registry 
(n=22,733) 
A mastectomy >180 days 
after the primary breast 
cancer 
(n= 21,974) 
Second breast 
cancer event 
(n=759) 
No second breast 
cancer event 
(n=20,939) 
Second breast 
cancer event 
(n=745) 
Second breast 
cancer event 
(n=1,706) 
Yes No 
Yes 
Yes 
Yes 
No 
No 
No 
Second breast 
cancer event 
(n=290) 
A code for a secondary 
non-breast malignant 
neoplasm >180 days after 
the primary breast cancer 
(n= 21,684) 
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Figure created with permission from Chubak J, Yu O, Pocobelli G, et al: Administrative Data Algorithms to 
Identify Second Breast Cancer Events Following Early-Stage Invasive Breast Cancer. J Natl Cancer Inst  
104:931-940, 2012. 
 
 
  
A code for a secondary malignant neoplasm >365 days after the 
primary breast cancer 
(n = 24,439) 
Breast surgery >180 days after 
the primary breast cancer 
(n=21,124) 
Maximum time between 
two consecutive visits for 
chemotherapy 
(n= 19,922) 
Second breast 
cancer event 
(n=1,202) 
No second breast 
cancer event 
(n=18,480) 
Second breast 
cancer event 
(n=532) 
Second breast 
cancer event 
(n=3,315) 
Yes No 
Yes 
Yes 
>43 days 
No 
No 
< 43 days 
Second breast 
cancer event 
(n=910) 
A second breast cancer 
record in the SEER registry  
(n= 19,012) 
Sensitivity was estimated to be 99%, 
specificity 81%, and positive predictive 
value 43% based on validation study 
using a different study population 
(Chubak et al. 2012) 
 
 
B.  Algorithm with estimated extremely high sensitivity 
 
 
Figure B.3. Additional algorithms for identifying a second breast cancer event 
(cont.) 
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Unadjusted data 
 
 
 
Data adjusted using inverse 
probability weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= 
11,362 
N= 
9,795 
N= 
1,567 N=9,765 N=1,560 
Preoperative breast MRI  (%) 13.8 0 100 <0.001 0 100 <0.001 
Re-excision after first surgical 
procedure 18.7 18.7 18.8 0.87 18.8 20.4 0.58 
Biopsy before first surgical 
procedure 86 84.3 96.3 <0.001 86.0 84.4 0.54 
Tumor size  (%)    <0.001   0.37 
≤ 2cm 77.3 76.8 80.7  77.3 79.2  
> 2cm, ≤ 5cm 22.7 23.2 19.3  22.7 20.8  
Tumor grade  (%)    <0.001   0.71 
       Well differentiated 27.7 27.3 30.1  27.6 27.0  
Moderately differentiated 44.4 44.1 46.1  44.2 43.1  
Poorly differentiated 23.4 24.0 19.7  23.6 25.8  
Grade unknown 4.5 4.6 4.1  4.6 4.0  
Hormone receptor status  (%)    0.03   0.37 
Positive 80.8 80.4 83.2  80.8 78.0  
Negative 12.0 12.3 10.5  12.1 15.1  
Unknown 7.2 7.3 6.3  7.2 6.9  
Node positivity  (%) 17.1 16.9 18.4 0.16 17.2 19.6 0.22 
Histology    <0.001   0.43 
Ductal 74.6 75.5 69.0  75.1 75.1  
Lobular 9.3 8.3 15.3  8.9 7.9  
Mixed ductal/lobular 8.2 7.8 10.6  8.1 9.9  
Other 7.9 8.3 5.2  7.9 7.1  
NCI Comorbidity Index (%)     <0.001   0.79 
0 67.0 65.8 74.0  66.8 65.3  
Between 0 and 1 26.2 26.8 22.5  26.3 26.7  
Greater than 1 6.8 7.4 3.5  6.9 7.9  
Age at diagnosis  (%)    <0.001   0.31 
65 to 69 22.2 20.1 35.4  21.7 20.7  
70 to 74 25.6 25.0 29.3  25.7 30.5  
75 to 79 23.5 24.3 18.9  23.8 22.2  
80 to 84 17.6 18.4 12.2  17.7 17.1  
85 and older 11.1 12.2 4.3  11.1 9.5  
Married  (%) 47.9 46.7 55.5 <0.001 47.8 50.8 0.24 
State buy-in coverage  (%)    <0.001   0.06 
No 91.6 91.1 94.9  91.6 93.7  
Yes 8.4 8.9 5.1  8.4 6.3  
Race  (%)    0.28   0.03 
White 87.8 87.7 88.6  87.9 90.5  
Non-white 12.2 12.3 11.4  12.1 9.5  
Cooperative group affiliation of 
surgical facility  (%)‡ 55.5 54.1 64.4 <0.001 55.4 55.9 0.86 
NCI affiliation of surgical 
facility  (%) 5.8 5.7 6.2 0.47 5.8 5.6 0.8 
Surgical facility a teaching 
hospital (or affiliated one) 54.7 54.8 54.2 0.66 55.4 53.4 0.46 
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Unadjusted data 
 
 
 
Data adjusted using inverse 
probability weighting 
 
Overall 
No 
breast 
MRI 
Breast 
MRI p-value 
No breast 
MRI 
Breast 
MRI p-
value 
  
N= 
11,362 
N= 
9,795 
N= 
1,567 N=9,765 N=1,560 
Surgical volume of surgical 
facility (%) 
<0.001 0.45 
 
Low  42.5 44.9 27.4  42.8 44.8  
High  57.5 55.1 72.6  57.2 55.2  
Zip code proportion with at 
least high school education 
(% in each quartile)    <0.001   0.27 
Low education 29.6 28.1 38.6  29.4 28.3  
Low-medium education 25.7 25.6 26.7  25.7 28.0  
Medium-high education 22.3 22.6 20.2  22.2 19.4  
High education 18.7 19.9 10.7  18.8 18.0  
Unknown education 3.8 3.8 3.8  3.8 6.4  
Year of diagnosis  (%)    <0.001   0.61 
2004 21.6 23.4 10.7  21.8 19.3  
2005 23.4 24.5 16.2  23.6 24.2  
2006 27.3 27.1 28.7  27.5 29.6  
2007 27.7 25.0 44.4  27.2 26.8  
SEER Region (%)    <0.001   0.73 
California registries 36.6 35.9 41.0  36.7 34.7  
Northeast registries 25.0 24.6 27.2  25.2 27.5  
Georgia 3.7 3.8 2.9  3.8 3.2  
Detroit 6.5 6.8 4.5  6.6 6.1  
Iowa 5.2 5.7 2.2  5.3 5.2  
New Mexico 1.9 1.3 5.4  1.6 1.5  
Seattle 6.7 6.0 11.0  6.5 6.2  
Utah 2.4 2.5 2.3  2.5 2.2  
Kentucky 6.2 7.0 1.7  6.3 6.5  
Louisiana 4.3 4.7 1.9  4.3 4.2  
Hawaii 1.4 1.7 0.1  1.3 2.7  
P-values by t-test for continuous variables and chi2 test for binary / categorical variables, Mean 
(Standard Deviation) or % 
MRI, Magnetic Resonance Imaging; SEER, Surveillance, Epidemiology and End Results; PM, Partial 
mastectomy; TM, Total mastectomy; NCI, National Cancer Institute 
‡  NCI Cooperative Groups having breast cancer research portfolios 
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Odds Ratio 
95% Conf. 
Interval 
Preoperative breast MRI 0.92 [0.79, 1.07] 
Biopsy before first surgical procedure 0.56*** [0.49, 0.64] 
Tumor size 
  ≤ 2cm (ref.) 
 > 2cm, ≤ 5cm 1.25*** [1.11, 1.41] 
Tumor grade 
  Well differentiated (ref.) 
 Moderately differentiated 1.21** [1.06, 1.36] 
Poorly differentiated 1.26** [1.08, 1.47] 
Grade unknown 1.57*** [1.24, 1.99] 
Hormone receptor status  
  Positive (ref.) 
 Negative 1.03 [0.87, 1.21] 
Unknown 1.00 [0.83, 1.22] 
Node positivity   1.45*** [1.29, 1.64] 
Histology   
Ductal (ref.)  
Lobular 1.64*** [1.39, 1.92] 
Mixed ductal/lobular 1.64*** [1.39, 1.93] 
Other 1.01 [0.83, 1.23] 
NCI Comorbidity Index (%)  
  0 (ref.) 
 Between 0 and 1 0.99 [0.88, 1.10] 
Greater than 1 1.04 [0.85, 1.26] 
Age at diagnosis  
  65 to 69 (ref.) 
 70 to 74 0.89 [0.78, 1.02] 
75 to 79 0.78*** [0.68, 0.90] 
80 to 84 0.74*** [0.64, 0.87] 
85 and older 0.48*** [0.39, 0.59] 
Married  1.09 [0.98, 1.20] 
State buy-in coverage  
  No (ref.) 
 Yes 0.98 [0.81, 1.18] 
Race  
  White (ref.) 
 Non-white 1.03 [0.88, 1.21] 
Cooperative group affiliation of surgical facility† 1.02 [0.91, 1.13] 
NCI affiliation of surgical facility 1.08 [0.87, 1.32] 
Surgical volume of surgical facility  
  Low  (ref.) 
 High  1.04 [0.93, 1.15] 
Zip code proportion with at least a high school education (quartiles) 
Low education (ref.) 
 Low-medium education 1.01 [0.89, 1.16] 
Medium-high education 0.89 [0.77, 1.03] 
High education 0.92 [0.78, 1.09] 
Unknown education 0.89 [0.68, 1.16] 
 
  
Table B.7. Likelihood of a re-excision after a partial mastectomy 
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Odds Ratio 
95% Conf. 
Interval 
Year of diagnosis  
2004 (ref.) 
 2005 1.05 [0.91, 1.21] 
2006 1.20* [1.04, 1.37] 
2007 1.06 [0.92, 1.22] 
SEER Region  
  California registries (ref.) 
 Northeast registries 1.16 [1.00, 1.35] 
Georgia 1.21 [0.93, 1.59] 
Detroit 2.24*** [1.84, 2.72] 
Iowa 0.77 [0.58, 1.02] 
New Mexico 1.25 [0.88, 1.79] 
Seattle 1.19 [0.97, 1.47] 
Utah 0.96 [0.69, 1.33] 
Kentucky 0.75* [0.58, 0.96] 
Louisiana 1.07 [0.83, 1.38] 
Hawaii 1.01 [0.64, 1.58] 
Observations 11,362 
AIC 10,610.1 
MRI, Magnetic Resonance Imaging; IPW, Inverse probability weighting; SEER, 
Surveillance, Epidemiology and End Results; NCI, National Cancer Institute; AIC, 
Akaike information criterion 
* p<0.05, ** p<0.01,  *** p<0.001 
† NCI Cooperative Groups having breast cancer research portfolios 
§ 383 groups (1,056 observations) were excluded because they had all patients 
with or all patients without re-excisions 
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Figure B.4. Brest MRI propensity score distribution (sub-analysis, 
n=11,362) 
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APPENDIX C: SUPPLEMENTAL TABLES AND FIGURES FOR CHAPTER 6 
 
Table C.1. SEER-Medicare inclusion/exclusion criteria 
Inclusion Criteria Included Excluded 
Breast cancer diagnosis in SEER 260,079  
Diagnosed between 2003 and 2007 (inclusive) 143,757 116,322 
First or primary cancer 131,974 11,783 
Age 66 or older at diagnosis 86,127 45,847 
Female 85,367 760 
Reporting source not autopsy or death certificate 84,466 901 
Laterality is not bilateral or unknown 83,659 807 
Original reason for Medicare entitlement not disability or ESRD 79,355 4,304 
Has valid month of diagnosis 79,114 241 
Has no HMO enrollment during study period* 56,652 22,462 
Has continuous enrollment in Part A & B during the study period* 52,038 4,614 
Has comorbidity score and was able to be matched to claims during the 
study period* 48,283 3,755 
Diagnosed between 2004 and 2007** 39,652 8,631 
*Study period is 12 months prior to diagnosis month until the end of data or death 
ESRD, end stage renal disease; HMO, Health Maintenance Organization; SEER, Surveillance, Epidemiology 
and End Results  **!We excluded patients diagnosed in 2003 because few patients (n=148) recieved a breast MRI 
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Table C.2. Codes for identifying breast cancer events  
Time frame Definition 
Initial treatment phase 
(main analysis) 
All claims from the first claim with a breast diagnosis code to the end 
of the initial treatment as defined as the last day of treatment before 
a gap in treatment of 90 days or more, the end of the study period 
(December 31, 2009), or patient’s death. 
Initial 12 months  
(sensitivity analysis) 
All claims from 12 months after the first claim with a breast diagnosis 
code. 
First breast diagnosis 
code date 
Definition 
Breast diagnosis code 
174.*     Malignant neoplasm of female breast 
217.      Benign neoplasm of breast 
233.0    Carcinoma in situ of breast 
238.3    Neoplasm of uncertain behavior of breast 
239.3     Neoplasms of unspecified nature breast 
610.0     Solitary cyst of breast 
610.1     Diffuse cystic mastopathy 
610.2     Fibroadenosis of breast 
610.3     Fibrosclerosis of breast 
610.9     Benign mammary dysplasia, unspecified 
611.0     Inflammatory disease of breast 
611.1     Hypertrophy of breast 
611.3     Fat necrosis of breast 
611.8     Other specified disorders of breast 
611.9     Unspecified breast disorder 
611.71   Signs and symptoms in breast 
611.72   Lump or mass in breast 
611.79   Signs and symptoms in breast 
793.80   Abnormal mammogram, unspecified 
793.81   Mammographic microcalcification 
793.89   Other (abnormal) findings on radiological examination of 
breast 
V711      Observation for suspected malignant neoplasm 
First breast diagnosis code 
date 
The day of the first breast diagnosis code listed above within 12 or 
fewer months prior to the SEER diagnosis month 
Procedures  Code identified in claims: 
Breast MRI HCPCS: 76093, 76094, 77058, 77059, C8903, C8904, C8905, C8906, C8907, C8908 
Biopsy* HCPCS: 19100, 19101, 19102, 19103, 10021, 10022 ICD-9-CM: 85.1, 85.11, 85.12, 85.19 
Breast excision* HCPCS: 19120, 19125, 19126, 19300 ICD-9-CM: 85.20, 85.21, 85.22, 85.2 
Partial mastectomy* HCPCS: 19160, 19162, 19301, 19302 ICD-9-CM: 85.23 
Mastectomy* 
HCPCS: 19180, 19182, 19200, 19220, 19240, 19303, 19304, 19305, 
19306, 19307 
ICD-9-CM: 85.4 
Radiation 
HCPCS: G0243, 77520, 77522, 77523, 77525, G0174, G0251, 
G0339, G0340, 77371, 77373, V580*, V661*, V671*, 774**, 77520, 
77522, 77523, 77525, 77750, 7776*, 7777*, 7778*, 7779* 
ICD-9-CM: 92.2 
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Table C.2. Codes for identifying breast cancer events (cont.) 
Procedures  Code identified in claims: 
Chemotherapy 
HCPCS: V581*, 96523", "96521", "96522", 0331, 0332, 0335, 410, 
492, V662*, V672* 964**, 9654*, C1167, C8953, C8954, C8955, 
C9127, C9214, C9240, C9257, C9280, C9414, C9415, C9418, 
C9420, C9421, C9425, C9431, C9438, C9440, G0359, G0360, 
G902, G9031, G9032,G0355, G0357, G0358, G0359, G0360, 
G0361, G0362, S9329, S9330, S9331, Q0083, Q0084, Q0085, 
J8520, J8521, J8530, J8540, J8560, J8579, J8610, J8999, or any 
code beginning with J9 
ICD-9-CM: 99.25 
Mammogram 
HCPCS: 76090, 76091, 76092, 76098, 77051, 77052, 77055, 77056, 
77057, G0202, G0204, G0206 
ICD-9-CM: 87.37 
Ultrasound HCPCS: 76645 ICD-9-CM: 88.72, 88.73 
Lymph node procedure 
HCPCS: 38308, 38500, 38505, 38510, 38525, 38530, 38740, 38745, 
38792 
ICD-9-CM: 40.0, 40.2, 40.3, 40.4, 40.6, 40.11, 40.19, 40.23 
Bone Scan HCPCS: 78305, 78306, 78300, 78315, 78399 ICD-9-CM: 92.14 
Brain MRI HCPCS: 70551, 70552, 70553 ICD-9-CM: 88.91 
CT scan 
HCPCS: 70480-82, 70486-88, 70490-92, 71250, 71260, 71270, 
72125-33, 72192-4, 73200-2, 73700, 73701, 73702, 74150, 74160, 
74170, 74176-8, 76497 
PET and PET CT HCPCS: 78811-78816, 78890, 78891, 78999, G0235, G0253, G0254 ICD-9-CM: 92.11, 92.12, 92.18, 92.19 
Nuclear medicine test 
HCPCS: 78195, 78320, 78464, 78465, 78472, 78473, 78478, 78480, 
78585, 78800, 78801 
ICD-9-CM: 92.16 
Office visit/ consultation HCPCS: 99201-05, 99211-15, 99241-45, 99251-55, 99273-5, G0101 ICD-9-CM: 87.44 
 
HCPCS, Healthcare Common Procedure Classification System; ICD-9-CM, International 
Classification of Diseases, 9th Revision, Clinical Modification; MRI, Magnetic resonance imaging; 
PET, Positron emission tomography; CT, Computed tomography; SEER, Surveillance, Epidemiology 
and End Results 
* If a claim for a biopsy occurred on the same day as a breast excision it was considered a breast 
excision. If a claim for a breast excision occurred on the same day as a partial mastectomy or a 
mastectomy, it was considered a partial mastectomy or a mastectomy, respectively. If there were 
conflicting claims for a partial mastectomy and a mastectomy on the same day, the patient was 
excluded. 
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All payments 
Breast cancer-
attributable 
payments† 
Payments not 
attributable to 
breast cancer 
 
 
Preoperative breast MRI 
receipt 1.10*** [1.08, 1.13] 1.14*** [1.12, 1.16] 0.98 [0.88, 1.10] 
Radiation receipt 1.54*** [1.51, 1.57] 1.61*** [1.59, 1.64]   
Chemotherapy receipt 2.49*** [2.42, 2.56] 2.38*** [2.32, 2.44]   
Advanced Imaging receipt 1.26*** [1.23, 1.29] 1.16*** [1.14, 1.18]   
Tumor size between 2 and 5 
cm 1.09*** [1.07, 1.12] 1.08*** [1.06, 1.10]   
Tumor grade       
Well differentiated (ref.)  (ref.)    
Moderately differentiated 1.00 [0.98, 1.02] 1.02 [1.00, 1.04]   
Poorly differentiated 1.02 [0.99, 1.05] 1.07*** [1.04, 1.09]   
Grade unknown 1.03 [0.99, 1.08] 1.03 [0.99, 1.07]   
Hormone receptor status       
Positive (ref.)  (ref.)    
Negative 1.04** [1.01, 1.07] 1.02 [1.00, 1.05]   
Unknown 1.02 [0.99, 1.06] 1.02 [0.99, 1.05]   
Node positivity 1.16*** [1.13, 1.19] 1.17*** [1.14, 1.19]   
Histology       
Ductal (ref.)  (ref.)    
Lobular 1.03 [0.99, 1.06] 1.01 [0.99, 1.04]   
Mixed ductal/lobular 1.01 [0.98, 1.05] 1.03 [1.00, 1.06]   
Other 0.96** [0.92, 0.99] 0.97 [0.94, 1.00]   
Positive nodal status 1.16*** [1.13, 1.19] 1.17*** [1.14, 1.19]   
NCI Comorbidity Index       
0 (ref.)  (ref.)  (ref.)  
Between 0 and 1 1.08*** [1.06, 1.11] 1.02* [1.00, 1.04] 1.49*** [1.37, 1.62] 
Greater than 1 1.34*** [1.28, 1.41] 1.03 [0.99, 1.06] 2.71*** [2.40, 3.06] 
Age at diagnosis       
65 to 69 (ref.)  (ref.)  (ref.)  
70 to 74   1.03* [1.00, 1.05] 1.02 [1.00, 1.04] 0.93 [0.85, 1.03] 
75 to 79   1.01 [0.98, 1.03] 0.98 [0.96, 1.00] 0.84** [0.76, 0.94] 
80 to 84   1.00 [0.97, 1.03] 0.97** [0.94, 0.99] 0.74*** [0.66, 0.83] 
85 and older   0.88*** [0.85, 0.92] 0.82*** [0.79, 0.84] 0.64*** [0.55, 0.73] 
State buy-in coverage       
No   (ref.)  (ref.)  (ref.)  
Yes   1.09*** [1.05, 1.14] 1.01 [0.99, 1.04] 1.41*** [1.25, 1.60] 
Race       
White   (ref.)  (ref.)  (ref.)  
Non-white   1.01 [0.98, 1.04] 1.01 [0.98, 1.03] 1.05 [0.94,  1.17] 
Married   1.00 [0.98, 1.01] 1.00  [0.99, 1.02] 1.00 [0.98, 1.01] 
Table C.3. Adjusted multiplicative effects on Medicare payments during the initial treatment phase 
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All payments 
Breast cancer-
attributable 
payments† 
Payments not 
attributable to 
breast cancer 
 
 
Zip residence       
Metropolitan (ref.)  (ref.)  (ref.)  
Non-Metropolitan 0.96** [0.93, 0.98] 0.98 [0.96, 1.00] 0.87* [0.77, 0.98] 
Surgical facility variables:       
Cooperative group 
affiliation§ 1.02 [1.00, 1.04] 1.03*** [1.01, 1.05]   
NCI affiliation 0.98 [0.94, 1.01] 0.99 [0.96, 1.03]   
Year of diagnosis       
2004 (ref.)  (ref.)  (ref.)  
2005 1.04** [1.01, 1.06] 1.02 [1.00, 1.04] 1.14** [1.04, 1.26] 
2006 1.06*** [1.03, 1.09] 1.04*** [1.02, 1.06] 1.18** [1.07, 1.31] 
2007 1.04** [1.01, 1.06] 1.03* [1.01, 1.05] 1.15** [1.03, 1.27] 
SEER region       
California registries (ref.)  (ref.)  (ref.)  
Northeast registries 1.03* [1.01, 1.06] 1.00 [0.98, 1.02] 1.25*** [1.14, 1.38] 
Georgia 0.97 [0.92, 1.01] 0.96* [0.92, 1.00] 0.93 [0.76, 1.13] 
Detroit 1.04 [1.00, 1.09] 1.00 [0.97, 1.03] 1.40*** [1.21, 1.63] 
Iowa 0.83*** [0.80, 0.86] 0.83*** [0.81, 0.86] 0.70*** [0.60, 0.83] 
New Mexico 0.90** [0.85, 0.96] 0.90*** [0.86, 0.95] 0.97 [0.75, 1.26] 
Seattle 0.86*** [0.83, 0.89] 0.89*** [0.86, 0.91] 0.75*** [0.64, 0.89] 
Utah 0.81*** [0.76, 0.86] 0.79*** [0.76, 0.83] 1.01 [0.77, 1.31] 
Kentucky 0.86*** [0.83, 0.90] 0.82*** [0.79, 0.85] 1.11 [0.94, 1.30] 
Louisiana 0.89*** [0.85, 0.93] 0.90*** [0.87, 0.93] 0.95 [0.82, 1.11] 
Hawaii 0.80*** [0.74, 0.87] 0.81*** [0.75, 0.86] 0.74* [0.55, 1.00] 
N 22974 22974 22974 
AIC 5.0e+05 4.9e+05 4.2e+05 
 
* p<0.05  ** p<0.01   *** p<0.001 
MRI, Magnetic resonance imaging; NCI, National Cancer Institute; AIC, Akaike information criterion,  
95% confidence intervals in brackets, All models are generalized linear models using log-link gamma with robust 
standard errors. 
†  Breast cancer-attributable payments include total Medicare payments from claims associated with breast 
cancer diagnosis or treatment or from claims with a breast cancer diagnosis code within the claim’s first four 
diagnosis codes.  
§  NCI Cooperative Groups having breast cancer research portfolios 
Table C.3 Adjusted multiplicative effects on Medicare payments during the initial treatment phase 
(cont.) 
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 All payments 
Breast cancer-
attributable 
payments† 
Payments not 
attributable to breast 
cancer  
 
Preoperative breast MRI receipt 1.03 [1.00, 1.06] 1.11*** [1.09, 1.14] 0.86*** [0.79, 0.94] 
Radiation receipt 1.18*** [1.15, 1.21] 1.50*** [1.47, 1.52]   
Chemotherapy receipt 1.81*** [1.76, 1.87] 2.05*** [2.00, 2.09]   
Advanced Imaging receipt 1.38*** [1.34, 1.42] 1.17*** [1.14, 1.19]   
Tumor size between 2 and 5 
cm 1.08*** [1.05, 1.11] 1.09*** [1.07, 1.11]   
Tumor grade         
Well differentiated (ref.)  (ref.)    
Moderately differentiated 0.99 [0.96, 1.02] 1.02* [1.01, 1.04]   
Poorly differentiated 1.04 [1.00, 1.08] 1.06*** [1.04, 1.09]   
Grade unknown 1.04 [0.98, 1.10] 1.04 [0.99, 1.09]   
Hormone receptor status       
Positive (ref.)  (ref.)    
Negative 1.01 [0.97, 1.04] 1.03* [1.00, 1.05]   
Unknown 1.02 [0.97, 1.06] 1.01 [0.98, 1.04]   
Node positivity         
Histology       
Ductal (ref.)  (ref.)    
Lobular 1.00 [0.96, 1.04] 1.02 [1.00, 1.05]   
Mixed ductal/lobular 1.03 [0.99, 1.08] 1.04* [1.01, 1.07]   
Other 0.93*** [0.90, 0.97] 0.97 [0.95, 1.00]   
Positive nodal status 1.16*** [1.13, 1.20] 1.20*** [1.18, 1.22]   
NCI Comorbidity Index       
0 (ref.)  (ref.)  (ref.)  
Between 0 and 1 1.18*** [1.15, 1.21] 1.03** [1.01, 1.04] 1.60*** [1.50, 1.71] 
Greater than 1 1.67*** [1.58, 1.76] 1.04* [1.01, 1.08] 2.93*** [2.68, 3.21] 
Age at diagnosis       
65 to 69 (ref.)  (ref.)  (ref.)  
70 to 74 1.02 [0.99, 1.05] 1.00 [0.98, 1.02] 1.08 [0.99, 1.17] 
75 to 79 1.04* [1.00, 1.07] 0.97* [0.95, 0.99] 1.17*** [1.07, 1.28] 
80 to 84 1.06** [1.02, 1.10] 0.94*** [0.92, 0.97] 1.25*** [1.14, 1.38] 
85 and older 1.07* [1.01, 1.12] 0.80*** [0.77, 0.83] 1.47*** [1.32, 1.63] 
State buy-in coverage       
No (ref.)  (ref.)  (ref.)  
Yes 1.17*** [1.11, 1.22] 1.03* [1.00, 1.06] 1.43*** [1.29, 1.58] 
Race       
White (ref.)  (ref.)  (ref.)  
Non-white 0.97 [0.93, 1.02] 1.01 [0.98, 1.03] 0.94 [0.85, 1.04] 
Table C.4. Sensitivity analysis: Adjusted multiplicative effects on Medicare payments during the 
first 12 months of diagnosis and treatment 
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 All payments 
Breast cancer-
attributable 
payments† 
Payments not 
attributable to breast 
cancer  
 
Married 0.99 [0.96, 1.01] 1.00 [0.98, 1.02] 0.95 [0.89, 1.01] 
Zip code of residence       
Metropolitan (ref.)  (ref.)  (ref.)  
Non-metropolitan 0.96 [0.93, 1.00] 0.99 [0.96, 1.01] 0.94 [0.86, 1.04] 
Cooperative group affiliation of 
surgical facility† 1.01 [0.99, 1.04] 1.03** [1.01, 1.04]   
NCI affiliation of surgical facility 1.00 [0.95, 1.06] 0.99 [0.96, 1.03]   
Year of diagnosis       
2004 (ref.)  (ref.)  (ref.)  
2005 1.03* [1.00, 1.07] 1.01 [0.99, 1.03] 1.09* [1.01, 1.18] 
2006 1.05** [1.02, 1.08] 1.03** [1.01, 1.05] 1.08* [1.00, 1.18] 
2007 1.02 [0.99, 1.05] 1.02* [1.00, 1.05] 1.04 [0.96, 1.13] 
SEER Region       
California registries (ref.)  (ref.)  (ref.)  
Northeast registries 1.02 [0.99, 1.05] 1.01 [0.99, 1.03] 1.06 [0.98, 1.14] 
Georgia 0.93** [0.88, 0.98] 0.95** [0.91, 0.99] 0.82** [0.70, 0.95] 
Detroit 1.06* [1.00, 1.11] 0.99 [0.96, 1.02] 1.23** [1.08, 1.39] 
Iowa 0.81*** [0.78, 0.85] 0.82*** [0.80, 0.85] 0.74*** [0.65, 0.83] 
New Mexico 0.84*** [0.78, 0.90] 0.90*** [0.86, 0.95] 0.78* [0.62, 0.97] 
Seattle 0.87*** [0.83, 0.91] 0.90*** [0.87, 0.92] 0.86* [0.76, 0.97] 
Utah 0.84*** [0.79, 0.90] 0.78*** [0.75, 0.81] 0.90 [0.76, 1.06] 
Kentucky 0.86*** [0.82, 0.90] 0.81*** [0.78, 0.83] 0.94 [0.83, 1.05] 
Louisiana 0.92** [0.87, 0.97] 0.89*** [0.86, 0.92] 1.02 [0.90, 1.15] 
Hawaii 0.73*** [0.67, 0.80] 0.80*** [0.75, 0.85]  0.61*** [0.48, 0.78] 
N 22,974 22,974 22,974 
AIC 5.2e+05 5.0e+05 4.7e+05 
 
* p<0.05  ** p<0.01   *** p<0.001 
MRI, Magnetic resonance imaging; NCI, National cancer institute; OLS, Ordinary least-squares regression; AIC, 
Akaike information criterion, 
95% confidence intervals in brackets, All models are generalized linear models using log-link gamma with robust 
standard errors. 
†  Breast cancer-attributable payments include total Medicare payments from claims associated with breast 
cancer diagnosis or treatment or from claims with a breast  
diagnosis code within the claim’s first four diagnosis codes.  
§  NCI Cooperative Groups having breast cancer research portfolios 
  
Table C.4. Sensitivity analysis: Adjusted multiplicative effects on Medicare payments during the 
first 12 months (cont.) 
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APPENDIX D: TECHNICAL APPENDIX 
 
Table D.1. Impact of preoperative breast MRI on the time until complete surgery, 
results of propensity score trimming 
 
Hazard 
Ratio 95% CI 
Included, 
n 
Excluded, n 
Withheld 
treatment 
Last 
resort 
Full proportional hazard model with IPW 0.90 [0.85 0.95] 25,038 
  Limited to overlapping PS distributions† 0.90 [0.84 0.95] 24,867 171† 
Trimmed at 1% and 99%§ 0.91 [0.86 0.96] 24,944 93 1 
Trimmed at 2.5% and 97.5%§  0.91 [0.86 0.96] 24,779 258 1 
Trimmed at 5% and 95%§ 0.92 [0.87 0.97] 24,409 626 3 
MRI, magnetic resonance Imaging; PS, propensity scores; IPW, inverse probability weighting 
Note: all models use IPW.  
† This model excluded women with non-overlapping propensity score distributions (i.e., women without a 
preoperative breast MRI who had a propensity score higher than the maximum or lower than the minimum 
propensity score of women with preoperative breast MRI) 
§  These models trimmed patients at three different cut points at the tails of the propensity score distribution in the 
treated (i.e., breast MRI) and untreated (i.e., no breast MRI) patients corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles, respectively. Patients with an MRI 
and a PS below the lower cut point were considered to be “last resort.” Patients with no MRI and a PS above 
upper cut point were considered to be “withheld treatment” 
 
Table D.2. Impact of preoperative breast MRI on the likelihood of a mastectomy 
compared to BCS, results of propensity score trimming 
 
Odds 
Ratio 95% CI 
Included, 
n 
Excluded, n 
Withheld 
treatment 
Last 
resort 
Full logistic regression model with IPW 1.30 [1.12 1.51] 24,339 
  Limited to overlapping PS distributions† 1.31 [1.13 1.52] 24,283 156† 
Trimmed at 1% and 99%§ 1.33 [1.15 1.53] 24,346 92 1 
Trimmed at 2.5% and 97.5%§  1.31 [1.13 1.52] 24,182 256 1 
Trimmed at 5% and 95%§ 1.28 [1.11 1.47] 23,829 607 3 
MRI, magnetic resonance Imaging; PS, propensity scores; IPW, inverse probability weighting; BCS, breast 
conserving surgery (i.e., breast excision or a partial mastectomy) 
Note: All models use IPW.  
† This model excluded women with non-overlapping propensity score distributions (i.e., women without a 
preoperative breast MRI who had a propensity score higher than the maximum or lower than the minimum 
propensity score of women with preoperative breast MRI) 
§  These models trimmed patients at three different cut points at the tails of the propensity score distribution in the 
treated (i.e., breast MRI) and untreated (i.e., no breast MRI) patients corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles, respectively. Patients with an MRI 
and a PS below the lower cut point were considered to be “last resort.” Patients with no MRI and a PS above 
upper cut point were considered to be “withheld treatment” 
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Table D.3. Impact of preoperative breast MRI on the likelihood of a re-excision, 
results of propensity score trimming 
 
Odds 
Ratio 95% CI 
Included, 
n 
Excluded, n 
Withheld 
treatment 
Last 
resort 
Full logistic regression model with IPW 1.11 [0.92 1.35] 24,339 
  Limited to overlapping PS distributions† 1.12 [0.92 1.36] 24,283 148† 
Trimmed at 1% and 99%§ 1.16 [0.96 1.39] 24,346 92 1 
Trimmed at 2.5% and 97.5%§  1.10 [0.93 1.30] 24,182 256 1 
Trimmed at 5% and 95%§ 1.07 [0.91 1.26] 23,829 607 3 
MRI, magnetic resonance Imaging; PS, propensity scores; IPW, inverse probability weighting 
Note: All models use IPW.  
† This model excluded women with non-overlapping propensity score distributions (i.e., women without a 
preoperative breast MRI who had a propensity score higher than the maximum or lower than the minimum 
propensity score of women with preoperative breast MRI) 
§  These models trimmed patients at three different cut points at the tails of the propensity score distribution in the 
treated (i.e., breast MRI) and untreated (i.e., no breast MRI) patients corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles, respectively. Patients with an MRI 
and a PS below the lower cut point were considered to be “last resort.” Patients with no MRI and a PS above 
upper cut point were considered to be “withheld treatment” 
 
 
Table D.4. Impact of preoperative breast MRI on the time until a second breast 
cancer event, results of propensity score trimming 
 
Hazard 
Ratio 95% CI 
Included, 
n 
Excluded, n 
Withheld 
treatment 
Last 
resort 
Full proportional hazard model with IPW 1.37 [1.11 1.68] 24,438 
  Limited to overlapping PS distributions† 1.40 [1.14 1.71] 24,267 171† 
Trimmed at 1% and 99%§ 1.39 [1.14 1.70] 24,345 92 1 
Trimmed at 2.5% and 97.5%§  1.40 [1.13 1.70] 24,175 262 1 
Trimmed at 5% and 95%§ 1.27 [1.06 1.52] 23,829 606 3 
MRI, magnetic resonance Imaging; PS, propensity scores; IPW, inverse probability weighting 
Note: all models use IPW.  
† This model excluded women with non-overlapping propensity score distributions (i.e., women without a 
preoperative breast MRI who had a propensity score higher than the maximum or lower than the minimum 
propensity score of women with preoperative breast MRI) 
§  These models trimmed patients at three different cut points at the tails of the propensity score distribution in the 
treated (i.e., breast MRI) and untreated (i.e., no breast MRI) patients corresponding to the 1st and 99th 
percentiles, the 2.5th and 97.5th percentiles, and the 5th and 95th percentiles, respectively. Patients with an MRI 
and a PS below the lower cut point were considered to be “last resort.” Patients with no MRI and a PS above 
upper cut point were considered to be “withheld treatment” 
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